<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001387.pub2" GROUP_ID="AIRWAYS" ID="408799080612364877" MERGED_FROM="" MODIFIED="2009-04-27 16:32:43 +0200" MODIFIED_BY="Toby Lasserson" NOTES="&lt;p&gt;CJC Edit Feb 14 06 Some changes in red.&lt;/p&gt;&lt;p&gt;Objectives : Better split.&lt;/p&gt;&lt;p&gt;References : Not rechecked.&lt;/p&gt;&lt;p&gt;Table of included studies : &lt;/p&gt;&lt;p&gt;Metaview Labels : Comp 2 altered so MDI is not cut off the end.&lt;/p&gt;&lt;p&gt;Synopsis: Cost sentence removed. &amp;quot;Should&amp;quot; does not flow from review so could used instead. &lt;/p&gt;&lt;p&gt;Abstract : Some rewording of results and conclusions in red. Abbreviations removed from abstract.&lt;/p&gt;&lt;p&gt;Background: Toby could you update ATS and BTS references please.&lt;/p&gt;&lt;p&gt;Methods : Minor changes in red. I have taken out the mention of changing the trials to N=1 where there is no SD reported. Toby could you change the 1 cells back to the number of participants (eg for Gross, Campbell in 2#1 and 2#7)? &lt;/p&gt;&lt;p&gt;Results: WMD changed to MD throughout. CI from zero altered to small difference of borderline significance.&lt;/p&gt;&lt;p&gt;Discussion : &amp;quot;The increase in FVC of 120 mls is of questionable clinical significance. &amp;quot;, &amp;quot;These data suggest that ipratropium offers little benefit over SABA, but it is perhaps useful on an as needed basis to prevent deterioration in symptoms prompting requirement for oral steroid use. &amp;quot; &lt;br&gt; Removed at the suggestion of peer reviewer.&lt;/p&gt;&lt;p&gt;Spellchecked : done&lt;/p&gt;&lt;p&gt;Next action : Toby can you change the data tables as mentioned above in methods. Then ready for authors approval and submission.&lt;/p&gt;&lt;p&gt;&lt;br&gt;========================================================&lt;br&gt;Review split by TJL &amp;amp; sent to SA: &lt;/p&gt;&lt;p&gt;I am excedingly happy with both versions. Thank god we have split the reviews- what a monstrosity it was. The only comment i have refers to the IpBr vs SABA review: the 5th paragraph form the end of the discussion starting &amp;quot;The present analysis shows that ipratropium and combination therapy was comparable to SABA therapy&amp;quot; can go west as this is covered in your earlier additions &amp;quot;...that ipratropium as monotherapy resulted in less adverse events and need for oral steroids........&amp;quot;&lt;br&gt;============================================================&lt;br&gt;25/1/06 CJC edit following Peer review responses.&lt;br&gt;I am afraid that both Peer reviewers found the review to be very long and quite difficult to read. I suspect that this is because the review has grown from the protocol (IPB v SABA) to now include LABA as well. Since these are both compared v each other and as IpB add on the review actually addresses 4 separate questions. I think for the sake of the readers these need to be separated out much more clearly. I have gone back to the protocol which clearly addressed IpB v SABA and in addition to SABA. &lt;br&gt;As this review will need a good deal of editing from the present version I think that the best way forward might be to simplify this review by restricting it to SABA and generating a new review for IpB v LABA or in addtion to LABA. Toby is ready with the new trial data to update the LABA question (which really cannot be answered from the small number of studies in the current review).&lt;br&gt;Toby could you contact Sarah to see if she would be happy for us to rework this topic on the basis of separate reviews for SABA and LABA. I think we could aim for the SABA review and LABA protocol for this submission and the LABA review for the next submission?&lt;br&gt;Cheers,&lt;br&gt;Chris.&lt;/p&gt;&lt;p&gt;*********************************************************************************&lt;br&gt;20/12/05&lt;br&gt;CJC edit&lt;br&gt;Apart from a couple of typos that I have changed this looks good and can go forward. It will be very interesting to see how the data from the two unpublished studies compare and contrast to the published data - but this can go in the next update or we may miss the deadline. Toby can you send this for peer review please?&lt;br&gt;Chris.&lt;/p&gt;&lt;p&gt;+++++++++++++++++++++++++++++++++++++++++++++++++++++++&lt;br&gt;22/11/2005&lt;br&gt;1. Thanks for sending the raw data - I assume the figures in brackets are standard errors and multiplying these by SQRT(N) = 13.5 for first arm I get slightly different SD for Rennard1996:627D so could you just let me know how you did the calculations in relation to change from baseline FEV1 as I make the SD 0.18 not 0.14? HAve I made a mistake?&lt;br&gt;2. The combivent cough symptoms have a very tight SD but this may reflect the way the outcome was measured. Does not matter too much but I would take more not of the quality of life scores which may be better validated.&lt;br&gt;Chris.&lt;/p&gt;&lt;p&gt;===============================================================&lt;br&gt;2/11/2005&lt;br&gt;Thanks for tidying this up Toby. I would still be grateful if the the authors could recheck the SDs as outlined in my comment on Oct 6th. This does not seem to come from the paper in the case of Rennard so must be from manufacturers and I would like the see the derivation of the SD entered into RevMan as it is so low! I am happy with the new discussion section and when the above has been checked this can out for peer review.&lt;br&gt;Chris.&lt;/p&gt;&lt;p&gt;==========================================================&lt;br&gt;131005&lt;/p&gt;&lt;p&gt;Dear Sarah and Phillippa,&lt;br&gt; A few additional musings in the attached file.&lt;/p&gt;&lt;p&gt;Essentially this is the detail of the changes I have made:&lt;/p&gt;&lt;p&gt;1) Funnel plot of FEV1 - this is added as a graphic in the review. See the symbol under figures 'Additional figures'. I have edited this image in photoshop for clarity (RevMan is incredibly unhelpful and does not always convey the exact meaning of what is labelled).&lt;/p&gt;&lt;p&gt;2) Sensitivity analysis - I have removed Friedman from the outcomes where there is some disharmony, and reported the different effect sizes in an additional table (Table 01).&lt;/p&gt;&lt;p&gt;3) Discussion - I have also alluded to the possible difference in effect sizes between Friedman and the other studies by explaining the differences in terms of adverse events related to metaproteronol. Who knows for sure what is going on here? It is possible that the consistently positive effect in the Friedman study reflects poor uptake of metaproteronol (see comment on adverse events), or that the difference is not necessarily indicative of a different true effect for that trial, and in fact could simply be an artefact of the reduction in requirement of oral steroids which although consistent across the studies may have given a more exagerated effect on health status measurement in this study (see reference to Spencer 2004 (i.e. Mrs Steve Milan) in the review).&lt;/p&gt;&lt;p&gt;All new text in the review is in red. I have kept a back-up of the review in case you thick wot I have written is duff. Chris did mention his concerns about the discrepancy between the Friedman study and the others to me, and I think that (hopefully!) the additional text strikes a balance between having to go through the studies with a fine toothcomb and giving a sensible treatment of the statistically heterogeneous outcomes in the review. Let me know what you reckon.&lt;/p&gt;&lt;p&gt;Cheers,&lt;/p&gt;&lt;p&gt;Toby &lt;br&gt;=========================================&lt;br&gt;CJC editing 6 October 2005&lt;/p&gt;&lt;p&gt;Authors' Contribution - fine, but I have taken my name off the list as I did not contribute in a major way to this review.&lt;/p&gt;&lt;p&gt;Objectives: simplified in abstract and methods. Thanks for making clear the changes from protocol (very sensible move). I have shortened this in the interventions paragraph.&lt;/p&gt;&lt;p&gt;Table of included studies: ***Could you review the allocation concealment for Friedman. The paper reports that the patients were randomized by order of admission. I would regard this as inadequate and you may need to change the Allocation concealment and Jadad scores accordingly!**** This will also need to be changed in the methodological quality of studies. Where does 'computer generated' come from? Correspondence with BI? &lt;/p&gt;&lt;p&gt;Metaview Labels: ***Toby could you go through and switch off totals for single study outcomes please****&lt;br&gt;Comparison 1 - Looks as if there is an error in SD for Combivent 94 symptom scores cough as this is much smaller than the other studies. Please check and amend this if appropriate. Similarly Rennard in Fatigue for CRQ has very low SD.&lt;br&gt;Comparison 2 - Title is via nebuliser but some of these studies are MDI ? change title please?&lt;/p&gt;&lt;p&gt;Synopsis: fine&lt;/p&gt;&lt;p&gt;Abstract: fine&lt;/p&gt;&lt;p&gt;Methods: I have removed the mention of direction of effect on the graphs as we no longer need to point this out.&lt;/p&gt;&lt;p&gt;Results: Fine but Friedman seems to stick out as different in several outcomes. ? There was a big differential dropout in this study which is only mentioned in passing in methodological quality but could have altered the results. I think this needs discussion in results or mention in the discussion section.&lt;/p&gt;&lt;p&gt;Discussion: See re Friedman above.&lt;/p&gt;&lt;p&gt;Contentious issues: What is different about the Friedman 1996 study? It seems to stand apart from the other results?&lt;/p&gt;&lt;p&gt;Spellchecked: done&lt;/p&gt;&lt;p&gt;Next action: Back to Toby to turn off totals and ask authors to attend to a couple of issues as above.&lt;/p&gt;&lt;p&gt;&lt;br&gt;==============================================&lt;br&gt;PP 2nd October&lt;/p&gt;&lt;p&gt;Well done the Poms, and well done Sarah- what a marathon. This is still valuable esp for guiding choice of therapy in early COPD when PRN dosing required. In more severe COPD agree that Tiotropium will over as patients require regular therapy for symptoms and / or to reduce exacerbations.&lt;/p&gt;&lt;p&gt;Review now includes another study. Taskkin (1986)-only reported lung function, and adverse events. &lt;/p&gt;&lt;p&gt;I have gone through an tidied a few typos, and amended some sentences for clarity, but not changing any meaning.&lt;/p&gt;&lt;p&gt;Havw changed the reference to Barr to update it to 2005 review&lt;/p&gt;&lt;p&gt;I think it is ready to go to Chris. and have sent it.&lt;/p&gt;&lt;p&gt;---------------------------------------------------------------------&lt;br&gt;Exported from Review Manager 4.2&lt;br&gt;SA 13/09/05 marking the decline of Australian test cricket supremacy, finally. &lt;br&gt;In re: &lt;br&gt;1. &lt;br&gt;in comparison 03 03, change from baseline FVC, the 0.18 is the value extracted from the graph for the salmeterol group only as AJRCCM accepted a paper that presented the data from only one of two treatment arms! (?dodgey). The equivalent data from the Mahler study is missing becasue they commented that FVC outcomes were similar to those for FEV1. In re 0301: Change from baseline FEV1, the Mahler ipratropium data looks like it is missing but the change = 0.0ml (extracted from the graph).&lt;br&gt;I'm not sure where the rogue data came from in 0307, it has been deleted.&lt;/p&gt;&lt;p&gt;2. On close inspection of the guideline criteria, I am not too bothered by the new NICE criteria. They are essentially the same as the 1997 BTS- which also says obstruction is partially reversible = not fully reversible (NICE). For this review reversibility isn't an issue, wasn't an exclusion criteria and the studies did not specify that COPD was classified according to any criteria in particular, but rather subjects had to have a ratio &amp;lt; 70%, an FEV1 &amp;lt;65% predicted, 10 pack year smoking history and no history of asthma or eosinophilia.&lt;/p&gt;&lt;p&gt;PP 09/05&lt;br&gt;Notes in PP ACBA0405 (attached)&lt;br&gt;1. Please look at analyses 0303 and 0307. There is one isolated mean value&lt;br&gt;in each of these (0.18 and 3.0 respectively). Are these suposed to be there?&lt;/p&gt;&lt;p&gt;2. you say that COPD has to be defined by BTS British Thoracic Society. See&lt;br&gt;below that there has been quite a shift from &amp;quot;fixed' in 1997 to &amp;quot;not fully&lt;br&gt;revesible&amp;quot; in 2004. Have you enforced the 1997 defintion strictly or have&lt;br&gt;you allowed trials over time with more reversibility? if so, should probably&lt;br&gt;amend the definiton of COPD for inlcusion.&lt;/p&gt;&lt;p&gt;Old BTS definition 1997&lt;br&gt;Chronic obstructive pulmonary disease (COPD) is a chronic, slowly&lt;br&gt;progressive disorder characterised by airflow obstruction re&lt;br&gt;duced FEV1 and FEV1/VC ratio) that does not change markedly over several&lt;br&gt;months. Most of the lung function impairment is fixed, although&lt;br&gt;some reversibility can be produced by bronchodilator (or other) therapy.&lt;/p&gt;&lt;p&gt;Usually a cigarette smoking history of more than 20 pack-years is obtained,&lt;br&gt;although COPD does occur rarely in non-smokers.&lt;/p&gt;&lt;p&gt;&lt;br&gt;Recent BTS NICE guidelines 2004&lt;br&gt;COPD is characterised by airflow obstruction, which is&lt;br&gt;usually progressive, not fully reversible and does not change&lt;br&gt;markedly over several months. The disease is predominantly&lt;br&gt;caused by smoking.&lt;/p&gt;&lt;p&gt;SA comments to Phillippa 03/05&lt;br&gt;I asked Toby about the equivalence limits issue and he has suggested that we say we are comparing the relative efficacy and safety of AC and BA. I made changes accordingly, but he said that Chris will no doubt have a go at the objectives anyway.&lt;br&gt;What I haven't done is replace all references to IpB with shorter acting AC. I'm not sure if this is what you meant anyway.&lt;br&gt;I have dealt with the statistical heterogeneity issue and have put the n's in for the Gross and Campbell studies as suggested. &lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;Exported from Review Manager 4.2.3&lt;br&gt;PJP notes 14 March 2005&lt;/p&gt;&lt;p&gt;Bit of a rush sorry! Is looking pretty good&lt;/p&gt;&lt;p&gt;Have made red text changes in the text and left notes in the text where more clarification required &lt;/p&gt;&lt;p&gt;Some random things:&lt;br&gt;1. Toby is Graham Barr's tio review now on the library ? If so change the Barr reference to 2005 &lt;/p&gt;&lt;p&gt;2. Need to consider the wording of the objective to determine if AC &amp;quot;is as effective as&amp;quot; BA. Toby does this imply that are looking to see if equivalent to, in which case should use equivalence limits and don't want to do that! Perhaps &amp;quot;compare the effects of AC and BA&amp;quot; , . Remember you are also comparing adverse effects!&lt;/p&gt;&lt;p&gt;3. suggest switch off totals in comparisons 0316, 0403&lt;/p&gt;&lt;p&gt;4. suggest Call Ipra a shorter acting AC ( as opoosed to tiotropium which is a long acting AC) &lt;/p&gt;&lt;p&gt;5. suggest consistency/readability in format for reporting results- I started to do!!!!&lt;br&gt;suggest (Peto OR = 0.42, 95% CI:0.18, 0.96).&lt;br&gt;(WMD = 0.42, 95% CI:0.18, 0.96). &lt;/p&gt;&lt;p&gt;&lt;br&gt;6. The discussion is very long and a little repetitive with the results, nonetheless it reads OKl. I have made soem minor changes but not major surgery- will take a bit of time if you do decide to cut it !&lt;/p&gt;&lt;p&gt;7. Haven't had time to check refs&lt;/p&gt;&lt;p&gt;please get back if comments above or in the text are not clear&lt;/p&gt;&lt;p&gt;Phillippa&lt;/p&gt;&lt;p&gt;&lt;br&gt;Exported from Review Manager 4.2&lt;br&gt;SA comments 24/01/04&lt;br&gt;Last search August 2004. &lt;br&gt;Number of trials clarified - In results: The review contains results from 15 trials presented in 16 published papers. Two papers presented different outcome measures generated by the same trial (van Noord 2000; R. -van Molken 1999). &lt;/p&gt;&lt;p&gt;-In re &amp;quot;These trials are listed as having n=1 in Metaview&amp;quot; : I have inserted sample sizes and means where possible. SOme of the outcomes for Mahler say results for FVC were similar to those for FEV1 and therefore I cant include means where none were given, but the n is shown at least. &lt;br&gt;-I think I have subscripted all of the FEV1s now. Sorry about that.&lt;br&gt;-The numbering is sorted out and comparison 05 is now 03.&lt;br&gt;-In re reduced CS use in those recieving IpB alone or in combination- I have made some small additions in red but I'm not able to make clinical statements re this and would appreciate your help as to whether you could reccommend Rx based on this in absence of subjective/objective improvements.&lt;br&gt;-All drugs are in lower case in analyses.&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;Exported from Review Manager 4.2.3&lt;br&gt;PP notes 4/10/04&lt;/p&gt;&lt;p&gt;Wow!pretty darn good! You have done so much good work. Very little that I can see to change this time thru'.&lt;/p&gt;&lt;p&gt;I have tried to highlight in red text areas I changed (apart from minor typos, the odd hyphen).-&lt;/p&gt;&lt;p&gt;Comments/questions to address:&lt;/p&gt;&lt;p&gt;When did you conduct do the last search?&lt;/p&gt;&lt;p&gt;Please clarify number of trials included in the systematic review (as well as number of paper reports). 15 and 16 are mentioned. It might help to indicate more clearly which are the reports of the same study&lt;/p&gt;&lt;p&gt;Think we leave out any ref to tiotropium and the reasons why. I have already moved your rationale up earlier. &lt;/p&gt;&lt;p&gt;&amp;quot;These trials are listed in Metaview as having n of 1 and in this case these studies are not included in the meta-analysis&amp;quot;. &lt;br&gt;PP Why don't you put the proper n's in? It tells the readers the size of the trials that have not been able to be included in the metaaanalysis.They still won't go into the metaanalysis if there is no mean or measure of spread. If there were means and no SDs good to put them in the anaysis table -then we could see, and you might discuss whether the means are consistent with other results you find by metanalysis.&lt;/p&gt;&lt;p&gt;Drug names are out of synopsis. May make this even simpler.&lt;/p&gt;&lt;p&gt;FEV1 should really have 1 as a subscript ( as you have done variably), but I couldn't get &amp;quot;find and replace&amp;quot; to work! Over to you&lt;/p&gt;&lt;p&gt;Take off the (!) next to Brian's name in coauthors.&lt;/p&gt;&lt;p&gt;Numbering- I renumbered for clarity in the results section. Currently the Analysis comparisons don't line up with this-minor change only required-05 should be 03 I think (Ipb vs LABA).&lt;/p&gt;&lt;p&gt;The fact that subjects on IpB or IpB/SABA were less likely to go onto systemic steroids is a very important finding , given the terrible adverse effect of long term use of oral steroids. It also might mean less exacerbations which is important. More needs to be made of this point in abstract/discussion/clinical implications.&lt;/p&gt;&lt;p&gt;Analyses: the headings (pharmaceutical names)-you variably use title and lower case- suggest use all lower case (e.g ipratropium rather than Ipratropium)&lt;/p&gt;&lt;p&gt;That's about all for now! Look forward to your responses.&lt;/p&gt;&lt;p&gt;Regards&lt;/p&gt;&lt;p&gt;Phillippa&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;br&gt;Exported from Review Manager 4.2&lt;br&gt;Comments SLA 16/2/04&lt;/p&gt;&lt;p&gt;Title changed from &amp;quot;anti-cholinergic therapy versus ........&amp;quot; to &amp;quot;Ipratropium bromide versus.......&amp;quot; because there is currently a review of tiotropium bromide underway. THis decision was made after correspondence with Toby Lasserson&lt;/p&gt;&lt;p&gt;Comments by PJP 28th October 2001&lt;/p&gt;&lt;p&gt;Well done Sarah. I have been through again and made very minor changes to test -typos, grammar, clarity. Took drug names out of synopsis.&lt;/p&gt;&lt;p&gt;Appreciate Chris and Paul's comments on how to best handle the BI lack of data issue. &lt;/p&gt;&lt;p&gt;Thanks to all involved.&lt;/p&gt;&lt;p&gt;Comments by Sarah Appleton, 25 October 2001.&lt;br&gt;Thanks for your changes. The Synopsis and implications read really well now.&lt;br&gt;1. Have corrected Meta-view titles- treatment and axis labels where necessary.&lt;br&gt;2. Have added a tile of anti-cholinergic + LABA vsLABA, then sub title IpB + LABA....etc, where required.&lt;br&gt;we state in the Description of Studies that Ipratropium was the only anti-chol medication used in these studies.&lt;br&gt;3. Deseslected totals in comparison 04 04. yes looks much better.&lt;br&gt;4. RE the Oxitropium study- I have only seen an abstract, and although it says RCT, double blind etc I am loathe to put in the included studies without seeing the full text. Besides, the abstract lists 95 people- which are distributed across 3 treatment groups and therefore not enough info to include even &amp;quot;N=....&amp;quot;.&lt;br&gt;5. Re drug costs- I feel that what we have said is enough probably as costs will certainly vary across continents. If you want to put in costs per puff then please go ahead, but I don't think it is worth spending a lot of time chasing the data.&lt;br&gt;6. Detailing my correspondence would take a long time- searching through old emails etc. This is partly troublesome as I didn't realise that Microsoft Outlook was dropping off messages older than 9 months old so I have lost some. I know I should have had hard copies but I didn't make any. Frankly, I would rather wait until we get hassled about this.&lt;/p&gt;&lt;p&gt;re comments 5 Sept 2001&lt;br&gt;Where n= 1 in Colice, it means that I wasn't able to input the data- eg they measured but didn't report. I put a comment in the review explaining this a while ago.&lt;br&gt;Have added hypertext links in the Description of studies explaining drug doses.&lt;br&gt;Re Results- &amp;quot;Day 85 Peak change from baseline- please explain.&amp;quot; - I can't find this in the text- SORRY! It means peak change of that parameter on day 85 from day 85 baseline.&lt;/p&gt;&lt;p&gt;&lt;br&gt;Comments PJP 12 October 2001&lt;/p&gt;&lt;p&gt;Have gone through again and made minor changes for clarity. This is a great amount of work, very well done. We are nearly there ? another publication by Christmas?.&lt;/p&gt;&lt;p&gt;Have a read through and see what you think- I have altered mainly the discussion and the implications&lt;/p&gt;&lt;p&gt;The synopsis and abstract have been tidied up.&lt;/p&gt;&lt;p&gt;Main tasks for you: &lt;br&gt;(i) to go through metaview and label the treatments and axes in a consistent way- some are ipra vs beta-2 ag, some e.g. 0105 0106 etc are treatment vs control. As the readers may be looking at the group means and not WMDs ( as there are so few) it would help to have that done to guide the reader. So on each metaview the axes are labelled and the treatments are labelled with the drugs. Scroll through them all- some need both doing, some axes, some treatments, some neither e.g.0101.&lt;br&gt;(ii) ensure consistency in spelling of beta-2 agonist in the metaview - I think I got all the text changes&lt;br&gt;(iii) ipra and beta-2 agonist do not have capitals as generic names or classes ( except where is is abbreviated to IpB).&lt;br&gt;(iv) do you think the titles in description and results should be anticholinergic, rather than ipratropium?&lt;br&gt;do you have any data on the oxitroptium study in 2)- should it go in the comparison tables (as a study) to remind us of its existence&lt;br&gt;(iv) comparison 0404 shouldn't have a total selected - makes it look better than it is&lt;br&gt;(v) are you able to check the cost of combivent in Australia say 2 puffs qid vs ipra 0.2 2 puffs qid vs salb 2 puffs qid- I will check NZ data when I get back and try to inlcude to strengthen the point about cost.&lt;/p&gt;&lt;p&gt;Do you want to detail exactly how many times you contacted BI and when (and clarify if it was BI Australia) as they may deny they were contacted.&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;br&gt;Comments PJP 5 Sept 2001&lt;/p&gt;&lt;p&gt;Sarah have made lots of little grammar style syntax changes - hope that's OK&lt;/p&gt;&lt;p&gt;Can you check reviewer details for contract reviewer- it has had Sonia Cendon's name on? why&lt;/p&gt;&lt;p&gt;the abstract search strategy and main search strategy are different - can you make these the same&lt;/p&gt;&lt;p&gt;scrolling through metaview- many of the studies appear to have only one patient ( e.g. COLICE) in some of the comparisons but in others it is OK - perhaps check data tables&lt;/p&gt;&lt;p&gt;Some bits that could be more clearly expressed-&lt;/p&gt;&lt;p&gt;Description of studies: when you detail the doses used it is a bit unclear which doses of b2 agonist relate to whcih study. perhaps put the hypertext link next to the dose.&lt;br&gt;Results: day 85 peak change from baseline - can this be defined &lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;br&gt;Comments PJP 14 July 2001&lt;/p&gt;&lt;p&gt;1. WOW! enormous review lots of work. FAntastic effort I'm not sure that we do need to split into 2 however, although one could argue that we are lumping together IB vs BA and IB (+ BA) vs placebo (+BA) and if the two are to be together maybe it makes more sense to put the IB +BA vs BA with the IB vs placebo review! The third alternative is to make a sep review of IB +BA vs BA. This may happen in the future, but for now leave together. It is hard to keep a track of sometime- all efforts need to be directed towwards making it as readable and useful as possible-esp discussion . Has Brian or anyone else had a look and thought about splitting it?&lt;/p&gt;&lt;p&gt;2. I need to go through and make some stylistic/ grammar changes e.g in the synopsis/ abstract /discussion which I haven't yet done. e.g don't really think the statement &amp;quot;inconsistent&amp;quot; is helpful-the effect was either significant or not. If not-either not enough studies, no effect, not clinically relevant, studies reaching significantly opposite conclusions. &lt;/p&gt;&lt;p&gt;Things I would suggest in the body of the review need a little more work include:&lt;/p&gt;&lt;p&gt;a.description of studies- needs hypertext links inn paras 1 and 2 for clarity&lt;br&gt;b. any details on % smokers, range of severity within the trial ( not just mean FEV1), ?&lt;/p&gt;&lt;p&gt;c. Main check- Analyses ( Metaview) : Can you check all outcomes that all the data possible is entered-e.g. there is no data in Outcomes 0104 0105, 0106, 0110, ) 0201 has some n's of 1 etc.&lt;br&gt;Is comparison O5 all forms ( i.e. inhaled and nebulised) IB? add this for clarity&lt;/p&gt;&lt;p&gt;Numbering of outcomes seems a little confusing some are the same as earlier and some not. ? renumber 1,2,3,4,5, etc for all outcomes e.g 0901 and 0902 rather 0909 and 0912 &lt;/p&gt;&lt;p&gt;Include in the review somewhere paper I think from this reference ( do you have and can you check? If not I can insert soemwhere later) - that half patients preferred IB and half BA. Were there any other papers which reported the patient preference?&lt;/p&gt;&lt;p&gt;a randomised db crossover study comparing the effects of ipratropium 2 puffs qid and salbutamol 2 puffs qid for 7 days in 15 patients with COPD, there was no difference in exercise tolerance or breathlessness scores at the end of the treatment interval Blosser SA, Maxwell SL, Reeves-Hoche MK, Localio AR, Zwillich CW. Is an anticholinergic agent superior to a beta 2-agonist in improving dyspnea and exercise limitation in COPD? Chest 1995;108:730-5.&lt;/p&gt;&lt;p&gt;Need to discuss the place of giving patients a therapeutic trial of one and then the other and allow them to choose which one is best&lt;br&gt;Agree little evidence for combination on benefit. Trials haven't really looked at step therapy as they may yet show that the addition of a second agent may be better than increasing the dose of one.&lt;/p&gt;&lt;p&gt;Add details of cost of IB vs BA, also cost of LABA in Aust or NZ. I would have thought that a decrease in steroid use is worth having. Need to include pharmacoeffectiveness. health care ultisation measures , exacerbation frequency. in future studies&lt;/p&gt;&lt;p&gt;? define tachyphylaxis &lt;/p&gt;&lt;p&gt;3. I wonder whether we need to think about and make a statement about equivalence limits (the differnece statistically exceeding the MCID)- with the lack of useable data not really an issue right now but if BI suddenly come in with data was are going to have to know how we say they are equivalent or different. ( a la Nick Barnes). &lt;/p&gt;&lt;p&gt;4. do we need to make a statment about changing the incl criteria to inlc 4 weeks (see below)&lt;/p&gt;&lt;p&gt;I guess get a few things ironed out and then will talk to Chris about it&lt;/p&gt;&lt;p&gt;&lt;br&gt;That's a start! get back to me&lt;/p&gt;&lt;p&gt;Phillippa&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;Short title (no longer in use): Anti-cholinergic bronchodilators for stable C copy&lt;/p&gt;&lt;p&gt;SA: Altered definition of long-term treatment from 8 weeks to 4 weeks, because we found two important large multi-centre RCTs of 4 and 6 weeks which were too important to be excluded ifrom the review.&lt;/p&gt;" NOTES_MODIFIED="2009-04-27 14:21:05 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" REVIEW_NO="ACB2-COP" REVMAN_SUB_VERSION="5.0.18" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.2">
<COVER_SHEET MODIFIED="2009-04-27 16:32:43 +0200" MODIFIED_BY="Toby Lasserson">
<TITLE>Ipratropium bromide versus short acting beta-2 agonists for stable chronic obstructive pulmonary disease</TITLE>
<CONTACT MODIFIED="2009-04-27 16:32:43 +0200" MODIFIED_BY="Toby Lasserson"><PERSON ID="4434" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Sarah</FIRST_NAME><LAST_NAME>Appleton</LAST_NAME><POSITION>Research Officer</POSITION><EMAIL_1>Sarah.Appleton@health.sa.gov.au</EMAIL_1><ADDRESS><DEPARTMENT>Deptartment of Medicine</DEPARTMENT><ORGANISATION>The Queen Elizabeth Hospital</ORGANISATION><ADDRESS_1>Woodville Road</ADDRESS_1><CITY>Adelaide</CITY><ZIP>5011</ZIP><REGION>South Australia</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>61 82227349</PHONE_1><FAX_1>61 82226042</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2009-04-27 16:32:43 +0200" MODIFIED_BY="Toby Lasserson"><PERSON ID="4434" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Sarah</FIRST_NAME><LAST_NAME>Appleton</LAST_NAME><POSITION>Research Officer</POSITION><EMAIL_1>Sarah.Appleton@health.sa.gov.au</EMAIL_1><ADDRESS><DEPARTMENT>Deptartment of Medicine</DEPARTMENT><ORGANISATION>The Queen Elizabeth Hospital</ORGANISATION><ADDRESS_1>Woodville Road</ADDRESS_1><CITY>Adelaide</CITY><ZIP>5011</ZIP><REGION>South Australia</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>61 82227349</PHONE_1><FAX_1>61 82226042</FAX_1></ADDRESS></PERSON><PERSON ID="411413A482E26AA20112E9E6FADC34DC" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Terry</FIRST_NAME><LAST_NAME>Jones</LAST_NAME><POSITION>Pharmacist</POSITION><ADDRESS><ORGANISATION>The Queen Elizabeth Hospital</ORGANISATION><CITY>Adelaide</CITY><COUNTRY CODE="AU">Australia</COUNTRY></ADDRESS></PERSON><PERSON ID="4917" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Phillippa</FIRST_NAME><LAST_NAME>Poole</LAST_NAME><POSITION>Associate Professor in Medicine FMHS</POSITION><EMAIL_1>p.poole@auckland.ac.nz</EMAIL_1><ADDRESS><ORGANISATION>University of Auckland</ORGANISATION><ADDRESS_1>Private Bag 92019</ADDRESS_1><CITY>Auckland</CITY><COUNTRY CODE="NZ">New Zealand</COUNTRY><PHONE_1>0064-9-373 7599 ext: 86747</PHONE_1><FAX_1>0064-9-373 7555</FAX_1></ADDRESS></PERSON><PERSON ID="12476" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Louis</FIRST_NAME><LAST_NAME>Pilotto</LAST_NAME><POSITION>Consultant Epidemiologist</POSITION><EMAIL_1>LPILOTTO@tqeh.nwahs.sa.gov.au</EMAIL_1><ADDRESS><DEPARTMENT>Clinical Epidemiology and Health Outcomes Unit</DEPARTMENT><ORGANISATION>The Queen Elizabeth Hospital</ORGANISATION><CITY>Adelaide</CITY><ZIP>5011</ZIP><REGION>South Australia</REGION><COUNTRY CODE="AU">Australia</COUNTRY></ADDRESS></PERSON><PERSON ID="58F7C87B82E26AA200D60225B030028B" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Robert</FIRST_NAME><LAST_NAME>Adams</LAST_NAME><POSITION>Respiratory Physician</POSITION><EMAIL_1>robert.adams@channing.harvard.edu</EMAIL_1><ADDRESS><DEPARTMENT>Department of Medicine</DEPARTMENT><ORGANISATION>The Queen Elizabeth Hospital</ORGANISATION><ADDRESS_1>Woodville Road</ADDRESS_1><CITY>Adelaide</CITY><ZIP>5011</ZIP><REGION>South Australia</REGION><COUNTRY CODE="AU">Australia</COUNTRY></ADDRESS></PERSON><PERSON ID="8583" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Toby</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Lasserson</LAST_NAME><POSITION>Review Group Coordinator, CAG</POSITION><EMAIL_1>tlassers@sgul.ac.uk</EMAIL_1><URL>www.airways.cochrane.org</URL><ADDRESS><DEPARTMENT>Community Health Sciences</DEPARTMENT><ORGANISATION>St George's, University of London</ORGANISATION><ADDRESS_1>Cranmer Terrace</ADDRESS_1><ADDRESS_2>Tooting</ADDRESS_2><CITY>London</CITY><ZIP>SW17 ORE</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+20 8725 2790</PHONE_1><FAX_1>+20 8725 3584</FAX_1></ADDRESS></PERSON><PERSON ID="4994" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Brian</FIRST_NAME><LAST_NAME>Smith</LAST_NAME><POSITION>Senior Lecturer</POSITION><EMAIL_1>Brian.Smith@nwahs.sa.gov.au</EMAIL_1><ADDRESS><DEPARTMENT>Department of Medicine, University of Adelaide</DEPARTMENT><ORGANISATION>The Queen Elizabeth Hospital</ORGANISATION><CITY>Adelaide</CITY><ZIP>5011</ZIP><REGION>South Australia</REGION><COUNTRY CODE="AU">Australia</COUNTRY></ADDRESS></PERSON><PERSON ID="12461" ROLE="AUTHOR"><PREFIX>Miss</PREFIX><FIRST_NAME>Julia</FIRST_NAME><LAST_NAME>Muhammed</LAST_NAME><POSITION>Medical Student</POSITION><EMAIL_1>sappleto@medicine.adelaide.edu.au</EMAIL_1><ADDRESS><DEPARTMENT>C/O Department of Medicine</DEPARTMENT><ORGANISATION>University of Adelaide</ORGANISATION><CITY>Adelaide</CITY><COUNTRY CODE="AU">Australia</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2009-04-27 13:58:59 +0100" MODIFIED_BY="Toby J Lasserson">
<UP_TO_DATE>
<DATE DAY="4" MONTH="7" YEAR="2008"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="4" MONTH="7" YEAR="2008"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="15" MONTH="1" YEAR="2011"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="1999"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2006"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2006"/>
</DATES>
<WHATS_NEW MODIFIED="2009-04-27 13:59:25 +0100" MODIFIED_BY="Toby J Lasserson">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-04-27 13:59:25 +0100" MODIFIED_BY="Toby J Lasserson">
<DATE DAY="27" MONTH="4" YEAR="2009"/>
<DESCRIPTION>
<P>Technical problem identified; resolved by programmer</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2009-04-27 13:59:08 +0100" MODIFIED_BY="Toby J Lasserson">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2009-04-27 13:59:08 +0100" MODIFIED_BY="Toby J Lasserson">
<DATE DAY="4" MONTH="7" YEAR="2008"/>
<DESCRIPTION>
<P>Search re-run; no new studies found </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-04-27 13:59:06 +0100" MODIFIED_BY="Toby J Lasserson">
<DATE DAY="3" MONTH="7" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="15" MONTH="2" YEAR="2006"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Nederlands Astma Fonds</NAME>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2009-04-27 14:00:26 +0100" MODIFIED_BY="Toby J Lasserson">
<SUMMARY MODIFIED="2008-07-03 16:20:28 +0100" MODIFIED_BY="Toby J Lasserson">
<TITLE MODIFIED="2008-07-03 16:20:28 +0100" MODIFIED_BY="Toby J Lasserson">Ipratropium bromide versus short acting beta-2 agonists for stable chronic obstructive pulmonary disease</TITLE>
<SUMMARY_BODY>
<P>This review looks at studies that compare the regular use for at least four weeks of different types of inhaled short-acting bronchodilator medication in people with chronic obstructive pulmonary disease (COPD, or emphysema/chronic bronchitis). There were eleven trials included. There were no major differences seen between the responses to ipratropium and salbutamol, or the combination. Where there were benefits, they were small and would not support a general recommendation for the use of ipratropium bromide or a combination with beta-2 agonist over a beta-2 agonist alone in COPD. People with COPD could use the short-acting bronchodilator that gives them the most improvement in their symptoms.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-07-04 14:23:55 +0100" MODIFIED_BY="Toby J Lasserson">
<ABS_BACKGROUND>
<P>Chronic obstructive pulmonary disease (COPD) is a condition associated with high morbidity, mortality and cost to the community. Patients often report symptomatic improvement with short-acting beta-2 agonists (SABA) and anticholinergic bronchodilator medications, and both are recommended in COPD guidelines. These medications have different mechanisms of action and therefore could have an additive effect when combined.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To compare the relative efficacy and safety of regular long term use (at least four weeks) of ipratropium bromide and short- acting beta-2 agonist therapy in patients with stable COPD.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2008-07-04 14:23:55 +0100" MODIFIED_BY="Toby J Lasserson">
<P>The Cochrane Airways Group Specialised Register of Trials was searched. Bibliographies were checked to identify relevant cross-references. Drug companies were contacted for relevant trial data. The searches are current to July 2008.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>All randomised controlled trials comparing at least 4 weeks of treatment with an anticholinergic agent (ipratropium bromide) alone or in combination with a beta-2 agonist (short acting) versus the beta-2 agonist alone, delivered via metered dose inhaler or nebuliser, in non-asthmatic adult subjects with stable COPD.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Data extraction and study quality assessment was performed independently by three reviewers. Authors of studies and relevant manufacturers were contacted if data were missing.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Eleven studies (3912 participants) met the inclusion criteria of the review. Small benefits of ipratropium over a short-acting beta-2 agonist were demonstrated on lung function outcomes. There were small benefits in favour of ipratropium on quality of life (HRQL), as well as a reduction in the requirement for oral steroids. Combination therapy with ipratropium plus a short-acting beta-2 agonist conferred benefits over a short-acting beta-2 agonist alone in terms of post-bronchodilator lung function. There was no significant benefit of combination therapy in subjective improvements in HRQL, but again there was a reduction in the requirement for oral steroids.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>The available data from the trials included in this review suggest that the advantage of regular long term use of ipratropium alone or in combination with a short-acting beta-2 agonist or over a beta-2 agonist alone are small, if the aim is to improve lung function, symptoms and exercise tolerance. Until further data are available, the strategy of providing a short-acting beta-2 agonist on a PRN basis, and then either continuing with the short-acting beta-2 agonist regularly or conducting an "n of 1" trial of regular beta-2 agonist or regular anticholinergic to determine the treatment that gives the best relief of symptoms (and continuing with it), would seem cost effective. This strategy does need formal evaluation. Patient preference is also important, as is the relative importance of avoiding the use of systemic corticosteroids.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2009-04-27 14:00:26 +0100" MODIFIED_BY="Toby J Lasserson">
<BACKGROUND>
<P>Chronic Obstructive Pulmonary Disease (COPD) is a chronic, slowly progressive condition characterised by airflow limitation that is at best only partially reversible. It is a condition associated with high mortality, morbidity and cost to the community. COPD encompasses two distinct processes of chronic bronchitis and emphysema, however in both, airflow is limited by structural changes. Emphysema is a destructive process of the alveolar structures and chronic bronchitis affects both large and small airways and is characterised by chronic excess mucus secretion which is accompanied by a chronic cough. It is generally recognised that the single most important cause of COPD is cigarette smoking and that smoking cessation is the only intervention that reduces the accelerated rate of decline in lung function observed in COPD.</P>
<P>Despite the lack of major reversibility of airways obstruction, patients often report symptomatic improvement with short-acting beta-2 agonist and anticholinergic bronchodilator medications. These agents are widely used and are recommended in management guidelines for symptomatic COPD, even though they do not slow the decline in lung function (<LINK REF="REF-ATS_x002f_ERS-2004" TYPE="REFERENCE">ATS/ERS 2004</LINK>; <LINK REF="REF-NICE_x002f_BTS-2004" TYPE="REFERENCE">NICE/BTS 2004</LINK>).</P>
<P>Anticholinergic medicines (such as ipratropium bromide) act on muscarinic receptors, whereas beta-2 agonists (such as salbutamol) act via the adrenergic system to cause bronchodilation. These bronchodilators can be delivered in several ways, e.g. by metered dose inhaler, dry powder device or by nebulisation. Some studies demonstrate that ipratropium bromide is at least as effective as short acting beta-2 agonists (<LINK REF="REF-Chapman-1991" TYPE="REFERENCE">Chapman 1991</LINK>; <LINK REF="REF-Matera-1995" TYPE="REFERENCE">Matera 1995</LINK>; <LINK REF="REF-Nisar-1992" TYPE="REFERENCE">Nisar 1992</LINK>). Ipratropium bromide may be more efficacious than beta-2 agonists in the predominantly elderly COPD patient population, as there is possibly a decline in response to beta-2 agonists with increasing age (<LINK REF="REF-van-Schayck-1991" TYPE="REFERENCE">van Schayck 1991</LINK>), possibly due to reduced receptor numbers (<LINK REF="REF-Ullah-1981" TYPE="REFERENCE">Ullah 1981</LINK>). In addition, beta-2 agonists potentially have more side-effects such as tachycardia and tremor than anticholinergic medicines.</P>
<P>The aim of this review was to compare the relative efficacy and safety of regular long term use of shorter-acting anti-cholinergic medications alone or in combination with a short acting beta-2 agonist (SABA) compared with SABA alone, for patients with stable COPD. The relative effects of ipratropium and long-acting beta-agonists are considered in a separate review (<LINK REF="REF-Appleton-2006" TYPE="REFERENCE">Appleton 2006</LINK>).</P>
</BACKGROUND>
<OBJECTIVES>
<P>To compare the relative efficacy and safety of regular long term use (at least four weeks) of ipratropium bromide and short-acting beta-2 agonist therapy in patients with stable COPD.</P>
</OBJECTIVES>
<METHODS MODIFIED="2009-04-27 14:00:26 +0100" MODIFIED_BY="Toby J Lasserson">
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>Randomised controlled trials (RCT). Included studies had to have data on at least one of the outcome variables.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Non-asthmatic adult subjects with stable COPD as defined by the British Thoracic Society (<LINK REF="REF-BTS-1997" TYPE="REFERENCE">BTS 1997</LINK>). These guidelines specify COPD as a tobacco smoking related, chronic, slowly progressive disorder characterised by airways obstruction ( FEV<SUB>1</SUB> &lt;80% predicted and FEV<SUB>1</SUB>/FVC ratio &lt;70%) which does not change markedly over several months and where the impairment is largely fixed but is partially reversible by bronchodilator or other therapy.</P>
<P>'Stable' was defined as no recent infections, exacerbations, hospitalisation in the past month. </P>
<P>Studies which included subjects with severe, concurrent other diseases, including cardiac, liver and renal disease were excluded.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>This review, therefore, is limited to studies considering ipratropium bromide (IpB), used regularly for at least four weeks in a stated dose, delivered via metered dose inhaler (MDI) or nebuliser, in an outpatient setting, in a randomised comparison with a short-acting beta-2 agonist (SABA). Studies were included if they compared:</P>
<P>1) Ipratropium bromide versus SABA<BR/>2) Ipratropium bromide + SABA versus SABA alone</P>
<P>The review protocol specified anticholinergic bronchodilators, and the study duration criteria had originally stipulated eight weeks, but this was revised down to four weeks minimum duration as there were significant large multi-centre RCTs of four and six weeks duration identified which the authors believed should not be omitted from this review. This review was intended to examine all anti-cholinergic agents (including ipratropium bromide, oxitropium bromide, tiotropium bromide or atropine methonitrate) versus beta-2 agonists. However, owing to the expanding literature concerning tiotropium it was felt that the scope of the review would become too extensive to be useful in helping to guide clinical practice. The efficacy of tiotropium bromide in comparison with long-acting beta-2 agonists to is examined in a separate Cochrane review (<LINK REF="REF-Barr-2005" TYPE="REFERENCE">Barr 2005</LINK>).</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>1) Lung function - including FEV<SUB>1</SUB>, FVC, PEF<BR/>2) Health status [health related quality of life scores (HRQL)]<BR/>3) Dyspnoea scores. These were measured directly, at rest or during exercise, or indirectly by self-report in symptom diaries.<BR/>4) Exercise capacity - six minute walk distance (6MWD), shuttle walk test<BR/>5) Adverse and haemodynamic effects - blood pressure and pulse rate effects from the medication<BR/>6) Use of other medication such as rescue bronchodilators, corticosteroids or theophylline<BR/>7) Acute exacerbations</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2009-04-27 14:00:20 +0100" MODIFIED_BY="Toby J Lasserson">
<ELECTRONIC_SEARCHES MODIFIED="2008-07-04 14:34:58 +0100" MODIFIED_BY="[Empty name]">
<P>Trials were identified using the Cochrane Airways Group Specialised Register of trials, which is derived from systematic searches of bibliographic databases including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE and CINAHL, and hand searching of respiratory journals and meeting abstracts. All records in the Specialised Register coded as 'COPD' were searched using the following terms:</P>
<P>(ipratropium or oxitropium or atropine or atrovent or oxivent or respontin ) AND (((beta* AND agonist*) AND short*) OR ((beta* AND adrenergic*) AND short*) OR (bronchodilator* AND short*) or fenoterol or metaproterenol or salbutamol or albuterol)</P>
<P>Searches are current to July 2008.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2009-04-27 14:00:20 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Handsearches of abstracts from meetings of the American and British Thoracic Societies, and the European Respiratory Society were conducted. Bibliographies were checked to identify relevant cross-references. Authors and drug companies were contacted for relevant trial data.</P>
<P>Online databases of unpublished trial summaries were searched (<A HREF="http://ctr.gsk.co.uk">http://ctr.gsk.co.uk</A>; <A HREF="http://www.clinicalstudyresults.org">http://www.clinicalstudyresults.org</A>).</P>
<P>The only anticholinergic agent studied in trials that met inclusion criteria was ipratropium bromide.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2009-04-27 14:00:26 +0100" MODIFIED_BY="Toby J Lasserson">
<STUDY_SELECTION MODIFIED="2008-07-03 16:22:22 +0100" MODIFIED_BY="Toby J Lasserson">
<P>All identified citations were reviewed to identify potentially relevant studies. Full text versions of these potential studies were assessed by three reviewers to determine if they met the inclusion criteria. Differences were resolved by discussion. Those that met inclusion criteria were assessed for study quality.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2008-07-03 16:22:38 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Data for trials was extracted independently by three reviewers and entered into the Cochrane Collaboration software program (Review Manager). Standard errors (when available) were converted to standard deviations.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2008-07-03 16:24:18 +0100" MODIFIED_BY="Toby J Lasserson">
<P>We judged the risk of bias for each study (high, low or unclear) based on the process of allocation (generation of allocation schedule and its concealment to investigators/participants).</P>
<P>1) Trial quality was assessed using the following:<BR/>(a) Cochrane approach to concealment of allocation.<BR/>i. Grade A: adequate<BR/>ii. Grade B: unclear<BR/>iii. Grade C: clearly inadequate</P>
<P>(b) Additional assessment was performed using the Jadad five point scale (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>)<BR/>i. The study was described as randomised (yes:1, no;0)<BR/>ii. Method of randomisation was described and was appropriate (yes:1, no:-1)<BR/>iii. The study was described as double blind (yes:1, no:0)<BR/>iv. The method of blinding was described and was appropriate (yes:1, no:-1)<BR/>v. The was a description of withdrawals and drop outs (yes:1, no:0)</P>
</QUALITY_ASSESSMENT>
<MISSING_DATA MODIFIED="2008-07-03 16:23:15 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Authors and drug companies were contacted in an attempt to obtain missing and raw data. The data able to be retrieved is entered in MetaView. In some cases there is no measure of spread of data, although means are known. These trials are listed in MetaView as having SD as zero, and in this case these studies are not included in the meta-analysis.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2009-04-27 14:00:26 +0100" MODIFIED_BY="Toby J Lasserson">
<P>We assessed the degree of statistical variation over what would be expected with the play of chance with the I square measurement. We undertook secondary analysis where this exceeded 20%.</P>
</HETEROGENEITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2008-07-03 16:24:38 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Results of the analyses for continuous outcomes are expressed as a mean difference (MD) together with 95% confidence interval (CI) or a standardised mean difference (SMD) SMDs for outcomes where there was variation in the method of reporting of those outcomes. For dichotomous outcomes, odds ratio (OR) are used.</P>
</DATA_SYNTHESIS>
<SENSITIVITY_ANALYSIS MODIFIED="2008-07-03 16:26:37 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Sensitivity analysis using risk of bias as a categorising variable was planned. If the heterogeneity was not explained in terms of study quality the following subgroup analyses were to be conducted:</P>
<P>i) Type of different short-acting beta-2 adrenoceptor agonists.<BR/>ii) Delivery system (e.g. metered dose inhaler versus nebuliser)</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-07-03 16:43:27 +0100" MODIFIED_BY="Toby J Lasserson">
<STUDY_DESCRIPTION MODIFIED="2008-07-03 16:29:08 +0100" MODIFIED_BY="Toby J Lasserson">
<SEARCH_RESULTS MODIFIED="2008-07-03 16:27:38 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Thirty studies reported in 35 references were identified and selected for possible inclusion in the review. </P>
<P>Eleven studies recruiting 3912 participants were included in the review. For full details of the included studies, see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>. </P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2008-07-03 16:29:08 +0100" MODIFIED_BY="Toby J Lasserson">
<SUBSECTION>
<HEADING LEVEL="4">Ipratropium bromide versus short acting beta-2 agonist (SABA)</HEADING>
<P>We identified eight studies published in 1986-1998, which compared the effects of ipratropium bromide (IpB) versus SABA. These included data available from three combination studies in which the IpB/beta-2 agonist combination was compared with the combination components (<LINK REF="STD-Combivent-1994" TYPE="STUDY">Combivent 1994</LINK>; <LINK REF="STD-Combivent-1997" TYPE="STUDY">Combivent 1997</LINK>; <LINK REF="STD-Gross-1998" TYPE="STUDY">Gross 1998</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="6">Type of SABA</HEADING>
<P>The beta-2 agonist in two studies was metaproterenol (<LINK REF="STD-Friedman-1996" TYPE="STUDY">Friedman 1996</LINK>; <LINK REF="STD-Tashkin-1986" TYPE="STUDY">Tashkin 1986</LINK>), and in another, (<LINK REF="STD-Hodzhev-1999" TYPE="STUDY">Hodzhev 1999</LINK>) the beta-2 agonist was fenoterol. The remaining five studies (<LINK REF="STD-Combivent-1994" TYPE="STUDY">Combivent 1994</LINK>; <LINK REF="STD-Combivent-1997" TYPE="STUDY">Combivent 1997</LINK>; <LINK REF="STD-Colice-1996" TYPE="STUDY">Colice 1996</LINK>; <LINK REF="STD-Rennard-1996" TYPE="STUDY">Rennard 1996</LINK>; <LINK REF="STD-Gross-1998" TYPE="STUDY">Gross 1998</LINK>) compared salbutamol (albuterol) with IpB.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Type of drug delivery</HEADING>
<P>IpB and the SABA were delivered as solutions by a nebuliser in four studies (<LINK REF="STD-Combivent-1997" TYPE="STUDY">Combivent 1997</LINK>; <LINK REF="STD-Colice-1996" TYPE="STUDY">Colice 1996</LINK>; <LINK REF="STD-Friedman-1996" TYPE="STUDY">Friedman 1996</LINK>; <LINK REF="STD-Gross-1998" TYPE="STUDY">Gross 1998</LINK>), and by MDI in four studies (<LINK REF="STD-Tashkin-1986" TYPE="STUDY">Tashkin 1986</LINK>; <LINK REF="STD-Rennard-1996" TYPE="STUDY">Rennard 1996</LINK>; <LINK REF="STD-Combivent-1994" TYPE="STUDY">Combivent 1994</LINK>; <LINK REF="STD-Hodzhev-1999" TYPE="STUDY">Hodzhev 1999</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Duration of these studies</HEADING>
<P>The duration of these studies was 30 days (<LINK REF="STD-Hodzhev-1999" TYPE="STUDY">Hodzhev 1999</LINK>), 42 days (parallel phase, following crossover phase of study, <LINK REF="STD-Gross-1998" TYPE="STUDY">Gross 1998</LINK>), 85 days (<LINK REF="STD-Combivent-1994" TYPE="STUDY">Combivent 1994</LINK>; <LINK REF="STD-Combivent-1997" TYPE="STUDY">Combivent 1997</LINK>; <LINK REF="STD-Colice-1996" TYPE="STUDY">Colice 1996</LINK>; <LINK REF="STD-Friedman-1996" TYPE="STUDY">Friedman 1996</LINK>) and 90 days (<LINK REF="STD-Tashkin-1986" TYPE="STUDY">Tashkin 1986</LINK>; <LINK REF="STD-Rennard-1996" TYPE="STUDY">Rennard 1996</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Drug dose</HEADING>
<P>The dose of IpB administered was 0.5 mg in all nebulised solution studies, as listed above and 21 mcg and 42 mcg in the two MDI studies (<LINK REF="STD-Combivent-1994" TYPE="STUDY">Combivent 1994</LINK> and <LINK REF="STD-Rennard-1996" TYPE="STUDY">Rennard 1996</LINK> respectively).</P>
<P>The dose of beta-2 agonist was as follows, 2.5 mg (<LINK REF="STD-Colice-1996" TYPE="STUDY">Colice 1996</LINK>; <LINK REF="STD-Gross-1998" TYPE="STUDY">Gross 1998</LINK>), 3 mg (<LINK REF="STD-Combivent-1997" TYPE="STUDY">Combivent 1997</LINK>; <LINK REF="STD-Rennard-1996" TYPE="STUDY">Rennard 1996</LINK>:649A), 15 mg salbutamol solutions (<LINK REF="STD-Rennard-1996" TYPE="STUDY">Rennard 1996</LINK>:593A), and 15 mg metaproterenol solution (<LINK REF="STD-Friedman-1996" TYPE="STUDY">Friedman 1996</LINK>). In the MDI studies the dose of salbutamol was 240 mcg (<LINK REF="STD-Rennard-1996" TYPE="STUDY">Rennard 1996</LINK>) and metaproterenol- 1500 mcg (<LINK REF="STD-Tashkin-1986" TYPE="STUDY">Tashkin 1986</LINK>).</P>
<P>The sample sizes in the eight studies ranged from N of 44 (<LINK REF="STD-Hodzhev-1999" TYPE="STUDY">Hodzhev 1999</LINK>) to 863 (<LINK REF="STD-Gross-1998" TYPE="STUDY">Gross 1998</LINK>). While 3146 people participated in these studies, data was contributed for meta-analysis by a maximum of 1572 participants (IpB = 795, beta-2 agonist = 777) owing to incomplete reporting of data (and 3 studies that included combination arms as mentioned above). The mean age of study participants was 64 years with a mean baseline FEV<SUB>1</SUB> of 1.00 litres. The mean gender distribution across these studies was 65% male:35% female.<BR/>The range of baseline FEV<SUB>1</SUB> reported in four of eight studies was 0.18-3.3 litres. No data was given on smoking status of subjects other than having a smoking history of at least 10 pack years, with the exception of <LINK REF="STD-Tashkin-1986" TYPE="STUDY">Tashkin 1986</LINK> who reported that participants smoked between 1.5 and 2.5 packs daily</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Ipratropium bromide plus short-acting beta-2 agonist versus short-acting beta-2 agonist</HEADING>
<P>We identified seven studies published between 1994 and 1999 which compared the effects of a combination of IpB and beta-2 agonist versus beta-2 agonist alone.</P>
<SUBSECTION>
<HEADING LEVEL="6">Type of SABA</HEADING>
<P>The beta-2 agonist used in these studies was salbutamol (<LINK REF="STD-Combivent-1994" TYPE="STUDY">Combivent 1994</LINK>; <LINK REF="STD-Combivent-1997" TYPE="STUDY">Combivent 1997</LINK>; <LINK REF="STD-Campbell-1999" TYPE="STUDY">Campbell 1999</LINK>; <LINK REF="STD-Gross-1998" TYPE="STUDY">Gross 1998</LINK>; Levin 1996; <LINK REF="STD-Rennard-1996" TYPE="STUDY">Rennard 1996</LINK>) and metaproterenol (<LINK REF="STD-Tashkin-1996" TYPE="STUDY">Tashkin 1996</LINK>). Three of these were three arm studies (<LINK REF="STD-Combivent-1994" TYPE="STUDY">Combivent 1994</LINK>; <LINK REF="STD-Combivent-1997" TYPE="STUDY">Combivent 1997</LINK>; <LINK REF="STD-Gross-1998" TYPE="STUDY">Gross 1998</LINK>), where the combination was compared with each component.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Type of drug delivery</HEADING>
<P>Drugs were delivered by MDI's in three studies (<LINK REF="STD-Combivent-1994" TYPE="STUDY">Combivent 1994</LINK>; <LINK REF="STD-Campbell-1999" TYPE="STUDY">Campbell 1999</LINK>; <LINK REF="STD-Rennard-1996" TYPE="STUDY">Rennard 1996</LINK>) and in the remaining four studies, the IpB and beta-2 agonists were delivered as solutions by a nebuliser (<LINK REF="STD-Combivent-1997" TYPE="STUDY">Combivent 1997</LINK>; <LINK REF="STD-Gross-1998" TYPE="STUDY">Gross 1998</LINK>; Levin 1996; <LINK REF="STD-Tashkin-1996" TYPE="STUDY">Tashkin 1996</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Drug dose</HEADING>
<P>The dose of IpB administered was 0.5 mg in all nebulised solution studies (Levin 1996; <LINK REF="STD-Combivent-1997" TYPE="STUDY">Combivent 1997</LINK>; <LINK REF="STD-Gross-1998" TYPE="STUDY">Gross 1998</LINK>; <LINK REF="STD-Tashkin-1996" TYPE="STUDY">Tashkin 1996</LINK>) and 42 mcg, 21 mcg and 18 mcg in the two MDI studies (<LINK REF="STD-Rennard-1996" TYPE="STUDY">Rennard 1996</LINK>; <LINK REF="STD-Combivent-1994" TYPE="STUDY">Combivent 1994</LINK>; <LINK REF="STD-Campbell-1999" TYPE="STUDY">Campbell 1999</LINK> respectively).</P>
<P>The dose of beta-2 agonist was as follows, 2.5 mg (<LINK REF="STD-Gross-1998" TYPE="STUDY">Gross 1998</LINK>; Levin 1996), 3 mg salbutamol solution (<LINK REF="STD-Combivent-1997" TYPE="STUDY">Combivent 1997</LINK>), and 15 mg metaproterenol solution (<LINK REF="STD-Tashkin-1996" TYPE="STUDY">Tashkin 1996</LINK>). The doses of salbutamol aerosol delivered by MDI were 240 mcg, 100 and 90 mcg (<LINK REF="STD-Rennard-1996" TYPE="STUDY">Rennard 1996</LINK>; <LINK REF="STD-Combivent-1994" TYPE="STUDY">Combivent 1994</LINK>; <LINK REF="STD-Campbell-1999" TYPE="STUDY">Campbell 1999</LINK> respectively).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Duration of studies</HEADING>
<P>The duration of these studies was 29 days (<LINK REF="STD-Campbell-1999" TYPE="STUDY">Campbell 1999</LINK>) 42 days (parallel phase, following crossover phase of study, <LINK REF="STD-Gross-1998" TYPE="STUDY">Gross 1998</LINK>), and 85 days (4 studies) and 90 days (<LINK REF="STD-Rennard-1996" TYPE="STUDY">Rennard 1996</LINK>).</P>
<P>The sample sizes in the seven studies ranged from an N of 195 (Levin 1996) to 863 (<LINK REF="STD-Gross-1998" TYPE="STUDY">Gross 1998</LINK>). A total of 3189 people participated in these studies, however, data was contributed for analysis by a maximum of 1858 participants (combination N = 942, beta-2 agonist N = 916). Participants had a mean age of 65 years and mean baseline FEV<SUB>1</SUB> of 1.00 litres (6 studies), and percent predicted FEV1=37%, (5 studies). The mean proportions of males and females were 65% and 35% respectively. The range of baseline FEV<SUB>1</SUB> reported in four of six studies was 0.18-3.3 litres. No data was given on current smoking status of subjects other than having a smoking history of at least 10 pack years.</P>
<P>The degree of FEV1 reversibility (after inhalation of a short acting beta-2 agonist) was not measured in any study, with the exception of <LINK REF="STD-Tashkin-1986" TYPE="STUDY">Tashkin 1986</LINK> where the demonstration of a significant bronchospastic component (increase of at least 15% of baseline FEV1) in the absence of a history of asthma or current allergic disease (as determined by IgE and levels of blood eosinophils) was an inclusion criteria. Three studies (<LINK REF="STD-Combivent-1994" TYPE="STUDY">Combivent 1994</LINK>; <LINK REF="STD-Combivent-1997" TYPE="STUDY">Combivent 1997</LINK>; <LINK REF="STD-Friedman-1996" TYPE="STUDY">Friedman 1996</LINK>) included subjects whose baseline FEV1 exceeded inclusion criteria of FEV1 &lt;65% of predicted, by up to 11.5 %.</P>
</SUBSECTION>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2008-07-03 16:27:43 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Nineteen studies failed to meet the inclusion criteria for the following reasons: comparison with placebo and not beta-2 agonist (2), review articles (2), studies were of too short a duration (10), not RCTs (4), study participants had asthma only (1).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-07-03 16:43:27 +0100" MODIFIED_BY="Toby J Lasserson">
<P>We present an assessment of the risk of bias for included studies in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>. This gives an overview of our judgements of the degree to which the studies are at risk of bias.</P>
<P>Eight of the eleven studies were rated A according to the Cochrane approach to concealment of allocation after correspondence with Boehringer Ingelheim and one author of a study (<LINK REF="STD-Hodzhev-1999" TYPE="STUDY">Hodzhev 1999</LINK>). This study, although small and unblinded designed primarily to determine benefits in individual patients, the investigators were initially blinded to the randomisation/ allocation of participants. Two studies were rated B (<LINK REF="STD-Gross-1998" TYPE="STUDY">Gross 1998</LINK>; <LINK REF="STD-Campbell-1999" TYPE="STUDY">Campbell 1999</LINK>; <LINK REF="STD-Tashkin-1986" TYPE="STUDY">Tashkin 1986</LINK>) as none of these reported randomisation procedures in sufficient detail to determine whether a satisfactory attempt to control selection bias had been made, and this information was not able to be obtained from the authors.</P>
<P>After correspondence with the authors or Boehringer Ingelheim, in terms of Jadad quality assessment scores, four studies scored 5 (<LINK REF="STD-Combivent-1994" TYPE="STUDY">Combivent 1994</LINK>; <LINK REF="STD-Combivent-1997" TYPE="STUDY">Combivent 1997</LINK>; <LINK REF="STD-Rennard-1996" TYPE="STUDY">Rennard 1996</LINK>; <LINK REF="STD-Tashkin-1996" TYPE="STUDY">Tashkin 1996</LINK>); three studies scored 4 because these did not describe withdrawals and dropouts adequately (<LINK REF="STD-Colice-1996" TYPE="STUDY">Colice 1996</LINK>; <LINK REF="STD-Friedman-1996" TYPE="STUDY">Friedman 1996</LINK>; <LINK REF="STD-Levin--1996" TYPE="STUDY">Levin 1996</LINK>) and <LINK REF="STD-Hodzhev-1999" TYPE="STUDY">Hodzhev 1999</LINK> scored 3 because this study was unblinded. Because information was unable to be obtained from the authors, two studies scored 4 as the randomisation method was unclear (<LINK REF="STD-Gross-1998" TYPE="STUDY">Gross 1998</LINK>; <LINK REF="STD-Tashkin-1986" TYPE="STUDY">Tashkin 1986</LINK>). <LINK REF="STD-Campbell-1999" TYPE="STUDY">Campbell 1999</LINK> scored 2 (randomisation and blinding method unclear, withdrawals and drop outs not adequately described).</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-07-03 16:43:06 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Boehringer Ingelheim provided missing data for all ipratropium (alone or combination) versus short acting beta-2 agonist studies. We could not obtain data for the studies by <LINK REF="STD-Gross-1998" TYPE="STUDY">Gross 1998</LINK> and <LINK REF="STD-Campbell-1999" TYPE="STUDY">Campbell 1999</LINK>.</P>
<P>In most studies, lung function was the major outcome and was measured in terms of FEV<SUB>1</SUB> and FVC. For each of these lung function parameters, there was a measure of mean pre-dose FEV<SUB>1</SUB> and FVC, mean peak change in FEV<SUB>1</SUB>, FVC from the test day baseline and mean area under the FEV1 and FVC curves (AUC) above test day baseline FEV<SUB>1</SUB> and FVC respectively.</P>
<P>Generally, statistical heterogeneity was not an issue in this review (I<SUP>2</SUP> value was negligible or low) with the exception of outcome 8 (Number of subjects experiencing medication-related adverse events) in the comparison of Ipratropium bromide versus short-acting beta-2 agonist. </P>
<SUBSECTION>
<HEADING LEVEL="5">Ipratropium bromide versus short-acting beta-2 agonist [or SABA, including salbutamol (albuterol), metaproterenol, fenoterol, delivered via MDI or nebuliser]</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">i) Lung Function</HEADING>
<P>
<I>Mean test day baseline FEV<SUB>1</SUB>
</I>
<BR/>Six studies reported the effects of treatment with IpB or SABA (5 studies of 3 months duration, 1 study of one month duration). There was a small difference (of borderline statistical significance) between treatments in the baseline/pre-bronchodilator FEV<SUB>1</SUB> measured at the end of the study (MD: 0.03 litres, 95% CI: 0.00, 0.06). After 90 days of therapy <LINK REF="STD-Tashkin-1986" TYPE="STUDY">Tashkin 1986</LINK> reported no significant difference between treatments.<BR/>
<I>
<BR/>Mean peak change from test day baseline FEV<SUB>1</SUB>
</I>
<BR/>Five studies reported the effects of 3 months treatment with IpB or SABA. There was no significant difference between treatments in the mean peak change in FEV<SUB>1 </SUB>(MD: 0 litres, 95% CI: -0.02, 0.01).</P>
<P>
<I>Mean Area under the FEV<SUB>1</SUB> curve (FEV<SUB>1</SUB> AUC) above test day baseline FEV<SUB>1</SUB>
</I>
<BR/>Five studies reported the effects of 3 months treatment with IpB or SABA. There was no significant difference between treatments in the mean area under the FEV<SUB>1</SUB> curve above test day baseline (MD: 0.10 litres, 95% CI: -0.02, 0.22). <LINK REF="STD-Tashkin-1986" TYPE="STUDY">Tashkin 1986</LINK> reported a significant difference favouring ipratropium.</P>
<P>
<I>Mean test day baseline FVC</I>
<BR/>Six studies reported the effects of treatment with IpB or SABA (5 studies of 3 months duration, 1 study of one month duration). IpB treatment was associated with a small but significant improvement in the baseline FVC measured at the end of the study compared with SABA. (MD: 0.07 litres, 95% CI: 0.01, 0.14). After 90 days of therapy <LINK REF="STD-Tashkin-1986" TYPE="STUDY">Tashkin 1986</LINK> reported no significant difference between treatments.</P>
<P>
<I>Mean test day peak change in FVC</I>
<BR/>Five studies reported the effects of 3 months treatment with IpB or SABA. There was no significant difference between treatments in the mean peak change in FVC (MD: -0.01 litres, 95% CI: -0.06, 0.03).</P>
<P>
<I>Mean area under the FVC curve (FVC AUC) above test day baseline FVC</I>
<BR/>Five studies reported the effects of 3 months treatment with IpB or SABA. The difference between IpB and SABA significantly favoured ipratropium (MD: 0.28 litres, 95% CI: 0.01, 0.55). <LINK REF="STD-Tashkin-1986" TYPE="STUDY">Tashkin 1986</LINK> reported a significant difference favouring ipratropium.<BR/>
<BR/>
<I>Peak Expiratory Flow (PEF)</I>
<BR/>Unpublished PEF data has been sought from Boehringer Ingelheim. However, no statistically or clinically significant changes were demonstrated in morning peak flows (four studies) and evening peak flows (two studies) between treatment groups after 85 days of treatment. Evening PEF readings were reported (<LINK REF="STD-Friedman-1996" TYPE="STUDY">Friedman 1996</LINK>) to be significantly higher in the IpB group (286 ml), than in the metaproterenol group (270 ml) on day 85 (data extracted from graph).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">ii) HRQL measured using the Chronic Respiratory Disease Questionnaire (CRQ)</HEADING>
<P>Clinically meaningful improvements (0.5 unit change or greater) after 85 days of treatment compared with day 1 were reported in the mean CRQ Dyspnoea and Fatigue domains within the IpB group in two studies (<LINK REF="STD-Colice-1996" TYPE="STUDY">Colice 1996</LINK>; <LINK REF="STD-Friedman-1996" TYPE="STUDY">Friedman 1996</LINK>) and in the Emotion domain in one study (<LINK REF="STD-Colice-1996" TYPE="STUDY">Colice 1996</LINK>). However, <LINK REF="STD-Colice-1996" TYPE="STUDY">Colice 1996</LINK> also demonstrated a clinically meaningful improvement in the mean CRQ Dyspnoea domain in the salbutamol group after 85 days of treatment compared with day 1.</P>
<P>Meta-analysis of "between treatment group" differences showed small, statistically significant differences in CRQ domain scores between treatments. These favoured IpB treatment and were found in all four domains of the CRQ: Dyspnoea: MD: 0.16 units (95% CI: 0.09, 0.23); Fatigue: MD: 0.13 units (95% CI: 0.02, 0.23); Emotion: MD: 0.17 units (95% CI: 0.04, 0.29); Mastery: MD: 0.18 units (95% CI: 0.06, 0.30).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">iii) Dyspnoea scores</HEADING>
<P>Five studies reported the effects of 3 months treatment with IpB or SABA on self reported symptoms scores. Symptoms scores did not change significantly over time within any treatment group (<LINK REF="STD-Friedman-1996" TYPE="STUDY">Friedman 1996</LINK>; <LINK REF="STD-Combivent-1994" TYPE="STUDY">Combivent 1994</LINK>; <LINK REF="STD-Combivent-1997" TYPE="STUDY">Combivent 1997</LINK>) and meta-analysis showed no statistically significant differences between treatments for: Wheezing: MD: -0.04 (95% CI: -0.13, 0.04); Shortness of Breath: MD: 0.00 (95% CI: -0.09, 0.09); Tightness of Chest: MD: 0.01 (95% CI: -0.06, 0.09). SABA treatment however, was associated with a small reduction in the scores for Coughing: MD: -0.08 (95% CI: -0.13, -0.03).</P>
<P>
<I>Borg<B> </B>Dyspnoea Scores</I> were reported by one small unblinded study (<LINK REF="STD-Hodzhev-1999" TYPE="STUDY">Hodzhev 1999</LINK>). For the IpB treated group, at the end of 30 days treatment, there were significant changes from baseline in Borg scores before and after the six minute walk test. This was not observed for the fenoterol group in the proportions of people reporting less dyspnoea (reduction in score of 1 unit) between treatments, before or after the six minute walk test.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">iv) Exercise Capacity</HEADING>
<P>One study (<LINK REF="STD-Hodzhev-1999" TYPE="STUDY">Hodzhev 1999</LINK>) reported data on the effect of IpB versus fenoterol after 30 days of treatment in terms of the six minute walk test distance. This small unblinded study found that ipratropium treatment was associated with a significant increase from baseline in the distance walked in the six minute walk test. Another study (<LINK REF="STD-Gross-1998" TYPE="STUDY">Gross 1998</LINK>) from which data was not obtainable, reported no significant difference in the distance walked in a six minute walk test between the IpB and salbutamol treated groups during the parallel phase (day 43-84) of the trial.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">v) Number of subjects experiencing medication-related adverse events</HEADING>
<P>Pooled analysis of five studies indicated that regardless of delivery method (MDI, nebulised), fewer subjects receiving IpB experienced medication-related adverse events compared with subjects receiving SABA, either salbutamol or metaproterenol (Peto OR = 0.71, 95% CI:0.53, 0.97). Significant statistical heterogeneity was demonstrated in this analysis (I<SUP>2</SUP> =63% with either fixed or random effects models) which appeared to be driven by the study comparing nebulised IpB with metaproterenol (<LINK REF="STD-Friedman-1996" TYPE="STUDY">Friedman 1996</LINK>). Removal of <LINK REF="STD-Friedman-1996" TYPE="STUDY">Friedman 1996</LINK> resolved the heterogeneity but there was no longer a significant difference between treatments for this outcome.<BR/>
<BR/>Subgroup analysis based on type of beta-2 agonist showed that there was no benefit of IpB treatment, when compared with salbutamol, delivered via MDI or nebuliser (Peto OR: 0.94, 95% CI:0.64, 1.39). However, IpB treatment was associated with significantly less adverse events compared to metaproterenol (Peto OR: 0.47, 95% CI:0.29, 0.76; I<SUP>2</SUP> =72%), however the I<SUP>2</SUP> was high.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">vi) Haemodynamic effects</HEADING>
<P>No clinically or statistically significant different changes in mean blood pressure and pulse rate recorded during the first three hours after treatment were reported (8 studies). No clinically significant acute or long-term ECG changes were noted.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">vii) Number of subjects increasing/adding systemic (oral) steroids </HEADING>
<P>Meta-analysis of four studies indicated that regardless of delivery method (MDI, nebulised), significantly fewer subjects receiving IpB added or increased oral steroid use compared with subjects receiving SABA, either salbutamol or metaproterenol (Peto OR = 0.52, 95% CI:0.37, 0.74). This gave a NNT of 15 (95% CI 12 to 28, <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Ipratropium plus short-acting beta-2 agonist versus short-acting beta-2 agonist</HEADING>
<P>
<U>i)Lung Function</U>
<BR/>
<I>Mean test day baseline FEV<SUB>1</SUB>
</I>
<BR/>Five studies of 3 months duration reported the effects of treatment with IpB combination therapy versus SABA alone. There was no significant difference between treatments in the baseline FEV<SUB>1</SUB> measured at the end of the study (MD= 0.00 litres, 95% CI: -0.03, 0.03). One study (<LINK REF="STD-Campbell-1999" TYPE="STUDY">Campbell 1999</LINK>) for which data was not able to be obtained, reported no significant differences between treatments after 29 days of treatment.</P>
<P>
<I>Peak change from test baseline FEV<SUB>1</SUB>
</I>
<BR/>Five studies reported the mean peak FEV<SUB>1</SUB> response to the IpB combination or SABA. There was a small significant increase in the mean peak response in FEV<SUB>1 </SUB>in the combination group (MD= 0.07 litres, 95% CI: 0.05, 0.08).<BR/>Data was not able to be obtained for two studies. One study (<LINK REF="STD-Gross-1998" TYPE="STUDY">Gross 1998</LINK>) reported the mean peak FEV<SUB>1</SUB> response after 42 days of approximately 0.3 litres for combination and 0.23 litres for salbutamol alone, but the statistical significance is unclear. This data was extracted from a graph. <LINK REF="STD-Campbell-1999" TYPE="STUDY">Campbell 1999</LINK> also reported the mean peak FEV<SUB>1</SUB> response after 29 days of treatment was significantly greater for the combination therapy (0.34 litres) compared to the SABA (0.27 litres) No P value was given however.</P>
<P>
<I>Area under the FEV<SUB>1</SUB> curve above test day baseline (FEV<SUB>1</SUB> AUC)</I>
<BR/>Data available from five studies showed that at the end of the treatment period, the IpB combination treated groups demonstrated a significantly greater FEV<SUB>1</SUB>-AUC than the SABA groups (MD: 0.37 litres/hr, 95% CI:0.24, 0.49).</P>
<P>
<I>Mean test day baseline FVC</I>
<BR/>Five studies showed that after 85 days of treatment, there were no significant differences between IpB combination and SABA therapy in mean baseline FVC (MD: 0.05 litres, 95% CI: -0.21, 0.12).</P>
<P>
<I>Peak change from test day baseline FVC</I>
<BR/>Five studies reported increases in mean peak FVC response after three months treatment with IpB combination therapy or SABA. Combination treatment was associated with significant increases in peak FVC response compared to SABA treatment (MD: 0.12 litres, 95% CI: 0.08, 0.17). <LINK REF="STD-Campbell-1999" TYPE="STUDY">Campbell 1999</LINK> also reported the mean peak FVC response after 29 days of treatment was significantly greater for the IpB combination therapy (0.71 litres) compared to the SABA group (0.61 litres). No P value was given however.</P>
<P>
<I>Area under the FVC curve above test day baseline (FVC-AUC)</I>
<BR/>Data from five studies showed that the FVC-AUC was significantly greater on IpB combination therapy compared to SABA treatment (MD: 0.77 litres/hr, 95% CI: 0.50, 1.05)</P>
<P>
<I>Peak Expiratory Flow (PEF)</I>
<BR/>Four studies reported no significant differences in mean daily morning and evening PEF recordings between treatment groups over 12 weeks study duration, except for one study (<LINK REF="STD-Combivent-1997" TYPE="STUDY">Combivent 1997</LINK>) which reported that evening measurements were significantly higher in the combination group than in the salbutamol group over the 12 week study.</P>
<SUBSECTION>
<HEADING LEVEL="6">ii) HRQL measured using the Chronic Respiratory Disease Questionnaire (CRQ)</HEADING>
<P>Two studies (<LINK REF="STD-Combivent-1997" TYPE="STUDY">Combivent 1997</LINK>; <LINK REF="STD-Rennard-1996" TYPE="STUDY">Rennard 1996</LINK>) reported that CRQ scores improved slightly/modestly for the entire study group and one study (<LINK REF="STD-Tashkin-1996" TYPE="STUDY">Tashkin 1996</LINK>) reported that neither treatments had a demonstrable effect on HRQL scores. It can be assumed that clinically meaningful improvements (0.5 unit change or greater) were not obtained as a result of either treatment.</P>
<P>Data subsequently obtained from five studies showed no significant differences in CRQ scores between treatment groups for the CRQ domains of<BR/>Dyspnoea (MD= 0.01 units, 95% CI: -0.06, 0.08)<BR/>Fatigue (MD= 0.02 units, 95% CI: -0.09, 0.13)<BR/>Emotion (MD= 0.02 units, 95% CI: -0.12, 0.16)<BR/>or Mastery (MD= 0.03 units, 95% CI: -0.09, 0.14).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">iii) Dyspnoea Scores</HEADING>
<P>Self reported symptoms scores did not change over the three month duration of five studies and there were no significant differences between treatment groups for :</P>
<P>Wheezing (MD= 0.01, 95% CI: -0.07, 0.08),</P>
<P>Coughing (MD= 0.00, 95% CI: -0.05, 0.05),</P>
<P>Shortness of Breath (MD= 0.04, 95% CI: -0.05, 0.13), or</P>
<P>Chest Tightness (MD= -0.02, 95% CI: -0.09, 0.6)</P>
<P>One study (<LINK REF="STD-Campbell-1999" TYPE="STUDY">Campbell 1999</LINK>) from which data was unobtainable, reported a significant improvement in symptoms (wheezing and shortness of breath) in the IpB combination group, compared with the salbutamol group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">iv) Exercise Capacity</HEADING>
<P>The only study to measure this outcome reported no significant difference in 6 MWD between treatments during the parallel phase of the study (<LINK REF="STD-Gross-1998" TYPE="STUDY">Gross 1998</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">v) Number of subjects experiencing medication related adverse events</HEADING>
<P>Pooled analysis indicated no significant difference in the number of subjects experiencing medication related adverse events when IpB plus beta-2 agonist was compared with beta-2 agonist treatment only (Peto OR: 1.16, 95% CI: 0.86, 1.57).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">vi) Haemodynamic effects</HEADING>
<P>Four studies reported no statistically or clinically significant changes in blood pressure or pulse rate over 85 days. No clinically significant acute or long-term ECG changes were noted in three studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">vii) Number of subjects increasing/adding systemic (oral) steroids</HEADING>
<P>Pooled analysis of four studies indicated that regardless of delivery method (MDI, nebulised), fewer subjects receiving IpB/SABA combination added or increased oral steroid use compared with subjects receiving SABA -salbutamol or metaproterenol, (Peto OR = 0.69, 95% CI:0.5, 0.94). This gave a NNT of 20 (95% CI 12 to 108; see <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">viii) Number of subjects experiencing exacerbations</HEADING>
<P>One study (<LINK REF="STD-Campbell-1999" TYPE="STUDY">Campbell 1999</LINK>) indicated that the number of subjects experiencing at least one exacerbation of COPD was reduced in subjects treated with combination therapy (nebulised) compared with those receiving salbutamol alone (Peto OR: 0.42, 95% CI:0.18, 0.96).</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-07-03 16:43:02 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Based on the available data, compared with treatment with SABA, long term treatment with IpB alone, (of one to three months duration) resulted in no significant improvements post-bronchodilator FEV<SUB>1</SUB> measurements, but there was a small benefit in pre-bronchodilator FEV<SUB>1</SUB> of borderline statistical significance. There was a small increase in pre-bronchodilator FVC and the post- bronchodilator increase in FVC area under the curve over 8 hours approached statistical significance. These data suggest that the benefits of ipratropium over SABA are small, in terms of lung function. </P>
<P>Ipratropium combination therapy offered statistically and clinically significant benefits over SABA in post-bronchodilator lung function outcomes. Funnel plot asymmetry was suggestive of publication bias, and further studies would help to establish the extent to which the pooled effect estimate may be affected by under-reporting of non-significant data (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>). The largest benefits were seen in terms of the FEV<SUB>1</SUB> and FVC area under the curve, over the test day baseline measured over 8 hours. These benefits were far above the cut off of 0.12 litres for clinical significance (<LINK REF="REF-Rossi-2002" TYPE="REFERENCE">Rossi 2002</LINK>) and demonstrate a role for maintenance therapy with the combination. The observed benefits are consistent with at least an additive effect given that the drugs have different pharmacological actions.<BR/> <BR/>It is perhaps important to note that in the ipratropium versus beta-2 agonist comparison, mean post-bronchodilator FEV<SUB>1</SUB> responses ranging from 0.2-0.3 L (24-29%) were observed in both groups. Combination studies demonstrated a significant difference between groups in terms of peak change in FEV<SUB>1</SUB> (in the order of 28-40% and 24-31% over baseline for the combination and beta-2 agonist groups respectively), and this degree of reversibility demonstrated in both treatment groups is higher than expected for subjects with COPD according to older definitions i.e.-reversibility of airways obstruction. The findings are probably generalisable to COPD patients defined by more recent criteria i.e. partially reversible, given that asthmatics were excluded based upon having a history of asthma, atopy and eosinophilia (<LINK REF="REF-ATS_x002f_ERS-2004" TYPE="REFERENCE">ATS/ERS 2004</LINK>; <LINK REF="REF-NICE_x002f_BTS-2004" TYPE="REFERENCE">NICE/BTS 2004</LINK>).</P>
<P>It is also important to note that reductions in the FEV<SUB>1</SUB> AUC and FVC AUC response were observed for both treatments at the end of the study compared with test day one responses. Tachyphylaxis to the FEV<SUB>1</SUB> response in IpB and combination treated groups ranged from 5-26% and 22-28% respectively of the day one response. Tachyphylaxis to the beta-2 agonist across studies ranged from 16-36%. It is uncertain whether these reductions compared with baseline are significant for any treatment group. The response to IpB (22-26%) or the combination (38-52%) remained consistently higher than the response to beta-2 agonist across all studies.</P>
<P>Generally, neither ipratropium alone or combination therapy resulted in significant reductions in symptom scores with the exception of two studies which also reported significant improvements in CRQ scores. These two studies also reported significantly higher physicians global evaluation scores in the IpB groups compared with the beta-2 agonist groups. However, the level of symptoms reported during the studies were "mild" and physicians global evaluations indicated that subjects were fair to good despite poor spirometric values. The significant improvement in symptoms (wheezing and shortness of breath) in the combination group in one study (<LINK REF="STD-Campbell-1999" TYPE="STUDY">Campbell 1999</LINK>) is difficult to explain given the similarity of participants' baseline FEV<SUB>1</SUB> as a % of predicted across studies. In spite of the apparent lack of impact on symptoms, there was an impact on the requirement of oral steroid therapy which favoured IpB when compared with SABA alone (NNT of 15), and also in combination with SABA (NNT of 20).<B> <BR/>
</B>
<BR/>The HRQL outcomes also seem to be incongruent with the bronchodilator responses seen in the participants in these studies. The subjects on combination therapy who experienced significant lung function benefits, experienced no significant HRQL improvements (measured using the CRQ), suggesting no subjective benefit of adding IpB. Paradoxically, inconsistent "within group" and "between group" improvements in CRQ domain scores at the threshold of clinical relevancy (<LINK REF="REF-Redelmeier-1996" TYPE="REFERENCE">Redelmeier 1996</LINK>) were demonstrated in two of six studies in subjects receiving IpB (which conferred no lung function benefits over a SABA), in Dyspnoea, Fatigue and Emotion domains. However, subjects in the SABA arm of one study also demonstrated improvements. </P>
<P>There are several considerations that should be borne in mind when assessing the effects of IpB on the subjective outcomes in this review. The first consideration is the relationship between quality of life and requirement of oral steroids as a proxy for exacerbations, and the second is the relationship between quality of life and the frequency of adverse events. There were significant differences in favour of IpB as a monotherapy in the requirement of oral steroids and the number of adverse events, and suggests that it is relative effects of therapy in these two variables that account for the otherwise apparent discordance between lung function outcome and HRQL. If the frequency of exacerbations influences health status measurements (<LINK REF="REF-Spencer-2004" TYPE="REFERENCE">Spencer 2004</LINK>), then it is possible that the reduced need for oral steroids in the IpB groups reflects a significant reduction in severe exacerbations requiring steroids, with an associated difference in the capacity for daily activity between IpB and beta-agonist. There was strong agreement between the studies in the size and direction of this effect in both sets of comparisons. Interestingly however, the significant reduction in oral steroids favouring combination therapy was not accompanied by an improvement in quality of life, and the impact on adverse events was more equivocal. This suggests that the frequency of adverse events between these therapies may also have a significant impact on quality of life, particularly where the effect sizes are small. Furthermore, <U>t</U>he mild symptoms at baseline seem inconsistent with the impaired lung function in people recruited to these studies but may be a consequence of people adapting their lifestyles to limit their activities and therefore symptoms. If this is the case then HRQL improvements may be difficult to detect in subjects who are "mildly" symptomatic at the outset of therapy. <U>
<BR/>
</U>
<BR/>The effect sizes reported in <LINK REF="STD-Friedman-1996" TYPE="STUDY">Friedman 1996</LINK> are larger than those reported in other studies for FEV1, symptom scores, and quality of life despite the similar disposition of the participants at baseline. We have performed a series of <I>post-hoc</I> sensitivity analyses on these outcomes (see <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). This study randomised participants to IpB or metaproterenol and consideration of adverse events leaves the validity of this finding in question. The adverse events for the beta-agonist group in <LINK REF="STD-Friedman-1996" TYPE="STUDY">Friedman 1996</LINK> are higher than those reported for the beta-agonist groups in the other trials and the more impressive effect of IpB could be explained by poorer control in participants who are intolerant of the metaproterenol, leading to a larger mean difference on symptoms and CRQ domains when compared with estimates from the other studies. </P>
<P>The lung function benefits seen with combination therapy might be expected to confer some exercise capacity gain (i.e. increase in six minute walk distance). However, none were seen and this is an outcome which should be measured in future studies.</P>
<P>Any marginal benefits of IpB or combination therapy over SABAs need to be weighed against the drug costs as IpB and the combination are more expensive than SABA therapy alone. The cost issue is particularly relevant for nebulised therapy. In this regard, it is important that IpB treatment has been shown to be at least as safe as SABAs in terms of adverse events and haemodynamic effects, which is supported by this review. A pharmacoeconomic evaluation of combination inhalation aerosol therapy compared with components was conducted in 1999 to determine the costs of health care resource utilisation associated with COPD exacerbations (<LINK REF="REF-Friedman-1999" TYPE="REFERENCE">Friedman 1999</LINK>). This used data from 1067 patients from two RCTs (<LINK REF="STD-Combivent-1994" TYPE="STUDY">Combivent 1994</LINK>; <LINK REF="STD-Rennard-1996" TYPE="STUDY">Rennard 1996</LINK>). Ipratropium and combination therapy was associated with significantly less exacerbations of COPD than beta-2 agonist (salbutamol) therapy. The length of hospital stay (and costs per patient) were 103 days ($US 269) for salbutamol, 20 days for ipratropium ($156) and 46 days ($197) for combination therapy. Total costs were significantly higher for the salbutamol group. However there was no significant difference in the costs between the ipratropium and combination therapy groups. It is not known whether such cost savings associated with exacerbations of COPD are generalisable to the clinical setting of stable COPD, and a study that provided a detailed, prospective, cost effectiveness analysis would be welcomed.</P>
<P>A role for "N=1 randomised trials" to identify patients who actually benefit from anticholinergic therapy has been suggested (<LINK REF="REF-van-Weel-1998" TYPE="REFERENCE">van Weel 1998</LINK>). Patient preference, acquired with methodological validity, may be valuable to determine which drug or drug combination is appropriate for which patient. The relevance of patient preference has been demonstrated in a randomised double-blind crossover study (<LINK REF="REF-Blosser-1995" TYPE="REFERENCE">Blosser 1995</LINK>) comparing the effects of ipratropium 36 mcg q.i.d. and salbutamol 180 mcg q.i.d. for seven days in 15 patients with COPD, which reported that the mean FEV<SUB>1</SUB> after seven days therapy was not significantly different between the treatments. No difference in exercise tolerance or dyspnoea scores were reported at the end of the treatment interval. However, in a subjective evaluation of the treatments, 7 subjects favoured ipratropium, 7 favoured albuterol and one had no preference. Importantly, only 5 of the 15 subjects preferred the drug to which they showed greatest reversibility in FEV1. As this review has shown that there is little objective difference between any of the bronchodilator strategies, therapy should be targeted to those patients shown to benefit from it.</P>
<P>Given the general acceptance and recommendation of IpB/beta-2 agonist combination therapy for the treatment of patients with COPD, the superiority of the type of beta-2 agonist, whether short - or long-acting remains to be determined. To date only one study (<LINK REF="REF-D_x0027_Urzo-2001" TYPE="REFERENCE">D'Urzo 2001</LINK>), a randomised, double blind, cross-over trial, has been reported, comparing IpB (40 mcg q.i.d.) plus formoterol (12 mcg b.d.) and IpB plus salbutamol (200 mcg q.i.d.). Evaluation after 3 weeks of treatment demonstrated statistically significant increases in mean pre-bronchodilator PEF (12 litres/min) and FEV<SUB>1</SUB> (0.120 litres) values with the formoterol/ipratropium combination compared with the salbutamol/ipratropium combination. Post-bronchodilator FEV<SUB>1</SUB> values were also shown to be significantly increased with the formoterol combination (in the order of 0.150 litres). These marginal clinical benefits will need to be weighed against the additional costs of adding a long-acting beta-2 agonist to ipratropium. </P>
<P>The conclusions in this review of the comparative effects of bronchodilators on simple spirometric outcomes are perhaps limited by the accumulating evidence which suggests that spirometric measurements of FEV<SUB>1</SUB> and FVC may not be the best measures of bronchodilator response in COPD. The role of spirometry in evaluating therapeutic responses has been reviewed (<LINK REF="REF-O_x0027_Donnell-2000" TYPE="REFERENCE">O'Donnell 2000</LINK>). In advanced COPD, exertional dyspnoea has been correlated with the level of dynamic lung hyperinflation (DH) (<LINK REF="REF-O_x0027_Donnell-1997" TYPE="REFERENCE">O'Donnell 1997</LINK>; <LINK REF="REF-Belman-1996" TYPE="REFERENCE">Belman 1996</LINK>; <LINK REF="REF-O_x0027_Donnell-1998" TYPE="REFERENCE">O'Donnell 1998</LINK>) as measured by inspiratory capacity (IC). Furthermore, a RCT using cross-over study design with three week treatment arms of ipratropium and placebo (<LINK REF="REF-O_x0027_Donnell-1999" TYPE="REFERENCE">O'Donnell 1999</LINK>) showed that of the available spirometric parameters which indirectly measure reduced lung hyperinflation, IC correlated better than expiratory flow measurements, with reduced dyspnoea and improvements in exercise tolerance. An increases in IC of 10% predicted (0.3 L) was associated with a significant increase (&gt;25%) in exercise endurance time. Perhaps, most significantly, the improvements in IC and exercise tolerance after ipratropium treatment occurred in a proportion of subjects (31%) who showed little or no improvement in FEV<SUB>1</SUB> (&lt;10% predicted). Future critical evaluation of the benefits of bronchodilator therapy will require the incorporation of measurements of lung hyperinflation in spirometric assessments, in addition to measures of symptoms, exercise tolerance and HRQL and longer trial duration to detect critical events such as hospitalisations due to exacerbations.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>Long term combination therapy over 12 weeks with ipratropium plus a short-acting beta-2 agonist was associated with some clinically meaningful post-bronchodilator outcomes compared to beta-2 agonist treatment but these were not reflected in subjective improvements in HRQL or symptom scores. Ipratropium or beta-2 agonist therapy, appeared to offer similar, small, but clinically relevant HRQL benefits (using the CRQ) in the absence of lung function benefits. </P>
<P>As none of the treatments was associated with lowering of baseline FEV<SUB>1</SUB> or FVC responses, the routine first line use of ipratropium alone or the combination, in preference to short-acting beta-2 agonist therapy, is difficult to rationalise on the basis of sustaining lung function in patients with COPD. The observed significant post-bronchodilator increases in FEV<SUB>1</SUB> and FVC with ipratropium, combination, and short acting beta-2 agonist treated groups, suggest that at least some of the study populations may have had a significant reversible component to their airways disease (present in around half of COPD patients). The generalisability of the observed "mean" benefits to the poorly reversible population is unclear. The observed reduction in the need for oral corticosteroids in people treated with ipratropium alone or in combination with a SABA is an important finding and suggests a benefit in terms of reducing exacerbations in COPD. It may also be a consideration if patients have relative contraindications to steroid use. However, this needs formal assessment in long-term studies.</P>
<P>Until further data is available, the strategy of providing a beta-2 agonist on a PRN basis, and then, when the patient requires regular treatment, either continuing with the beta agonist regularly or conducting an "n of 1" trial of regular beta-2 agonist or regular anticholinergic to determine the treatment that gives the best relief of symptoms (and continuing with it), would seem cost effective, although this needs formal evaluation. Patient preference is an important factor which requires consideration when agents perform similarly. Given the available evidence, this review does not support the routine first line use of ipratropium alone or the combination, over initial short acting beta-2 agonist therapy alone, for patients with symptomatic COPD over a range of severities.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>The relative value of ipratropium therapy alone or in combination with short acting beta-2 agonists needs still to be determined in studies which measure outcomes such as measures of inspiratory capacity or dynamic hyperinflation in combination with other measures such as exercise tolerance, dyspnoea scores, HRQL and effects on exacerbation rates. Studies should incorporate measures of health utilisation measures and need to be of longer duration to capture effects on exacerbation rates. The important issue of patient preferences need to be considered in future studies, as does the question of how therapy is escalated in COPD. It is arguable however that given the emergence of the long-acting anti-cholinergic tiotropium on to the market, that future studies should focus on the evaluation of this therapy using relevant outcomes, for long term use in COPD, including comparisons with existing effective therapies. Its relative cost effectiveness also needs to be considered.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We would like to express our thanks to Nicole Pushlar from Boerhinger Ingelheim US for providing us with extensive unpublished data. Thanks also to Elisabeth Strom for supplying unpublished data, and Dr Hodzhev for responding to our requests for clarification. We are grateful to Professor Vasily Vlassov for translating the Russian articles excluded from the review, and to Drs Phillippa Poole and Chris Cates for their excellent editorial assistance.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>SA: Second draft of protocol, study assessment, data extraction, first draft of review, manuscript revisions<BR/>LP: Protocol draft review, study assessment, data extraction, manuscript review<BR/>TJ: Protocol draft review, study assessment, data extraction, manuscript review<BR/>BA: Manuscript review<BR/>BS: Protocol draft review, study assessment<BR/>PP: Review editing<BR/>JM: First draft of protocol<BR/>TL: Write-up and manuscript revisions<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2009-04-27 14:04:00 +0100" MODIFIED_BY="Toby J Lasserson">
<STUDIES MODIFIED="2008-07-04 14:43:31 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2008-07-04 14:41:42 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Campbell-1999" NAME="Campbell 1999" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Campbell S</AU>
<TI>For COPD a combination of ipratropium bromide and albuterol sulfate is more effective than albuterol base</TI>
<SO>Archives Internal Medicine</SO>
<YR>1999</YR>
<VL>159</VL>
<NO>Jan 25</NO>
<PG>156-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Colice-1996" MODIFIED="2008-07-04 14:39:33 +0100" MODIFIED_BY="[Empty name]" NAME="Colice 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-07-04 14:38:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Brown D, et al</AU>
<TI>A randomized, double blind, parallel, multi-centre comparison of inhalation solution with albuterol inhalation solution following single-dose and chronic administration (85 days) in patients with chronic obstructive pulmonary disease</TI>
<SO>Boehringer Ingelheim unpublished report USA U91-0865</SO>
<YR>1991</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-07-04 14:39:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Colice GL</AU>
<TI>Nebulized bronchodilators for outpatient management of stable chronic obstructive pulmonary disease</TI>
<SO>The American Journal of Medicine</SO>
<YR>1996</YR>
<VL>100</VL>
<NO>1A</NO>
<PG>11S-18S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rennard SI, Serby CW, Ghafouri M, Johnson PA, Friedman M</AU>
<TI>Extended therapy with ipratropium is associated with improved lung function in patients with COPD. A retrospective analysis of data from seven clinical trials</TI>
<SO>Chest</SO>
<YR>1996</YR>
<VL>110</VL>
<PG>62-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Combivent-1994" MODIFIED="2008-07-04 14:39:59 +0100" MODIFIED_BY="[Empty name]" NAME="Combivent 1994" YEAR="1994">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>"COMBIVENT" Inhalation Aerosol Study Group</AU>
<TI>In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone</TI>
<SO>Chest</SO>
<YR>1994</YR>
<VL>105</VL>
<NO>5</NO>
<PG>1411-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-07-04 14:39:59 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;. .&lt;/p&gt;" NOTES_MODIFIED="2008-07-04 14:39:59 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Alexander KM et al</AU>
<TI>A randomized, double blind, parallel, multi-centre comparison of Combivent (ipratropium bromide and albuterol sulfate) inhalation aerosol with its components following single-dose and chronic administration (85 days) in patients with chronic obstructive pulmonary disease</TI>
<SO>Boehringer Ingelheim unpublished report: USA U92-0462.</SO>
<YR>1992</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Combivent-1997" NAME="Combivent 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Alexander KM et al</AU>
<TI>A randomized, double blind, parallel, multi-centre comparison of Combivent (ipratropium bromide and albuterol sulfate) inhalation solution with its components following single-dose and chronic administration (85 days) in patients with chronic obstructive pulmonary disease</TI>
<SO>Boehringer Ingelheim unpublished report: USA U92-0801</SO>
<YR>1992</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rennard SI, Serby CW, Ghafouri M, Johnson PA, Friedman M.</AU>
<TI>Extended therapy with ipratropium is associated with improved lung function in patients with COPD. A retrospective analysis of data from seven clinical trials</TI>
<SO>Chest</SO>
<YR>1996</YR>
<VL>110</VL>
<PG>62-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>The COMBIVENT Inhalation Study Group</AU>
<TI>Routine nebulized ipratropium and albuterol together are better than either alone in COPD</TI>
<SO>Chest</SO>
<YR>1997</YR>
<VL>112</VL>
<NO>6</NO>
<PG>1514-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Friedman-1996" MODIFIED="2008-07-04 14:40:41 +0100" MODIFIED_BY="[Empty name]" NAME="Friedman 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-07-04 14:40:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Brown D, et al</AU>
<TI>A randomized, double blind, parallel, multi-centre comparison of Atrovent (ipratropium bromide) inhalation solution with metaproterenol inhalation solution following single-dose and chronic administration (85 days) in patients with chronic obstructive pulmonary disease</TI>
<SO>Boehringer Ingelheim unpublished report USA U91-0866.</SO>
<YR>1991</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-07-04 14:40:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Friedman M</AU>
<TI>A multicenter study of nebulized bronchodilator solutions in chronic obstructive pulmonary disease</TI>
<SO>The American Journal of Medicine</SO>
<YR>1996</YR>
<VL>100</VL>
<NO>1A</NO>
<PG>30s-39s</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gross-1998" NAME="Gross 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gross N, Tashkin D, Miller R, Oren J, Coleman W, Linberg S, et al</AU>
<TI>Inhalation by nebulization of albuterol-ipratropium combination (Dey Combination) is superior to either agent alone in the treatment of chronic obstructive pulmonary disease</TI>
<SO>Respiration</SO>
<YR>1998</YR>
<VL>65</VL>
<PG>354-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hodzhev-1999" NAME="Hodzhev 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hodzhev B, Kostianev S, Todorov I, Belev G, Kartev S</AU>
<TI>Individual results of treatment of COPD with low doses of fenoterol compared with treatment with ipratropium bromide</TI>
<SO>Folia Med (Plovdiv)</SO>
<YR>1999</YR>
<VL>41</VL>
<PG>46-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Levin--1996" MODIFIED="2008-07-04 14:41:09 +0100" MODIFIED_BY="[Empty name]" NAME="Levin  1996" YEAR="1996">
<REFERENCE MODIFIED="2008-07-04 14:41:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Levin DC, Little KS, Laughlin KR, Galbraith JM, Gustman PM, et al</AU>
<TI>Addition of anticholinergic solution prolongs bronchodilator effect of Beta2 agonists in patients with chronic obstructive pulmonary disease</TI>
<SO>The American Journal of Medicine</SO>
<YR>1996</YR>
<VL>100</VL>
<NO>1A</NO>
<PG>40s-48s</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Rennard-1996" NAME="Rennard 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rennard SI, Serby CW, Ghafouri M, Johnson PA, Friedman M</AU>
<TI>Extended therapy with ipratropium is associated with improved lung function in patients with COPD. A retrospective analysis of data from seven clinical trials</TI>
<SO>Chest</SO>
<YR>1996</YR>
<VL>110</VL>
<PG>62-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tashkin-1986" NAME="Tashkin 1986" YEAR="1986">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tashkin DP, Ashutosh K, Bleeker ER, Britt EJ, Cugell DW, Cumminsky JM, et al</AU>
<TI>Comparison of the anticholinergic bronchodilator ipratropium bromide with metaproterenol in chronic obstructive pulmonary disease. A 90-Day Multi-Centre Study</TI>
<SO>The American Journal of Medicine</SO>
<YR>1986</YR>
<VL>81</VL>
<NO>Suppl 5A</NO>
<PG>81-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Tashkin-1996" MODIFIED="2008-07-04 14:41:42 +0100" MODIFIED_BY="[Empty name]" NAME="Tashkin 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-07-04 14:41:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tashkin DP, Bleeker E, Braun S, Campbell S, DeGraff AC, Hudgell DW, et al</AU>
<TI>Results of a multicentre study of nebulised inhalant bronchodilator solutions</TI>
<SO>The American Journal of Medicine</SO>
<YR>1996</YR>
<VL>100</VL>
<NO>1A</NO>
<PG>62s-69s</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-07-04 14:43:31 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Bauer-1975" NAME="Bauer 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bauer VP, Kummer F</AU>
<TI>The action of a tropic acid ester on bronchospasm:A double-blind study</TI>
<TO>Zur wirkung eines tropasaure-esters auf den bronchospasmus</TO>
<SO>Wiener Klinische Wochenschrift</SO>
<YR>1975</YR>
<VL>87</VL>
<NO>4</NO>
<PG>132-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brown-1984" NAME="Brown 1984" YEAR="">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Brown IG, Chan CS, Kelly CA, Dent AG, Zimmerman PV</AU>
<TI>Assessment of the clinical usefulness of nebulised ipratropium bromide in patients with chronic airflow limitation</TI>
<SO>Thorax</SO>
<YR>1984</YR>
<VL>39</VL>
<PG>272-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dejaegher-1984" NAME="Dejaegher 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dejaegher Ph, Demedts M, Rochette F, Van der Veken J</AU>
<TI>Effects of 40ug and 400ug of ipratropium bromide in obstructive lung disease</TI>
<SO>Acta Clinica Belgica</SO>
<YR>1984</YR>
<VL>39</VL>
<NO>3</NO>
<PG>136-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Disse-1999" NAME="Disse 1999" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Disse B, Speck GA, Rominger KL, Witek TJ, Hammer R</AU>
<TI>Tiotropium (SPIRIVA): Mechanistical considerations and clinical profile in obstructive lung disease</TI>
<SO>Life Sciences</SO>
<YR>1999</YR>
<VL>64</VL>
<NO>6/7</NO>
<PG>457-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heimer-1991" NAME="Heimer 1991" YEAR="1991">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Heimer D, Brami JL, Liberman D, Bark H</AU>
<TI>Comparison of a B2 adrenergic agonist and an anticholinergic agent given by sequential inhalation in patients with severe chronic obstructive pulmonary disease</TI>
<SO>Israel Journal of Medical Science</SO>
<YR>1991</YR>
<VL>27</VL>
<PG>307-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hidalgo-1983" NAME="Hidalgo 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Banos Hidalgo P, Ramos Martos A, Cabrera Moreno R, Luque Leal J, Palcios Giner YA</AU>
<TI>Comparacion en estudio doble ciego de la asociacion de un aerosol de salbutamol y bromuro de ipratropio y de su efecto individual en bronquitis cronica y asma bronquial</TI>
<SO>Revista Clinica Espanola</SO>
<YR>1983</YR>
<VL>171</VL>
<NO>4</NO>
<PG>265-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kheir-1993" NAME="Kheir 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kheir A, Ying Y, Hannhart B, Duvivier C, Peslin R, Polu JM</AU>
<TI>Comparison de l'effet bronchodilatateur at du site d'action du fenoterol et de l'ipratropium chez bronchiteux chroniques obstructifs</TI>
<TO>A comparison of the bronchodilator effect and the site of action of fenoterol and of ipratropium in bronchitis with airflow obstruction</TO>
<SO>Revue des Maladies Respiratoires</SO>
<YR>1993</YR>
<VL>10</VL>
<PG>9-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Khristoliubova-1999" NAME="Khristoliubova 1999" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Khristoliubova EI, Volkova LI, Shcherbakova IV</AU>
<TI>Long-term atrovent treatment of chronic obstructive bronchitis</TI>
<SO>Klinicheskaia Meditsina (Mosk)</SO>
<YR>1999</YR>
<VL>77</VL>
<NO>12</NO>
<PG>51-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lees-1980" MODIFIED="2008-07-04 14:43:31 +0100" MODIFIED_BY="[Empty name]" NAME="Lees 1980" YEAR="1980">
<REFERENCE MODIFIED="2008-07-04 14:43:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lees AW, Allan GW, Smith J</AU>
<TI>Nebulised ipratropium bromide and salbutamol in chronic bronchitis</TI>
<SO>British Journal of Clinical Practice</SO>
<YR>1980</YR>
<VL>34</VL>
<NO>11-12</NO>
<PG>340-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leitch-1978" NAME="Leitch 1978" YEAR="1978">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Leitch AG, Hopkins JM, Ellis DA, Merchant S, McHardy GJR</AU>
<TI>The effect of aerosol ipratropium bromide and salbutamol on exercise tolerance in chronic bronchitis</TI>
<SO>Thorax</SO>
<YR>1978</YR>
<VL>33</VL>
<PG>711-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lien-1980" NAME="Lien 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lien J Th</AU>
<TI>Klinisk sammenligning av Atrovent og placebo hos pasienter med kronisk ostruktiv lungesykdom</TI>
<SO>Idsskr Nor Loegeforen</SO>
<YR>1980</YR>
<VL>100</VL>
<PG>1193-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Matera-1996" NAME="Matera 1996" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Matera MG, Caputi M, Cazzola M</AU>
<TI>A combination with clinical recommended dosages of salmeterol and ipratropium is not more effective than salmeterol alone in patients with chronic obstructive pulmonary disease</TI>
<SO>Respiratory Medicine</SO>
<YR>1996</YR>
<VL>90</VL>
<PG>497-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nardini-1996" NAME="Nardini 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nardini S</AU>
<TI>Inhaled antimuscarinic agents and COPD</TI>
<SO>Monaldi Archives for Chest Disease</SO>
<YR>1996</YR>
<VL>51</VL>
<NO>1</NO>
<PG>52-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nishimura-1992" NAME="Nishimura 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nishimura K, Koyama H, Izumi T</AU>
<TI>A comparison of bronchodilating drugs for the treatment of stable COPD</TI>
<SO>Nihon Hyobu Shikkan Gakkai Zasshi</SO>
<YR>1992</YR>
<VL>30</VL>
<NO>5</NO>
<PG>835-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Petro-1981" NAME="Petro 1981" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Petro W, Nakhosteen JA, Konietzko N.</AU>
<TI>Bronchodilator effect of a combination of a beta-adrenergic agonist and a cholinergic antagonist</TI>
<TO>Broncholyse unter kombinierter anwendung von Beta-adrenergen agonisten und cholinergen antagonisten</TO>
<SO>Prax Pneumol</SO>
<YR>1981</YR>
<VL>35</VL>
<PG>779-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pierce-1982" NAME="Pierce 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pierce RJ, Holmes PW, Campbell AH</AU>
<TI>Use of ipratropium bromide in pateints with severe airways obstruction</TI>
<SO>Australian and New Zealand Journal of Medicine</SO>
<YR>1982</YR>
<VL>12</VL>
<PG>38-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shmelev-1999" NAME="Shmelev 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shmelev EI, Khmel'kova NG, Nonikov DV, Melent'eva EM, Abubikirov AF, Makarova VL, et al</AU>
<TI>Experience in long-term use of berodual in the treatment of patients with chronic obstructive bronchitis</TI>
<SO>Terapevticheskii Arkhiv</SO>
<YR>1999</YR>
<VL>71</VL>
<NO>3</NO>
<PG>22-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simanenkov-1998" NAME="Simanenkov 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Simanenkov VI, Il'iashevich IG, Liparteliani BG, Ledovaia AV</AU>
<TI>Long-term atrovent treatment of chronic obstructive bronchitis</TI>
<TO>Dlitel'noe lechenie atroventom pri khronicheskom obstruktivnom bronkhite</TO>
<SO>Terapevticheskii Arkhiv</SO>
<YR>1998</YR>
<VL>70</VL>
<NO>9</NO>
<PG>77-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tang-1984" NAME="Tang 1984" YEAR="1984">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tang OT, Flatley M</AU>
<TI>A comparison of effects of inhaling a combined preparation of fenoterol with ipratropium bromide (Duovent) with those of fenoterol and salbutamol</TI>
<SO>Postgraduate Medical Journal</SO>
<YR>1984</YR>
<VL>60</VL>
<PG>24-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2009-04-27 14:04:00 +0100" MODIFIED_BY="Toby J Lasserson">
<ADDITIONAL_REFERENCES MODIFIED="2009-04-27 14:03:10 +0100" MODIFIED_BY="Toby J Lasserson">
<REFERENCE ID="REF-Anthonisen-1986" NAME="Anthonisen 1986" TYPE="JOURNAL_ARTICLE">
<AU>Anthonisen NR, Wright EC</AU>
<TI>Bronchodilator response in chronic obstructive pulmonary disease</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1986</YR>
<VL>133</VL>
<PG>814-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Anthonisen-1994" NAME="Anthonisen 1994" TYPE="JOURNAL_ARTICLE">
<AU>Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, et al</AU>
<TI>Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: The Lung Health Study</TI>
<SO>JAMA</SO>
<YR>1994</YR>
<VL>272</VL>
<PG>1497-505</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Appleton-1999" MODIFIED="2008-07-04 14:46:44 +0100" MODIFIED_BY="[Empty name]" NAME="Appleton 1999" TYPE="COCHRANE_REVIEW">
<AU>Appleton S, Smith B, Veale A, Bara A</AU>
<TI>Regular long-acting beta-2 adrenoceptor agonists for chronic obstructive pulmonary disease (Cochrane review)</TI>
<SO>The Cochrane Database of Systematic Reviews</SO>
<YR>1999</YR>
<NO>4</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Appleton-2006" MODIFIED="2008-07-04 14:46:27 +0100" MODIFIED_BY="[Empty name]" NAME="Appleton 2006" TYPE="COCHRANE_REVIEW">
<AU>Appleton S, Jones T, Poole P, Pilotto L, Adams R, Lasserson TJ, et al</AU>
<TI>Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2008-07-04 14:46:27 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-07-04 14:46:27 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="Art. No.: CD006101. DOI: 10.1002/14651858.CD006101"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-ATS-1995" MODIFIED="2009-04-27 14:02:40 +0100" MODIFIED_BY="Toby J Lasserson" NAME="ATS 1995" TYPE="JOURNAL_ARTICLE">
<AU>American Thoracic Society</AU>
<TI>Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease</TI>
<SO>American Journal of Respiratory &amp; Critical Care Medicine</SO>
<YR>1995</YR>
<VL>152</VL>
<PG>s78-s121</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ATS_x002f_ERS-2004" MODIFIED="2008-07-03 16:43:08 +0100" MODIFIED_BY="Toby J Lasserson" NAME="ATS/ERS 2004" TYPE="JOURNAL_ARTICLE">
<AU>Celli BR, MacNee W, ATS/ERS Task Force</AU>
<TI>Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper</TI>
<SO>European Respiratory Journal</SO>
<YR>2004</YR>
<VL>23</VL>
<PG>932-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barnes-1993" NAME="Barnes 1993" TYPE="BOOK_SECTION">
<AU>Barnes PJ</AU>
<TI>Theoretical aspects of anticholinergic treatment</TI>
<SO>Anticholinergic therapy in obstructive airways disease</SO>
<YR>1993</YR>
<ED>Gross NJ</ED>
<PB>Franlkin Scientific Publications</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barr-2005" MODIFIED="2008-07-04 14:51:17 +0100" MODIFIED_BY="[Empty name]" NAME="Barr 2005" TYPE="COCHRANE_REVIEW">
<AU>Barr RG, Bourbeau J, Camargo CA, Ram FS</AU>
<TI>Tiotropium for stable chronic obstructive pulmonary disease (Cochrane review)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-07-04 14:51:17 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-07-04 14:51:17 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="Art. No.: CD002876. DOI: 10.1002/14651858.CD002876.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Belman-1996" MODIFIED="2008-07-03 16:43:08 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Belman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Belman M, Botnick W, Shin J</AU>
<TI>Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease</TI>
<SO>American Journal of Respiratory &amp; Critical Care Medicine</SO>
<YR>1996</YR>
<VL>153</VL>
<PG>967-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Blosser-1995" MODIFIED="2008-07-03 16:43:08 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Blosser 1995" TYPE="JOURNAL_ARTICLE">
<AU>Blosser SA, Maxwell SL, Reeves-Hoche MK, Localio AR, Zwillich CW</AU>
<TI>Is an anti-cholinergic agent superior to a beta-2 agonist in improving dyspnea and exercise limitation in COPD?</TI>
<SO>Chest</SO>
<YR>1995</YR>
<VL>108</VL>
<PG>730-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boyd-1997" MODIFIED="2009-04-27 14:02:45 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Boyd 1997" TYPE="JOURNAL_ARTICLE">
<AU>Boyd G, Morice AH, Pounsford JC, Siebert M, Peslis N, Crawford C</AU>
<TI>An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD)</TI>
<SO>European Respiratory Journal</SO>
<YR>1997</YR>
<VL>10</VL>
<PG>815-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-BTS-1997" MODIFIED="2008-07-03 16:43:08 +0100" MODIFIED_BY="Toby J Lasserson" NAME="BTS 1997" NOTES="&lt;p&gt;British Thoracic Society. Chronic Obstructive Pulmonary Disease Guidelines. Thorax 1997;52(Suppl 5): S2-S28.&lt;/p&gt;" NOTES_MODIFIED="2008-07-03 16:43:08 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="JOURNAL_ARTICLE">
<AU>British Thoracic Society</AU>
<TI>Chronic Obstructive Pulmonary Disease Guidelines</TI>
<SO>Thorax</SO>
<YR>1997</YR>
<VL>52</VL>
<NO>Suppl 5</NO>
<PG>S2-S28</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Calverly-2003" NAME="Calverly 2003" TYPE="JOURNAL_ARTICLE">
<AU>Calverly PM, Burge PS, Spencer S, Anderson JA, Jones PW</AU>
<TI>Bronchodilator reversibility testing in chronic obstructive pulmonary disease</TI>
<SO>Thorax</SO>
<YR>2003</YR>
<VL>58</VL>
<PG>659-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chapman-1991" MODIFIED="2008-07-03 16:43:08 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Chapman 1991" TYPE="JOURNAL_ARTICLE">
<AU>Chapman KR</AU>
<TI>Clinical implications of anticholinergic bronchodilator therapy in COPD</TI>
<SO>Res Clin Forums</SO>
<YR>1991</YR>
<VL>13</VL>
<NO>2</NO>
<PG>43-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cwealth-of-Aust-2000" MODIFIED="2008-07-04 14:57:44 +0100" MODIFIED_BY="[Empty name]" NAME="Cwealth of Aust 2000" TYPE="OTHER">
<AU>Commonwealth of Australia</AU>
<TI>Schedule of Pharmaceutical Benefits Effective from May 2001; GENERAL Respiratory system</TI>
<SO>http://www.health.gov.au/pbs/scripts/dispgp.cfm</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-D_x0027_Urzo-2001" MODIFIED="2008-07-03 16:43:08 +0100" MODIFIED_BY="Toby J Lasserson" NAME="D'Urzo 2001" TYPE="JOURNAL_ARTICLE">
<AU>D'Urzo A, De Salvo M, Ramirez-Rivera A, Almeida J, Sichletidis L, Rapatz G, Kottakis J</AU>
<TI>In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium: A 3 week, randomized, double-blind, with-in patient, multicentre study</TI>
<SO>Chest</SO>
<YR>2001</YR>
<VL>119</VL>
<PG>1347-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ferguson-2000" NAME="Ferguson 2000" TYPE="JOURNAL_ARTICLE">
<AU>Ferguson G</AU>
<TI>Recommendations for the management of COPD</TI>
<SO>Chest</SO>
<YR>2000</YR>
<VL>117</VL>
<NO>2 Suppl</NO>
<PG>23s-28s</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Friedman-1999" MODIFIED="2008-07-03 16:43:08 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Friedman 1999" TYPE="JOURNAL_ARTICLE">
<AU>Friedman M, Serby C, Menjoge S, Wilson D, Hilleman D, Witek T</AU>
<TI>Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone</TI>
<SO>Chest</SO>
<YR>1999</YR>
<VL>115</VL>
<PG>635-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GOLD-2003" NAME="GOLD 2003" TYPE="OTHER">
<AU>National Heart, Lung, and Blood Institute</AU>
<TO>Global Initiative on Obstructive Lung Disease (GOLD) Pocket Guide (updated 2003)</TO>
<SO>www.goldcopd.com</SO>
<YR>[accessed 16/02/04]</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GOLD-2004" NAME="GOLD 2004" TYPE="OTHER">
<AU>National Heart, Lung, and Blood Institute</AU>
<TI>Global Initiative for Chronic Obstructive Pulmonary Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease (Updated 2004)</TI>
<SO>www.goldcopd.com [accessed 21/03/05]</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" MODIFIED="2008-07-04 15:02:21 +0100" MODIFIED_BY="[Empty name]" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Moore A, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al</AU>
<TI>Assessing the quality of reports of randomised controlled trials: Is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lipworth-1989" NAME="Lipworth 1989" TYPE="JOURNAL_ARTICLE">
<AU>Lipworth B, Tregaskis B, McDevitt D</AU>
<TI>Beta-adrenoceptor responses to inhaled salbutamol in the elderly</TI>
<SO>British Journal of Pharmacology</SO>
<YR>1989</YR>
<VL>28</VL>
<PG>725-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mahler-2002" NAME="Mahler 2002" TYPE="JOURNAL_ARTICLE">
<AU>Mahler DA, Wire P, Horstman D, Chang CN, Yates J, Fischer T, Shah T</AU>
<TI>Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease</TI>
<SO>American Journal of Respiratory &amp; Critical Care Medicine</SO>
<YR>2002</YR>
<VL>166</VL>
<PG>1084-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Matera-1995" MODIFIED="2009-04-27 14:02:56 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Matera 1995" TYPE="JOURNAL_ARTICLE">
<AU>Matera MG, Cazzola M, Vinciguerraaa A, et al</AU>
<TI>Comparison of the bronchodilating effects of salmeterol, salbutamol and ipratropium bromide in patients with chronic obstructive pulmonary disease</TI>
<SO>Pulmonary Pharmacology</SO>
<YR>1995</YR>
<VL>8</VL>
<PG>267-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NICE_x002f_BTS-2004" MODIFIED="2008-07-03 16:43:08 +0100" MODIFIED_BY="Toby J Lasserson" NAME="NICE/BTS 2004" TYPE="OTHER">
<AU>National Institute for Clinical Excellence (NICE)</AU>
<TI>Chronic obstructive pulmonary disease: national clinical guideline for management of chronic obstructive pulmonary disease in adults in primary and secondary care</TI>
<SO>Thorax</SO>
<YR>2004</YR>
<VL>59</VL>
<NO>Suppl I</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nisar-1992" MODIFIED="2009-04-27 14:02:59 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Nisar 1992" TYPE="JOURNAL_ARTICLE">
<AU>Nisar M, Earis JE, Pearson MG, Calverly PMA</AU>
<TI>Acute bronchodilator trials in chronic obstructive pulmonary disease</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1992</YR>
<VL>146</VL>
<PG>555-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-O_x0027_Donnell-1997" MODIFIED="2008-07-03 16:43:08 +0100" MODIFIED_BY="Toby J Lasserson" NAME="O'Donnell 1997" TYPE="JOURNAL_ARTICLE">
<AU>O'Donnell D, Bertley J, Chau L, Webb K</AU>
<TI>Qualitative aspects of exertional breathlessness in chronic airflow limitation: pathophysiological mechanisms</TI>
<SO>American Journal of Respiratory &amp; Critical Care Medicine</SO>
<YR>1997</YR>
<VL>155</VL>
<PG>109-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-O_x0027_Donnell-1998" MODIFIED="2008-07-03 16:43:08 +0100" MODIFIED_BY="Toby J Lasserson" NAME="O'Donnell 1998" TYPE="JOURNAL_ARTICLE">
<AU>O'Donnell DE, Lam M, Webb KA</AU>
<TI>Measurement of symptoms, lung hyperinflation and endurance during exercise in chronic obstructive pulmonary disease</TI>
<SO>American Journal of Respiratory &amp; Critical Care Medicine</SO>
<YR>1998</YR>
<VL>158</VL>
<PG>1557-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-O_x0027_Donnell-1999" MODIFIED="2008-07-03 16:43:08 +0100" MODIFIED_BY="Toby J Lasserson" NAME="O'Donnell 1999" TYPE="JOURNAL_ARTICLE">
<AU>O' Donnell D, Lam M, Webb K</AU>
<TI>Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease</TI>
<SO>American Journal of Respiratory &amp; Critical Care Medicine</SO>
<YR>1999</YR>
<VL>160</VL>
<PG>542-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-O_x0027_Donnell-2000" MODIFIED="2008-07-03 16:43:08 +0100" MODIFIED_BY="Toby J Lasserson" NAME="O'Donnell 2000" TYPE="JOURNAL_ARTICLE">
<AU>O' Donnell D</AU>
<TI>Assessment of bronchodilator efficacy in symptomatic COPD. Is spirometry useful?</TI>
<SO>Chest</SO>
<YR>2000</YR>
<VL>117</VL>
<NO>2 Suppl</NO>
<PG>42s-47s</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pauwels-2000" NAME="Pauwels 2000" TYPE="JOURNAL_ARTICLE">
<AU>Pauwels R</AU>
<TI>National and international guidelines for COPD: The need for evidence</TI>
<SO>Chest</SO>
<YR>2000</YR>
<VL>117</VL>
<NO>2 Suppl</NO>
<PG>20s-22s</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Redelmeier-1996" MODIFIED="2008-07-03 16:43:08 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Redelmeier 1996" TYPE="JOURNAL_ARTICLE">
<AU>Redelmeier DA, Guyatt GH, Goldstein RS</AU>
<TI>Assessing the minimal important difference in symptoms: a comparison of two techniques</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>1996</YR>
<VL>49</VL>
<NO>11</NO>
<PG>1215-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rossi-2002" MODIFIED="2008-07-03 16:43:08 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Rossi 2002" TYPE="JOURNAL_ARTICLE">
<AU>Rossi A, Kristufek P, Levine BE, Thomson MH, Till D, Kottakis J, et al</AU>
<TI>Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD</TI>
<SO>Chest</SO>
<YR>2002</YR>
<VL>121</VL>
<PG>1058-69</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Snider-1985" MODIFIED="2009-04-27 14:03:02 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Snider 1985" TYPE="JOURNAL_ARTICLE">
<AU>Snider GL, Klenerman J, Thurlbeck WM, Bengali ZH</AU>
<TI>The definition of emphysema: Report of a National Heart and Blood Institute, Division of Lung Disease, Workshop</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1985</YR>
<VL>132</VL>
<PG>182-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spencer-2004" MODIFIED="2008-07-03 16:43:08 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Spencer 2004" TYPE="JOURNAL_ARTICLE">
<AU>Spencer S, Calverley PM, Burge PS, Jones PW</AU>
<TI>Impact of preventing exacerbations on deterioration of health status in COPD</TI>
<SO>European Respiratory Journal</SO>
<YR>2004</YR>
<VL>23</VL>
<NO>5</NO>
<PG>698-702</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tashkin-2003" NAME="Tashkin 2003" TYPE="JOURNAL_ARTICLE">
<AU>Tashkin D, Kesten S</AU>
<TI>Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses</TI>
<SO>Chest</SO>
<YR>2003</YR>
<VL>123</VL>
<PG>1441-49</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ullah-1981" MODIFIED="2009-04-27 14:03:07 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Ullah 1981" TYPE="JOURNAL_ARTICLE">
<AU>Ullah MI, Newman GB, Saunders KB</AU>
<TI>Influence of age in response to ipratropium and salbutamol in asthma</TI>
<SO>Thorax</SO>
<YR>1981</YR>
<VL>36</VL>
<PG>523-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ulrik-1995" NAME="Ulrik 1995" TYPE="JOURNAL_ARTICLE">
<AU>Ulrik C</AU>
<TI>Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre, randomised, double blind, placebo controlled, cross over study</TI>
<SO>Thorax</SO>
<YR>1995</YR>
<VL>50</VL>
<PG>750-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-Schayck-1991" MODIFIED="2009-04-27 14:03:10 +0100" MODIFIED_BY="Toby J Lasserson" NAME="van Schayck 1991" TYPE="JOURNAL_ARTICLE">
<AU>van Schayck CP, Folgering H, Harbers H, et al</AU>
<TI>Effects of allergy and age on responses to salbutamol and ipratropium bromide in moderate asthma and chronic bronchitis</TI>
<SO>Thorax</SO>
<YR>1991</YR>
<VL>46</VL>
<PG>355-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-Weel-1998" MODIFIED="2008-07-03 16:43:08 +0100" MODIFIED_BY="Toby J Lasserson" NAME="van Weel 1998" TYPE="JOURNAL_ARTICLE">
<AU>van Weel C</AU>
<TI>Combining nebulised ipratropium and albuterol improved FEV1 but did not improve symptoms or quality of life in COPD</TI>
<SO>Evidence-Based Medicine</SO>
<YR>1998</YR>
<PG>120</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2009-04-27 14:04:00 +0100" MODIFIED_BY="Toby J Lasserson"/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2009-04-27 14:02:00 +0100" MODIFIED_BY="Toby J Lasserson">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2009-04-27 14:01:52 +0100" MODIFIED_BY="Toby J Lasserson" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Campbell-1999">
<CHAR_METHODS>
<P>RCT: 29 day (two arm) parallel group MDI study.<BR/>Randomisation: unclear<BR/>Blinding: double blind<BR/>Excluded: not described.<BR/>Withdrawals: not adequately described.<BR/>Baseline characteristics: comparable<BR/>Power calculation: not given.<BR/>Intention to treat analysis: not stated<BR/>Jadad Score:2</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Setting: USA, multi-centre (17) study.<BR/>357 subjects with stable COPD.<BR/>mean age: 65.6 years male/female: n= 251/103 (not equal to 357)<BR/>mean baseline FEV1: 36.2% predicted. No range given.<BR/>Inclusion criteria:&gt;or =40 years of age, &gt; 10 year pack history of smoking, stable disease, FEV1 &lt; or = 65% predicted, FEV1/FVC &lt; or =70 %, and using 2 prescribed therapeutic medication for COPD control in 3 months prior to entry into trial.<BR/>Exclusion criteria: history of asthma, allergic rhinitis or atopy, total blood eosinophil count &gt; 300,000/ml.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1) a combination of albuterol (90 mcg) and ipratropium (18 mcg), (2 puffs), four times daily.<BR/>2 ) 90 mcg albuterol (2 puffs), four times daily.<BR/>All medication administered via MDI for 29 days.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcomes measured on Test Day 1 and 29 : pulmonary function tests i.e.<BR/>1)Test Day baseline FEV1.<BR/>2) Test Day peak change in FEV1.<BR/>3) Test Day AUC (0-6 hr) FEV1. <BR/>Secondary Outcomes included:<BR/>i) the above responses for FVC measured day 1 and 29.<BR/>Measured on fortnightly visits to the clinic to monitor:<BR/>1) COPD symptoms (wheeze, dyspnoea, cough, chest tightness) recorded daily in symptom diary on a scale of 0-3.<BR/>2) adverse events.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No SDs published, but sought from authors</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Colice-1996">
<CHAR_METHODS>
<P>RCT: 85 day (two arm) parallel group inhalation solution study.<BR/>Randomisation: computer generated<BR/>Blinding: double blind<BR/>Excluded: not described.<BR/>Withdrawals: described.<BR/>Baseline characteristics: comparable<BR/>Power calculation: not given.<BR/>Intention to treat analysis: not stated<BR/>Jadad Score:4</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Setting: USA, multi-centre (11) study.<BR/>223 subjects with stable COPD.<BR/>mean age: 64 years <BR/>male/female: 60% / 40%<BR/>mean baseline FEV1: 1.00 Litres or 39% predicted. No range given.<BR/>Inclusion criteria: &gt; or = 40 years of age, &gt;10 year pack history of smoking, stable disease, FEV1 &lt; or = 65% predicted, FEV1/FVC &lt; or =70 %<BR/>Exclusion criteria: history of asthma, allergic rhinitis or atopy, total blood eosinophil count &gt;500/mm3, recent use of large doses of corticosteroids, recent MI (3 years), use of beta blockers, chronic home oxygen, other significant disease.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1) 0.5 mg ipratropium 0.1% inhalation solution, three times daily.<BR/>2) 2.5 mg albuterol 0.5% inhalation solution, three times daily.<BR/>Medication was provided in 2.5ml vials and delivered by nebuliser, for 85 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcomes measured on Test Day 1, 43, 85 : pulmonary function tests i.e.<BR/>1)Test Day baseline FEV1, FVC<BR/>2) Test Day peak change in FEV1, FVC<BR/>3) Test Day AUC above test day baseline (0-8 hr) FEV1, FVC.<BR/>Secondary Outcomes included:<BR/>i) HRQL using the Chronic Respiratory Disease Questionnaire (CRQ) measured day 1, 43 and 85.<BR/>Secondary Outcomes measured on fortnightly clinic visits to monitor:<BR/>2) Daily PEFR- measured morning and evening and recorded in diary.<BR/>3) adverse events.<BR/>4) concomitant medication.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Unpublished standard errors obtained from Boehringer Ingelheim and converted to standard deviations. Study quality details provided by Boehringer Ingelheim.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Combivent-1994">
<CHAR_METHODS>
<P>RCT: 12 week (three arm) parallel group MDI study.<BR/>Randomisation: computer generated<BR/>Blinding: double blind<BR/>Excluded: not described.<BR/>Withdrawals: described.<BR/>Baseline characteristics: comparable<BR/>Power calculation: not given.<BR/>Intention to treat analysis.<BR/>Jadad Score:5</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Setting: USA, multi-centre (24) study.<BR/>534 subjects with stable COPD.<BR/>mean age: 63.4 years <BR/>male/female: 65% / 35%<BR/>mean baseline FEV1: 0.99 Litres or 37% predicted.<BR/>range: 0.29-2.78 litres or 11.5-76.2% predicted.</P>
<P>Inclusion criteria:&gt; or= 40 years of age, stable, FEV1 &lt; or =65% predicted, FEV1/FVC &lt; or =70 %, &gt;10 year pack history of smoking, and using 2 prescribed therapeutic medication for COPD control in 3 months prior to entry into trial.<BR/>Exclusion criteria: history of asthma, allergic rhinitis or atopy, total blood eosinophil count &gt;500/mm3, daily use of &gt;10mg oral prednisone within 1 month before entry.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1) a combination of albuterol (100 mcg) and ipratropium (21 mcg), (2 puffs), four times daily.<BR/>2 ) 21 mcg ipratropium (2 puffs), four times daily.<BR/>3) 100 mcg albuterol (2 puffs), four times daily.<BR/>All medication administered via MDI for 85 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcomes measured on Test Day 1, 29, 57, 85 : pulmonary function tests i.e.<BR/>1)Test Day baseline FEV1, FVC<BR/>2) Test Day peak change in FEV1, FVC<BR/>3) Test Day AUC (0-8 hr) FEV1, FVC <BR/>Secondary Outcomes measured on fortnightly visits:<BR/>1) Daily PEFR- measured morning and evening and recorded in diary.<BR/>2) COPD symptoms (wheeze, dyspnoea, cough, chest tightness) recorded daily in symptom diary.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Inclusion criteria state FEV &lt; 65%.<BR/>FEV1 range at baseline= 11.5% - 76.2% predicted, suggesting some subjects with only mild disease.<BR/>Unpublished standard errors obtained from Boehringer Ingelheim and converted to standard deviations. Study quality details provided by Boehringer Ingelheim.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Combivent-1997">
<CHAR_METHODS>
<P>RCT: 12 week (three arm) parallel group inhalation solution study.<BR/>Randomisation: computer generated<BR/>Blinding: double blind<BR/>Excluded: not described.<BR/>Withdrawals: described.<BR/>Baseline characteristics: comparable<BR/>Power calculation: not given.<BR/>Intention to treat analysis.<BR/>Jadad Score:5</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Setting: USA, multi-centre (25) study.<BR/>652 subjects with stable COPD.<BR/>mean age: 64.9 years <BR/>male/female: 65% / 35%<BR/>mean baseline FEV1: 0.91 Litres or 34% predicted.<BR/>range: 0.18-2.49 litres or 9.2-64.4% predicted.</P>
<P>Inclusion criteria:&gt; or =40 years of age, &gt; or =10 year pack history of smoking, stable disease, FEV1 &lt; or =65% predicted, FEV1/FVC &lt; or =70 %, &gt; or =10 year pack history of smoking, and using 2 prescribed therapeutic medication for COPD control in 3 months prior to entry into trial.<BR/>Exclusion criteria:history of asthma, allergic rhinitis or atopy, total blood eosinophil count &gt;500/mm3.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1) a combination of albuterol (3.0 mg) and ipratropium (0.5 mg) inhalation solution , three times daily.<BR/>2 ) ipratropium inhalation solution (0.5 mg) , three times daily.<BR/>3) albuterol inhalation solution (3mg), three times daily.<BR/>Medication was provided in identical 2.5ml vials and delivered by nebuliser, for 85 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcomes measured on Test Day 1, 29, 57, 85 : pulmonary function tests i.e.<BR/>1)Test Day baseline FEV1, FVC<BR/>2) Test Day peak change in FEV1, FVC<BR/>3) Test Day AUC (0-8 hr) FEV1, FVC <BR/>Secondary Outcomes measured on fortnightly visits to monitor:<BR/>1) Daily PEFR- measured morning and evening and recorded in diary.<BR/>2) HRQL using the Chronic Respiratory Disease Questionnaire (CRQ).<BR/>3) COPD symptoms (wheeze, dyspnoea, cough, chest tightness) recorded daily in symptom diary.<BR/>4) adverse events<BR/>5)concomitant medication</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Unpublished standard errors obtained from Boehringer Ingelheim and converted to standard deviations. Study quality details provided by Boehringer Ingelheim.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Friedman-1996">
<CHAR_METHODS>
<P>RCT: 85 day (two arm) parallel group inhalation solution study.<BR/>Randomisation: computer generated<BR/>Blinding: double blind<BR/>Excluded: not described.<BR/>Withdrawals: not adequately described.<BR/>Baseline characteristics: comparable<BR/>Power calculation: not given.<BR/>Intention to treat analysis not stated.<BR/>Jadad Score:4</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Setting: USA, multi-centre (9) study.<BR/>213 subjects with stable COPD.<BR/>mean age: 61.5 years<BR/>male/female: 76% / 24%<BR/>Mean baseline FEV1: 1.07 litres or 37% predicted.<BR/>range: 0.3-2.3 litres or 12-72% predicted.</P>
<P>Inclusion criteria: &gt; or = 40 years of age, stable disease, FEV1 &lt; or = 65% predicted, FEV1/FVC &lt; or =70 %, &gt; 10 year pack history of smoking.<BR/>Exclusion criteria: history of asthma, allergic rhinitis or atopy, total blood eosinophil count &gt;500/mm3, other significant disease, recent MI (&lt; 1 year).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1) 0.5 mg ipratropium 0.167% inhalation solution, three times daily.<BR/>2) 15 mg metaproterenol 5% inhalation solution, three times daily.<BR/>Medication was provided in 2.0 ml vials and delivered by nebuliser, for 85 days.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcomes measured on Test Day 1, 43, 85 : pulmonary function tests i.e.<BR/>1) Test Day baseline FEV1, FVC<BR/>2) Test Day peak change in FEV1, FVC<BR/>3) Test Day AUC above test day baseline (0-8 hr) FEV1, FVC.<BR/>Secondary Outcomes included:<BR/>i) HRQL using the Chronic Respiratory Disease Questionnaire (CRQ) measured day 1, 43 and 85.<BR/>Secondary Outcomes measured on fortnightly clinic visits to monitor:<BR/>2) Daily PEFR- measured morning and evening and recorded in diary.<BR/>3) COPD symptoms (wheeze, dyspnoea, cough, chest tightness) <BR/>4) adverse events.<BR/>5) concomitant medication.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Unpublished standard errors obtained from Boehringer Ingelheim and converted to standard deviations. Study quality details provided by Boehringer Ingelheim.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Gross-1998">
<CHAR_METHODS>
<P>Six week 3 arm cross over, followed by 6 week parallel phase. Drug administered during parallel phase was the drug administered in the last arm of the crossover.<BR/>Randomisation: unclear<BR/>Blinding: double blind<BR/>Excluded: not described.<BR/>Withdrawals: described.<BR/>Power calculation: not given.<BR/>Intention to treat analysis not stated.<BR/>Jadad Score:4</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Setting: USA, multi-centre (60) study.<BR/>863 subjects with stable chronic bronchitis.<BR/>mean age: 66.3 years <BR/>male/female: 62% / 38%<BR/>mean baseline FEV1: 1.15 Litres. <BR/>range: 0.4-3.30 litres<BR/>Inclusion criteria: FEV1 &gt;25% and &lt; or = 65% predicted, at least 40 years of age, using at least one bronchodilator for COPD control in 3 months prior to entry into trial, &gt;10 year pack history of smoking, able to complete 6 minute walk and abstain from use of salmeterol, theophylline and beta-2 agonists. <BR/>Exclusion criteria: history of allergic rhinitis, atopy, asthma, polycythaemia, cor pulmonale, hypoxia, any parenchymal disease not attributable to COPD, recent hospitalisation (2 months) for pulmonary exacerbation, unstable angina, recent MI (6 months), hypersensitivity to components of study drugs, narrow angle glaucoma.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1) 2.5 mg albuterol, four times daily,<BR/>2) 0.5 mg ipratropium, four times daily<BR/>3) a combination of albuterol (2.5 mg) and ipratropium (0.5 mg). <BR/>Medication was provided in 3.0 ml vials and delivered by nebuliser, for 42 days during the parallel phase of the study.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Outcomes measured on Test Day 1, 14, 28, 42, 56, 70, 84:<BR/>Primary outcome: Pulmonary function testing i.e.<BR/>1) Change from pre-dose FEV1 to peak FEV1, measured within 8 hours of dosing on test days 14, 28 and 42 during the cross-over phase.<BR/>Secondary outcomes: <BR/>1)Change from pre-dose FEV1 and FVC to peak FEV1 and FVC measured within 8 hours of dosing <BR/>2) FEV1 and FVC AUC (0-8 hr) <BR/>3) six minute walk <BR/>measured after 2 weeks of treatment on each of the study medications on days 14, 28 and 42 of the crossover phase, and day 84, after 6 weeks of parallel phase.<BR/>4) adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No SDs published, but sought from authors</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-04-27 14:00:51 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Hodzhev-1999">
<CHAR_METHODS>
<P>RCT: 30 day parallel group study.<BR/>Randomisation: block randomisation using a random number table.<BR/>Blinding: unblinded<BR/>Excluded: not described<BR/>Withdrawals: described<BR/>Baseline characteristics: comparable<BR/>Power calculation: not given.<BR/>Jadad Score:3</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-04-27 14:00:51 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: Medical Institute, Bulgaria.<BR/>44 subjects with stable, severe COPD (FEV1 &lt; 35% pred).<BR/>Only subjects with non-reversible obstruction included in the study.<BR/>fenoterol n=22<BR/>ipratropium n=22<BR/>mean age: 63 years<BR/>mean FEV1% predicted (SD): fenoterol- 24.6 (1.5); ipratropium-22.6 (1.3).<BR/>Exclusion criteria: History of asthma, allergic rhinitis or atopy; Eosinophilia; Active lung tuberculosis or lung carcinoma; cardiovascular disorders; disorders of locomotor apparatus; Anemias; renal, liver or metabolic disorders; Hypertrophy of the prostate and glaucoma; patients with supporting inhalator and peroral corticosteroid therapy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1) 40 mcg ipratropium, four times daily.<BR/>3) 100 mcg fenoterol, four times daily.<BR/>All medication administered via MDI for 30 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Outcomes:<BR/>1) Forced expiratory parameters (FEV1, FVC) <BR/>2) Dyspnoea according to American Thoracic Society Dyspnoea Scale and Borg Scale.<BR/>3) Exercise tolerance using the six minute walk distance test.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Levin--1996">
<CHAR_METHODS>
<P>RCT: 85 day (two arm) parallel group inhalation solution study.<BR/>Randomisation: computer generated<BR/>Blinding: double blind<BR/>Excluded: not described.<BR/>Withdrawals: not adequately described.<BR/>Baseline characteristics: comparable<BR/>Power calculation: not given.<BR/>Intention to treat analysis not stated.<BR/>Jadad Score:4</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Setting: USA, multi-centre (8) study.<BR/>195 subjects with stable COPD.<BR/>mean age: 64.0 years<BR/>male/female: 63% / 37%<BR/>mean baseline FEV1: 1.02 Litres or 39% predicted. No range given.</P>
<P>Inclusion criteria: &gt; or = 40 years of age, stable disease, FEV1 &lt; or = 65% predicted, FEV1/FVC &lt; or =70 %, &gt; or =10 year pack history of smoking.<BR/>Exclusion criteria: history of asthma, allergic rhinitis or atopy, total blood eosinophil count &gt;500/mm3, recent MI (&lt; 1 year), other significant disease, viral infection or febrile illness in past month.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1) a combination of albuterol (2.5 mg, 3.0 ml) solution plus ipratropium (0.5 mg) solution.<BR/>2) albuterol (2.5 mg, 3.0 ml) solution, plus placebo, three times daily.<BR/>Medication delivered via nebuliser.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcomes measured on Test Days 1, 43 and 85<BR/>1) Peak change in FEV1<BR/>2) FEV1 AUC above test day baseline<BR/>3) baseline FEV1<BR/>Secondary Outcomes included:<BR/>1)Peak change in FVC<BR/>2) FVC AUC (0-8 hr) above test day baseline<BR/>3) baseline FVC<BR/>4) HRQL using the Chronic Respiratory Disease Questionnaire (CRQ) measured day 1, 43 and 85.<BR/>Secondary Outcomes measured on fortnightly clinic visits to monitor:<BR/>1) Daily PEFR- measured morning and evening and recorded in diary.<BR/>2) COPD symptoms.<BR/>3) adverse events.<BR/>4) concomitant medication.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Unpublished standard errors obtained from Boehringer Ingelheim and converted to standard deviations. Study quality details provided by Boehringer Ingelheim.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Rennard-1996">
<CHAR_METHODS>
<P>RCT: 90 day MDI study<BR/>Randomisation: computer generated<BR/>Blinding: double blind<BR/>Excluded: not described.<BR/>Withdrawals: described.<BR/>Baseline characteristics: comparable<BR/>Power calculation: not given.<BR/>Intention to treat analysis not stated.<BR/>Jadad Score:5</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Setting: USA.<BR/>357 subjects with COPD.<BR/>mean age: 65.1 years<BR/>male : female= 70% : 30%<BR/>mean baseline FEV1: 0.90 Litres<BR/>range not given. </P>
<P>Inclusion criteria: &gt; or = 40 years of age, &gt;10 year pack history of smoking, stable disease, FEV1 &lt; or = 65% predicted, FEV1/FVC &lt; or =70 % predicted.<BR/>Exclusion criteria: history of asthma, allergic rhinitis or atopy, elevated blood eosinophil count, daily use of &gt;10mg oral prednisone and use of cromolyn sodium.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1) ipratropium 42 mcg, 4 x times daily<BR/>2) albuterol 240 mcg, x times daily<BR/>Medication delivered via MDI for 90 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcomes measured beginning and end of trial : pulmonary function tests i.e.<BR/>1) Change in Test Day baseline FEV1, FVC.<BR/>2) Change in Test Day AUC (0-4 hr) FEV1, FVC. <BR/>3) HRQL: CRQ.<BR/>4) COPD symptoms.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Combination study but only subjects treated with beta-2 agonist alone or ipratropium alone were included.<BR/>Unpublished data for all 3 arms, including standard errors obtained from Boehringer Ingelheim. SEs were converted to SDs. Study not described as double-blind but study quality details obtained from author. Allocation concealment details provided by Boehringer Ingelheim.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Tashkin-1986">
<CHAR_METHODS>
<P>RCT: 90 day (two arm) parallel group MDI study.<BR/>Randomisation: unclear<BR/>Blinding: double blind<BR/>Excluded: not described.<BR/>Withdrawals: described.<BR/>Baseline characteristics: comparable<BR/>Power calculation: not given.<BR/>Intention to treat analysis not stated.<BR/>Jadad Score:4</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Setting: USA.<BR/>261 stable subjects with COPD.<BR/>mean age: 61.5 years<BR/>male : female=84% : 16%<BR/>mean baseline FEV1: 1.09 Litres or 36% predicted.</P>
<P>Inclusion criteria: &gt; or = 37 years of age, &gt; or =10 year pack history of smoking, stable disease, FEV1 &lt; or = 75% predicted, FEV1/FVC &lt; or =70 %.<BR/>Subjects had to demonstrate significant reversible airflow obstruction with a bronchodilator (at least 15%).<BR/>Exclusion criteria: history of asthma, allergic rhinitis or atopy, total blood eosinophil count &gt;500/microlitre, recent respiratory tract infection, febrile disease, serious other significant disease (cardiac, renal, hepatic, endocrine, metabolic disease, TB, Prostatic hypertrophy, narrow angle glaucoma, hypersensitivity to test drugs. <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1) 40 mcg ipratropium, 4 times daily.<BR/>2) 1500 mcg metaproterenol 4 times daily.<BR/>Medication was delivered by MDI, for 85 days.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Outcomes measured on Days 1, 45 and 90:<BR/>1) pulmonary function i.e Test Day baseline FEV1, FVC.<BR/>Peak change in FEV1, FVC from test day baseline. <BR/>% change in FEV1, FVC from test day baseline.<BR/>FEV1, FVC AUC (0-6 hr).<BR/>2) Symptoms (wheeze, dyspnoea, cough, chest tightness), medications were recorded in a daily diary card during run-in period and study.<BR/>3) Global evaluations.<BR/>5) 12 lead ECG, BP.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Subjects had to demonstrate significant reversible airflow obstruction with a bronchodilator (at least 15%)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Tashkin-1996">
<CHAR_METHODS>
<P>RCT: 85 day (two arm) parallel group inhalation solution study.<BR/>Randomisation: computer generated<BR/>Blinding: double blind<BR/>Excluded: not described.<BR/>Withdrawals: described.<BR/>Baseline characteristics: comparable<BR/>Power calculation: not given.<BR/>Intention to treat analysis not stated.<BR/>Jadad Score:5</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Setting: USA, multi-centre (8) study.<BR/>213 stable subjects with COPD.<BR/>mean age: 60.6 years<BR/>male : female= 67% : 33%<BR/>mean baseline FEV1: 1.07 Litres or 37.4% predicted.<BR/>range:0.36-2.37 litres or 13-64% predicted.</P>
<P>Inclusion criteria: &gt; or = 40 years of age, &gt; or =10 year pack history of smoking, stable disease, FEV1 &lt; or = 65% predicted, FEV1/FVC &lt; or =70 %.<BR/>Exclusion criteria: history of asthma, allergic rhinitis or atopy, total blood eosinophil count &gt;500/mm3, recent MI (&lt; 1 year), other significant disease, recent respiratory tract infection, narrow angle.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1) 0.5 mg ipratropium 0.167% inhalation solution (0.3 ml), plus 15 mg metaproterenol 0.6% inhalation solution (2.5 ml), three times daily.<BR/>2) placebo (0.3 ml diluent) plus 15 mg metaproterenol 0.6% inhalation solution (2.5 ml), three times daily.<BR/>Medication was delivered by nebuliser, for 85 days.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Outcomes measured on Days 1, 43 and 85:<BR/>1) pulmonary function i.e Test Day baseline FEV1, FVC.<BR/>2) peak change in FEV1, FVC from test day baseline.<BR/>3) % change in FEV1, FVC from test day baseline.<BR/>4) FEV1, FVC AUC (0-8 hr).<BR/>5) HRQL: Chronic Respiratory Disease Questionnaire (CRQ).<BR/>Recorded in a daily diary card during run-in period and study:<BR/>6) daily morning and evening PEFR. <BR/>7) COPD symptoms (wheeze, dyspnoea, cough, chest tightness).<BR/>8) additional medication use.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Testing for reversible airflow obstruction with a bronchodilator was not required.<BR/>Unpublished standard errors obtained from Boehringer Ingelheim and converted to standard deviations. Study quality details provided by Boehringer Ingelheim.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2009-04-27 14:02:00 +0100" MODIFIED_BY="Toby J Lasserson" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Bauer-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison of ipratropium bromide and placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Brown-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Time course study over 5 hours on three separate days.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dejaegher-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Time course study over seven hours, conducted on two days, in patients with reversible airways obstruction.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Disse-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review article.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Heimer-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Time course study over one hour.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hidalgo-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Time course study on one day.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kheir-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Time course study over six hours, on three days.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Khristoliubova-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lees-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Time course study on three separate days.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Leitch-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>Short duration study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lien-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison of ipratropium bromide and placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Matera-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Time course study over 12 hours on four separate days.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nardini-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nishimura-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Treatment given for two weeks only.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-04-27 14:02:00 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Petro-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-04-27 14:02:00 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Short study over 4 weeks not randomised or blinded and measured airways resistance only. Long term study of fenoterol/ipratropium combination over twelve months was uncontrolled, i.e. pre-post study design.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pierce-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study conducted in subjects with reversible airways disease due to asthma.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Shmelev-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Simanenkov-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tang-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study conducted in subjects with reversible airways obstruction on three consecutive days.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2009-04-27 14:01:52 +0100" MODIFIED_BY="Toby J Lasserson">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2009-04-27 14:01:29 +0100" MODIFIED_BY="Toby J Lasserson" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-03 16:31:28 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Campbell-1999">
<DESCRIPTION>
<P>Described as randomised; other information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-03 16:31:53 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Colice-1996">
<DESCRIPTION>
<P>Computer-generated randomisation schedule </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-03 16:32:15 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Combivent-1994">
<DESCRIPTION>
<P>Computer-generated randomisation schedule</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-03 16:32:44 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Combivent-1997">
<DESCRIPTION>
<P>Computer-generated randomisation schedule</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-03 16:32:59 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Friedman-1996">
<DESCRIPTION>
<P>Computer-generated randomisation schedule</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-03 16:33:23 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Gross-1998">
<DESCRIPTION>
<P>Computer-generated randomisation schedule</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-03 16:33:28 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Hodzhev-1999">
<DESCRIPTION>
<P>Computer-generated randomisation schedule</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-03 16:33:34 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Levin--1996">
<DESCRIPTION>
<P>Computer-generated randomisation schedule</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-03 16:33:44 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Rennard-1996">
<DESCRIPTION>
<P>Computer-generated randomisation schedule</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-03 16:36:22 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Tashkin-1986">
<DESCRIPTION>
<P>Described as randomised; other information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-04-27 14:01:29 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Tashkin-1996">
<DESCRIPTION>
<P>Computer generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2009-04-27 14:01:52 +0100" MODIFIED_BY="Toby J Lasserson" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-03 16:31:35 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Campbell-1999">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-03 16:32:36 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Colice-1996">
<DESCRIPTION>
<P>Third party randomisation </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-03 16:32:25 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Combivent-1994">
<DESCRIPTION>
<P>Third party randomisation </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-03 16:32:54 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Combivent-1997">
<DESCRIPTION>
<P>Third party randomisation </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-03 16:34:32 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Friedman-1996">
<DESCRIPTION>
<P>Third party randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-03 16:34:36 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Gross-1998">
<DESCRIPTION>
<P>Third party randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-03 16:34:39 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Hodzhev-1999">
<DESCRIPTION>
<P>Third party randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-03 16:36:09 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Levin--1996">
<DESCRIPTION>
<P>Third party randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-03 16:36:13 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Rennard-1996">
<DESCRIPTION>
<P>Third party randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-03 16:36:31 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Tashkin-1986">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-04-27 14:01:52 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Tashkin-1996">
<DESCRIPTION>
<P>Third party, off site. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-07-03 16:43:08 +0100" MODIFIED_BY="Toby J Lasserson">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2008-07-03 16:43:08 +0100" MODIFIED_BY="Toby J Lasserson" NO="1">
<TITLE>Sensitivty analyses</TITLE>
<TABLE COLS="4" ROWS="10">
<TR>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>Effect size &amp; I2</P>
</TH>
<TH>
<P>Study removed</P>
</TH>
<TH>
<P>Effect size &amp; I2</P>
</TH>
</TR>
<TR>
<TD>
<P>Comparison 01:01; Test day 85 mean baseline FEV1</P>
</TD>
<TD>
<P>0.03 [0, 0.06]; I2: 0%</P>
</TD>
<TD>
<P>Friedman 1996</P>
</TD>
<TD>
<P>0.01 [-0.02, 0.05]; I2: 0%</P>
</TD>
</TR>
<TR>
<TD>
<P>Comparison 01; 07 Wheezing subgroup</P>
</TD>
<TD>
<P>-0.05 [-0.13, 0.03]; I2: 52.9%</P>
</TD>
<TD>
<P>Friedman 1996</P>
</TD>
<TD>
<P>0.01 [-0.08, 0.1]; I2: 0%</P>
</TD>
</TR>
<TR>
<TD>
<P>Comparison 01; 07 Coughing subgroup</P>
</TD>
<TD>
<P>-0.08 [-0.13, 0.04]; I2: 43.8%</P>
</TD>
<TD>
<P>Friedman 1996</P>
</TD>
<TD>
<P>-0.08 [-0.13, -0.03]; I2: 26.1%</P>
</TD>
</TR>
<TR>
<TD>
<P>Comparison 01; 07 Shortness of breath subgroup</P>
</TD>
<TD>
<P>0 [-0.09, 0.08]; I2: 41.5%</P>
</TD>
<TD>
<P>Friedman 1996</P>
</TD>
<TD>
<P>0.02 [-0.07, 0.11]; I2: 35.8%</P>
</TD>
</TR>
<TR>
<TD>
<P>Comparison 01; 07 Tightness of chest subgroup</P>
</TD>
<TD>
<P>0.02 [-0.06, 0.09]; I2: 53.3%</P>
</TD>
<TD>
<P>Friedman 1996</P>
</TD>
<TD>
<P>0.05 [-0.03, 0.13]; I2: 0%</P>
</TD>
</TR>
<TR>
<TD>
<P>Comparison 01:09; CRQ dyspnea domain</P>
</TD>
<TD>
<P>0.16 [0.09, 0.23]; I2: 49.9%</P>
</TD>
<TD>
<P>Friedman 1996</P>
</TD>
<TD>
<P>0.15 [0.08, 0.22]; I2: 48.6%</P>
</TD>
</TR>
<TR>
<TD>
<P>Comparison 01:09; CRQ fatigue domain</P>
</TD>
<TD>
<P>0.16 [0.07, 0.25]; I2: 52.2%</P>
</TD>
<TD>
<P>Friedman 1996</P>
</TD>
<TD>
<P>0.11 [0, 0.22]; I2 42.7%</P>
</TD>
</TR>
<TR>
<TD>
<P>Comparison 01:09; CRQ emotion domain</P>
</TD>
<TD>
<P>0.16 [0.04, 0.29]; I2: 52.3%</P>
</TD>
<TD>
<P>Friedman 1996</P>
</TD>
<TD>
<P>0.09 [-0.05, 0.23]; I2: 19.7%</P>
</TD>
</TR>
<TR>
<TD>
<P>Comparison 01:09; CRQ mastery domain</P>
</TD>
<TD>
<P>0.18 [0.06, 0.3]; I2: 33.5%</P>
</TD>
<TD>
<P>Friedman 1996</P>
</TD>
<TD>
<P>0.11 [-0.03, 0.25]; I2: 0%</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-07-03 16:42:40 +0100" MODIFIED_BY="Toby J Lasserson">
<COMPARISON ID="CMP-001" MODIFIED="2008-07-03 16:42:31 +0100" MODIFIED_BY="Toby J Lasserson" NO="1">
<NAME>Ipratropium bromide versus short acting beta-2 agonist via nebuliser or MDI</NAME>
<CONT_OUTCOME CHI2="3.416390047279597" CI_END="0.06345833501602907" CI_START="-0.004089636264109606" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.02968434937595973" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.01" NO="1" P_CHI2="0.6360749957040042" P_Q="1.0" P_Z="0.08495451975881371" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1086" TOTAL_2="1062" UNITS="" WEIGHT="100.0" Z="1.722635175528714">
<NAME>Test day 85 mean baseline FEV1 (absolute, litres)</NAME>
<GROUP_LABEL_1>ipratropium</GROUP_LABEL_1>
<GROUP_LABEL_2>beta-2 agonist</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours B-2 agonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ipratropium</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.08627273988111014" CI_START="-0.04627273988111011" EFFECT_SIZE="0.020000000000000018" ESTIMABLE="YES" MEAN_1="0.99" MEAN_2="0.97" ORDER="1155" SD_1="0.24" SD_2="0.25" SE="0.03381324371460957" STUDY_ID="STD-Colice-1996" TOTAL_1="103" TOTAL_2="107" WEIGHT="25.971365082924333"/>
<CONT_DATA CI_END="0.09141936934736944" CI_START="-0.09141936934736944" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.95" MEAN_2="0.95" ORDER="1153" SD_1="0.42" SD_2="0.44" SE="0.0466433924645931" STUDY_ID="STD-Combivent-1994" TOTAL_1="176" TOTAL_2="165" WEIGHT="13.648602536530198"/>
<CONT_DATA CI_END="0.07687700080059932" CI_START="-0.07687700080059932" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.91" MEAN_2="0.91" ORDER="1154" SD_1="0.4" SD_2="0.4" SE="0.039223680336473166" STUDY_ID="STD-Combivent-1997" TOTAL_1="209" TOTAL_2="207" WEIGHT="19.300642434697302"/>
<CONT_DATA CI_END="0.14866733135630883" CI_START="0.011332668643691313" EFFECT_SIZE="0.08000000000000007" ESTIMABLE="YES" MEAN_1="1.07" MEAN_2="0.99" ORDER="1156" SD_1="0.26" SD_2="0.24" SE="0.035034996509092975" STUDY_ID="STD-Friedman-1996" TOTAL_1="102" TOTAL_2="102" WEIGHT="24.191583103213983"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.0" MEAN_2="0.0" ORDER="1157" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Gross-1998" TOTAL_1="184" TOTAL_2="195" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.2772397047953502" CI_START="-0.11723970479535009" EFFECT_SIZE="0.08000000000000007" ESTIMABLE="YES" MEAN_1="0.92" MEAN_2="0.84" ORDER="1158" SD_1="0.28" SD_2="0.38" SE="0.10063435162643385" STUDY_ID="STD-Hodzhev-1999" TOTAL_1="22" TOTAL_2="22" WEIGHT="2.932080847128023"/>
<CONT_DATA CI_END="0.11040784084864791" CI_START="-0.07040784084864787" EFFECT_SIZE="0.020000000000000018" ESTIMABLE="YES" MEAN_1="0.88" MEAN_2="0.86" ORDER="1159" SD_1="0.42" SD_2="0.45" SE="0.046127297012482575" STUDY_ID="STD-Rennard-1996" TOTAL_1="183" TOTAL_2="174" WEIGHT="13.955725995506155"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="1.04" MEAN_2="1.1" ORDER="1160" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Tashkin-1986" TOTAL_1="107" TOTAL_2="90" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.1035034865764812" CI_END="0.01375683379375987" CI_START="-0.023716994844248777" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.004980080525244453" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" NO="2" P_CHI2="0.5406563140930496" P_Q="1.0" P_Z="0.6024096748176504" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="967" TOTAL_2="950" UNITS="" WEIGHT="100.0" Z="0.5209384161877905">
<NAME>Test day 85 mean peak FEV1 response (change from day 85 baseline, litres)</NAME>
<GROUP_LABEL_1>ipratropium</GROUP_LABEL_1>
<GROUP_LABEL_2>beta-2 agonist</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours B-2 agonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ipratropium</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.04328796999040048" CI_START="-0.04328796999040048" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.29" MEAN_2="0.29" ORDER="1163" SD_1="0.16" SD_2="0.16" SE="0.022086104812052906" STUDY_ID="STD-Colice-1996" TOTAL_1="103" TOTAL_2="107" WEIGHT="18.735345310508567"/>
<CONT_DATA CI_END="0.05035344117277228" CI_START="-0.030353441172772264" EFFECT_SIZE="0.010000000000000009" ESTIMABLE="YES" MEAN_1="0.3" MEAN_2="0.29" ORDER="1161" SD_1="0.19" SD_2="0.19" SE="0.020588868719565803" STUDY_ID="STD-Combivent-1994" TOTAL_1="176" TOTAL_2="165" WEIGHT="21.559316627139527"/>
<CONT_DATA CI_END="0.016516575380284712" CI_START="-0.05651657538028464" EFFECT_SIZE="-0.019999999999999962" ESTIMABLE="YES" MEAN_1="0.27" MEAN_2="0.29" ORDER="1162" SD_1="0.19" SD_2="0.19" SE="0.01863124815982475" STUDY_ID="STD-Combivent-1997" TOTAL_1="209" TOTAL_2="207" WEIGHT="26.32789023568442"/>
<CONT_DATA CI_END="0.09044131050662405" CI_START="-0.030441310506623992" EFFECT_SIZE="0.030000000000000027" ESTIMABLE="YES" MEAN_1="0.34" MEAN_2="0.31" ORDER="1164" SD_1="0.23" SD_2="0.21" SE="0.030837969974641045" STUDY_ID="STD-Friedman-1996" TOTAL_1="102" TOTAL_2="102" WEIGHT="9.61011084902393"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.0" MEAN_2="0.0" ORDER="1165" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Gross-1998" TOTAL_1="194" TOTAL_2="195" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.018433311775248637" CI_START="-0.05843331177524867" EFFECT_SIZE="-0.020000000000000018" ESTIMABLE="YES" MEAN_1="0.25" MEAN_2="0.27" ORDER="1166" SD_1="0.18" SD_2="0.19" SE="0.019609192861912622" STUDY_ID="STD-Rennard-1996" TOTAL_1="183" TOTAL_2="174" WEIGHT="23.767336977643556"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.258128574393886" CI_END="0.21714045928243558" CI_START="-0.01712324302196859" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.10000860813023349" ESTIMABLE="YES" I2="6.062019262314762" I2_Q="0.0" ID="CMP-001.03" NO="3" P_CHI2="0.37219770181304224" P_Q="1.0" P_Z="0.09424046527420686" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1064" TOTAL_2="1040" UNITS="" WEIGHT="99.99999999999999" Z="1.6734412386647595">
<NAME>Test day 85 mean FEV1 AUC (absolute, litres)</NAME>
<GROUP_LABEL_1>ipratropium</GROUP_LABEL_1>
<GROUP_LABEL_2>beta-2 agonist</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours B-2 agonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ipratropium</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.2933202297054388" CI_START="-0.25332022970543877" EFFECT_SIZE="0.020000000000000018" ESTIMABLE="YES" MEAN_1="1.02" MEAN_2="1.0" ORDER="1169" SD_1="1.02" SD_2="1.0" SE="0.13945165924545241" STUDY_ID="STD-Colice-1996" TOTAL_1="103" TOTAL_2="107" WEIGHT="18.36565660564955"/>
<CONT_DATA CI_END="0.4386655115624923" CI_START="-0.05866551156249217" EFFECT_SIZE="0.19000000000000006" ESTIMABLE="YES" MEAN_1="1.03" MEAN_2="0.84" ORDER="1167" SD_1="1.15" SD_2="1.19" SE="0.12687249027223665" STUDY_ID="STD-Combivent-1994" TOTAL_1="176" TOTAL_2="165" WEIGHT="22.188038108989897"/>
<CONT_DATA CI_END="0.4171767913293204" CI_START="-0.017176791329320457" EFFECT_SIZE="0.19999999999999996" ESTIMABLE="YES" MEAN_1="0.97" MEAN_2="0.77" ORDER="1168" SD_1="1.14" SD_2="1.12" SE="0.11080652146793676" STUDY_ID="STD-Combivent-1997" TOTAL_1="209" TOTAL_2="207" WEIGHT="29.088624745561166"/>
<CONT_DATA CI_END="0.6470363872506746" CI_START="-0.20703638725067464" EFFECT_SIZE="0.21999999999999997" ESTIMABLE="YES" MEAN_1="1.24" MEAN_2="1.02" ORDER="1170" SD_1="1.61" SD_2="1.5" SE="0.2178797113717819" STUDY_ID="STD-Friedman-1996" TOTAL_1="102" TOTAL_2="102" WEIGHT="7.523505611845121"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.0" MEAN_2="0.0" ORDER="1171" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Gross-1998" TOTAL_1="184" TOTAL_2="195" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.15512203024236562" CI_START="-0.33512203024236553" EFFECT_SIZE="-0.08999999999999997" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="0.89" ORDER="1172" SD_1="1.15" SD_2="1.21" SE="0.1250645584183469" STUDY_ID="STD-Rennard-1996" TOTAL_1="183" TOTAL_2="174" WEIGHT="22.83417492795426"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.0" MEAN_2="0.0" ORDER="1173" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Tashkin-1986" TOTAL_1="107" TOTAL_2="90" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.4782938120221845" CI_END="0.1368635651822579" CI_START="0.011537443898036487" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.07420050454014719" ESTIMABLE="YES" I2="8.730707560309428" I2_Q="0.0" ID="CMP-001.04" NO="4" P_CHI2="0.36033200487785333" P_Q="1.0" P_Z="0.020296015957009972" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1086" TOTAL_2="1062" UNITS="" WEIGHT="100.0" Z="2.32083008782462">
<NAME>Test day 85 mean baseline FVC (absolute, litres)</NAME>
<GROUP_LABEL_1>ipratropium</GROUP_LABEL_1>
<GROUP_LABEL_2>beta-2 agonist</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours B-2 agonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ipratropium</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.19501738933916052" CI_START="-0.03501738933916036" EFFECT_SIZE="0.08000000000000007" ESTIMABLE="YES" MEAN_1="2.11" MEAN_2="2.03" ORDER="1176" SD_1="0.43" SD_2="0.42" SE="0.05868341982118188" STUDY_ID="STD-Colice-1996" TOTAL_1="103" TOTAL_2="107" WEIGHT="29.68220737351734"/>
<CONT_DATA CI_END="0.1621146940261184" CI_START="-0.18211469402611796" EFFECT_SIZE="-0.009999999999999787" ESTIMABLE="YES" MEAN_1="2.2" MEAN_2="2.21" ORDER="1174" SD_1="0.8" SD_2="0.82" SE="0.08781523302659483" STUDY_ID="STD-Combivent-1994" TOTAL_1="176" TOTAL_2="165" WEIGHT="13.255231231978895"/>
<CONT_DATA CI_END="0.15414437650112395" CI_START="-0.13414437650112349" EFFECT_SIZE="0.010000000000000231" ESTIMABLE="YES" MEAN_1="2.12" MEAN_2="2.11" ORDER="1175" SD_1="0.75" SD_2="0.75" SE="0.07354440063088719" STUDY_ID="STD-Combivent-1997" TOTAL_1="209" TOTAL_2="207" WEIGHT="18.89852017423607"/>
<CONT_DATA CI_END="0.30865830225400936" CI_START="0.03134169774599052" EFFECT_SIZE="0.16999999999999993" ESTIMABLE="YES" MEAN_1="2.52" MEAN_2="2.35" ORDER="1177" SD_1="0.52" SD_2="0.49" SE="0.07074533172432167" STUDY_ID="STD-Friedman-1996" TOTAL_1="102" TOTAL_2="102" WEIGHT="20.423560198214876"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.0" MEAN_2="0.0" ORDER="1178" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Gross-1998" TOTAL_1="184" TOTAL_2="195" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.7055448338731978" CI_START="-0.045544833873197244" EFFECT_SIZE="0.3300000000000003" ESTIMABLE="YES" MEAN_1="2.22" MEAN_2="1.89" ORDER="1179" SD_1="0.61" SD_2="0.66" SE="0.19160802792063897" STUDY_ID="STD-Hodzhev-1999" TOTAL_1="22" TOTAL_2="22" WEIGHT="2.784194828041756"/>
<CONT_DATA CI_END="0.20203159972203008" CI_START="-0.12203159972203001" EFFECT_SIZE="0.040000000000000036" ESTIMABLE="YES" MEAN_1="2.05" MEAN_2="2.01" ORDER="1180" SD_1="0.76" SD_2="0.8" SE="0.08267070262520874" STUDY_ID="STD-Rennard-1996" TOTAL_1="183" TOTAL_2="174" WEIGHT="14.956286194011062"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="2.38" MEAN_2="2.3" ORDER="1181" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Tashkin-1986" TOTAL_1="107" TOTAL_2="90" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.6544363707080925" CI_END="0.030209361741622177" CI_START="-0.05512933382532815" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.012459986041852986" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.05" NO="5" P_CHI2="0.7989767217351639" P_Q="1.0" P_Z="0.5670956368937438" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="957" TOTAL_2="950" UNITS="" WEIGHT="99.99999999999999" Z="0.572334126451339">
<NAME>Test day peak FVC</NAME>
<GROUP_LABEL_1>ipratropium</GROUP_LABEL_1>
<GROUP_LABEL_2>beta-2 agonist</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours B-2 agonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ipratropium</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.10231208278124351" CI_START="-0.12231208278124353" EFFECT_SIZE="-0.010000000000000009" ESTIMABLE="YES" MEAN_1="0.66" MEAN_2="0.67" ORDER="1184" SD_1="0.42" SD_2="0.41" SE="0.05730313601022616" STUDY_ID="STD-Colice-1996" TOTAL_1="103" TOTAL_2="107" WEIGHT="14.433745614165705"/>
<CONT_DATA CI_END="0.0904231241780669" CI_START="-0.0904231241780669" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.69" MEAN_2="0.69" ORDER="1182" SD_1="0.41" SD_2="0.44" SE="0.04613509477281877" STUDY_ID="STD-Combivent-1994" TOTAL_1="176" TOTAL_2="165" WEIGHT="22.267578545062072"/>
<CONT_DATA CI_END="0.0249550757805843" CI_START="-0.12495507578058439" EFFECT_SIZE="-0.050000000000000044" ESTIMABLE="YES" MEAN_1="0.61" MEAN_2="0.66" ORDER="1183" SD_1="0.39" SD_2="0.39" SE="0.038243088328061337" STUDY_ID="STD-Combivent-1997" TOTAL_1="209" TOTAL_2="207" WEIGHT="32.40633475887927"/>
<CONT_DATA CI_END="0.1617645150072582" CI_START="-0.10176451500725814" EFFECT_SIZE="0.030000000000000027" ESTIMABLE="YES" MEAN_1="0.75" MEAN_2="0.72" ORDER="1185" SD_1="0.49" SD_2="0.47" SE="0.06722802870185363" STUDY_ID="STD-Friedman-1996" TOTAL_1="102" TOTAL_2="102" WEIGHT="10.486608954069666"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.0" MEAN_2="0.0" ORDER="1186" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Gross-1998" TOTAL_1="184" TOTAL_2="195" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.10445825406086276" CI_START="-0.08445825406086274" EFFECT_SIZE="0.010000000000000009" ESTIMABLE="YES" MEAN_1="0.67" MEAN_2="0.66" ORDER="1187" SD_1="0.45" SD_2="0.46" SE="0.048193872339460014" STUDY_ID="STD-Rennard-1996" TOTAL_1="183" TOTAL_2="174" WEIGHT="20.405732127823285"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.8941419547629743" CI_END="0.5518898982244012" CI_START="0.006135633828001474" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.27901276602620134" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.06" NO="6" P_CHI2="0.7552211134790353" P_Q="1.0" P_Z="0.045066449105703045" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1064" TOTAL_2="1040" UNITS="" WEIGHT="100.0" Z="2.0040337137560367">
<NAME>Test day FVC AUC</NAME>
<GROUP_LABEL_1>ipratropium</GROUP_LABEL_1>
<GROUP_LABEL_2>beta-2 agonist</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours B-2 agonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ipratropium</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.966514876826968" CI_START="-0.4865148768269676" EFFECT_SIZE="0.2400000000000002" ESTIMABLE="YES" MEAN_1="2.41" MEAN_2="2.17" ORDER="1190" SD_1="2.7" SD_2="2.67" SE="0.37067766681307635" STUDY_ID="STD-Colice-1996" TOTAL_1="103" TOTAL_2="107" WEIGHT="14.107344142206319"/>
<CONT_DATA CI_END="1.1376790238685084" CI_START="0.06232097613149168" EFFECT_SIZE="0.6000000000000001" ESTIMABLE="YES" MEAN_1="2.43" MEAN_2="1.83" ORDER="1188" SD_1="2.49" SD_2="2.57" SE="0.2743310734838252" STUDY_ID="STD-Combivent-1994" TOTAL_1="176" TOTAL_2="165" WEIGHT="25.75657408774378"/>
<CONT_DATA CI_END="0.6414369888489488" CI_START="-0.32143698884894906" EFFECT_SIZE="0.15999999999999992" ESTIMABLE="YES" MEAN_1="2.13" MEAN_2="1.97" ORDER="1189" SD_1="2.52" SD_2="2.49" SE="0.2456356303720183" STUDY_ID="STD-Combivent-1997" TOTAL_1="209" TOTAL_2="207" WEIGHT="32.12590540186774"/>
<CONT_DATA CI_END="1.042028199918331" CI_START="-0.7620281999183308" EFFECT_SIZE="0.14000000000000012" ESTIMABLE="YES" MEAN_1="2.56" MEAN_2="2.42" ORDER="1191" SD_1="3.39" SD_2="3.18" SE="0.46022692612385446" STUDY_ID="STD-Friedman-1996" TOTAL_1="102" TOTAL_2="102" WEIGHT="9.151537304899016"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.0" MEAN_2="0.0" ORDER="1192" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Gross-1998" TOTAL_1="184" TOTAL_2="195" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.7683649726754894" CI_START="-0.4883649726754892" EFFECT_SIZE="0.14000000000000012" ESTIMABLE="YES" MEAN_1="2.39" MEAN_2="2.25" ORDER="1193" SD_1="2.95" SD_2="3.1" SE="0.3206002649191271" STUDY_ID="STD-Rennard-1996" TOTAL_1="183" TOTAL_2="174" WEIGHT="18.85863906328314"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.0" MEAN_2="0.0" ORDER="1194" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Tashkin-1986" TOTAL_1="107" TOTAL_2="90" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="36.288268997989086" CI_END="-0.008730079437657051" CI_START="-0.0778512760170849" CI_STUDY="95" CI_TOTAL="95" DF="19.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.043290677727370976" ESTIMABLE="YES" I2="47.641481600974444" I2_Q="45.90497895033768" ID="CMP-001.07" NO="7" P_CHI2="0.009727169336121388" P_Q="0.13592507694963485" P_Z="0.01408630394677331" Q="5.545796899211535" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="3104" TOTAL_2="3028" UNITS="" WEIGHT="400.00000000000006" Z="2.4550549877844645">
<NAME>Symptom scores</NAME>
<GROUP_LABEL_1>ipratropium</GROUP_LABEL_1>
<GROUP_LABEL_2>beta-2 agonist</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ipratropium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours B-2 agonist</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="7.87677551000574" CI_END="0.038739849418759346" CI_START="-0.1285745085742395" DF="4.0" EFFECT_SIZE="-0.04491732957774008" ESTIMABLE="YES" I2="49.217798642111035" ID="CMP-001.07.01" NO="1" P_CHI2="0.096197835710927" P_Z="0.2926405722820692" STUDIES="5" TAU2="0.0" TOTAL_1="776" TOTAL_2="757" WEIGHT="100.00000000000003" Z="1.0523466044410856">
<NAME>wheezing</NAME>
<CONT_DATA CI_END="0.4110925115015917" CI_START="-0.21109251150159153" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="1.9" ORDER="1197" SD_1="1.14" SD_2="1.16" SE="0.15872358571659972" STUDY_ID="STD-Colice-1996" TOTAL_1="103" TOTAL_2="107" WEIGHT="7.231482127121749"/>
<CONT_DATA CI_END="0.13587545178632623" CI_START="-0.13587545178632623" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="1.1" MEAN_2="1.1" ORDER="1195" SD_1="0.65" SD_2="0.63" SE="0.06932548396710064" STUDY_ID="STD-Combivent-1994" TOTAL_1="176" TOTAL_2="165" WEIGHT="37.907437625741565"/>
<CONT_DATA CI_END="0.338258803522637" CI_START="-0.338258803522637" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.9" MEAN_2="0.9" ORDER="1196" SD_1="1.76" SD_2="1.76" SE="0.1725841934804819" STUDY_ID="STD-Combivent-1997" TOTAL_1="209" TOTAL_2="207" WEIGHT="6.116573721888796"/>
<CONT_DATA CI_END="-0.09934885856769046" CI_START="-0.50065114143231" EFFECT_SIZE="-0.30000000000000027" ESTIMABLE="YES" MEAN_1="1.9" MEAN_2="2.2" ORDER="1198" SD_1="0.74" SD_2="0.74" SE="0.10237491250605643" STUDY_ID="STD-Friedman-1996" TOTAL_1="105" TOTAL_2="104" WEIGHT="17.38293723495393"/>
<CONT_DATA CI_END="0.14938408200814157" CI_START="-0.14938408200814157" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.9" MEAN_2="0.9" ORDER="1199" SD_1="0.73" SD_2="0.71" SE="0.07621776889088991" STUDY_ID="STD-Rennard-1996" TOTAL_1="183" TOTAL_2="174" WEIGHT="31.36156929029398"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="7.0208679810021595" CI_END="-0.03241304411291324" CI_START="-0.13371206230730243" DF="4.0" EFFECT_SIZE="-0.08306255321010783" ESTIMABLE="YES" I2="43.02698739210533" ID="CMP-001.07.02" NO="2" P_CHI2="0.13478974329660076" P_Z="0.001307908914571265" STUDIES="5" TAU2="0.0" TOTAL_1="776" TOTAL_2="757" WEIGHT="100.0" Z="3.2142387094679754">
<NAME>coughing</NAME>
<CONT_DATA CI_END="0.2705118039631868" CI_START="-0.2705118039631868" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="2.2" MEAN_2="2.2" ORDER="1202" SD_1="0.99" SD_2="1.01" SE="0.13801876263898183" STUDY_ID="STD-Colice-1996" TOTAL_1="103" TOTAL_2="107" WEIGHT="3.5057265666904995"/>
<CONT_DATA CI_END="-0.04161831070838076" CI_START="-0.15838168929161897" EFFECT_SIZE="-0.09999999999999987" ESTIMABLE="YES" MEAN_1="1.1" MEAN_2="1.2" ORDER="1200" SD_1="0.28" SD_2="0.27" SE="0.02978712351457803" STUDY_ID="STD-Combivent-1994" TOTAL_1="176" TOTAL_2="165" WEIGHT="75.26571062280199"/>
<CONT_DATA CI_END="0.34408447754190286" CI_START="-0.14408447754190287" EFFECT_SIZE="0.09999999999999998" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="0.9" ORDER="1201" SD_1="1.27" SD_2="1.27" SE="0.1245351850683023" STUDY_ID="STD-Combivent-1997" TOTAL_1="209" TOTAL_2="207" WEIGHT="4.305961653554823"/>
<CONT_DATA CI_END="-0.047830322253988866" CI_START="-0.5521696777460108" EFFECT_SIZE="-0.2999999999999998" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="2.4" ORDER="1203" SD_1="0.93" SD_2="0.93" SE="0.12866036301436823" STUDY_ID="STD-Friedman-1996" TOTAL_1="105" TOTAL_2="104" WEIGHT="4.034268080286928"/>
<CONT_DATA CI_END="0.1410837078392868" CI_START="-0.1410837078392868" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="1.0" ORDER="1204" SD_1="0.69" SD_2="0.67" SE="0.07198280629243041" STUDY_ID="STD-Rennard-1996" TOTAL_1="183" TOTAL_2="174" WEIGHT="12.888333076665761"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="6.761997498792031" CI_END="0.08690669309372452" CI_START="-0.08507674874189626" DF="4.0" EFFECT_SIZE="9.14972175914134E-4" ESTIMABLE="YES" I2="40.84588169820288" ID="CMP-001.07.03" NO="3" P_CHI2="0.1490130714228377" P_Z="0.9833617394567712" STUDIES="5" TAU2="0.0" TOTAL_1="776" TOTAL_2="757" WEIGHT="100.00000000000001" Z="0.020854478692919412">
<NAME>shortness of breath</NAME>
<CONT_DATA CI_END="0.07718952246587762" CI_START="-0.2771895224658778" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="2.4" MEAN_2="2.5" ORDER="1207" SD_1="0.65" SD_2="0.66" SE="0.09040447878814409" STUDY_ID="STD-Colice-1996" TOTAL_1="103" TOTAL_2="107" WEIGHT="23.55251046292369"/>
<CONT_DATA CI_END="0.23587545178632632" CI_START="-0.035875451786326146" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" MEAN_1="1.6" MEAN_2="1.5" ORDER="1205" SD_1="0.65" SD_2="0.63" SE="0.06932548396710064" STUDY_ID="STD-Combivent-1994" TOTAL_1="176" TOTAL_2="165" WEIGHT="40.052652119389734"/>
<CONT_DATA CI_END="0.16041799317796118" CI_START="-0.36041799317796136" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="1.4" MEAN_2="1.5" ORDER="1206" SD_1="1.36" SD_2="1.35" SE="0.13286876454470856" STUDY_ID="STD-Combivent-1997" TOTAL_1="209" TOTAL_2="207" WEIGHT="10.90363500225212"/>
<CONT_DATA CI_END="0.0711501911247428" CI_START="-0.47115019112474316" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" MEAN_1="2.4" MEAN_2="2.6" ORDER="1208" SD_1="1.0" SD_2="1.0" SE="0.13834447635953573" STUDY_ID="STD-Friedman-1996" TOTAL_1="105" TOTAL_2="104" WEIGHT="10.05757896457809"/>
<CONT_DATA CI_END="0.31888837157637945" CI_START="-0.11888837157637927" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="1.4" ORDER="1209" SD_1="1.07" SD_2="1.04" SE="0.11167979274259267" STUDY_ID="STD-Rennard-1996" TOTAL_1="183" TOTAL_2="174" WEIGHT="15.433623450856388"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="9.082831108977624" CI_END="0.09120662447321837" CI_START="-0.06250882657671264" DF="4.0" EFFECT_SIZE="0.014348898948252871" ESTIMABLE="YES" I2="55.96086779543515" ID="CMP-001.07.04" NO="4" P_CHI2="0.05906219383635036" P_Z="0.7144291783917347" STUDIES="5" TAU2="0.0" TOTAL_1="776" TOTAL_2="757" WEIGHT="99.99999999999999" Z="0.36591409600385666">
<NAME>tightness of chest</NAME>
<CONT_DATA CI_END="0.4260579756887847" CI_START="-0.4260579756887847" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="1.7" MEAN_2="1.7" ORDER="1212" SD_1="1.56" SD_2="1.59" SE="0.21738051262649496" STUDY_ID="STD-Colice-1996" TOTAL_1="103" TOTAL_2="107" WEIGHT="3.254150668097267"/>
<CONT_DATA CI_END="0.17197768088699325" CI_START="-0.17197768088699325" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.9" MEAN_2="0.9" ORDER="1210" SD_1="0.82" SD_2="0.8" SE="0.08774532707923781" STUDY_ID="STD-Combivent-1994" TOTAL_1="176" TOTAL_2="165" WEIGHT="19.972428716514006"/>
<CONT_DATA CI_END="0.1720103535212026" CI_START="-0.1720103535212026" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.7" MEAN_2="0.7" ORDER="1211" SD_1="0.9" SD_2="0.89" SE="0.0877619970968846" STUDY_ID="STD-Combivent-1997" TOTAL_1="209" TOTAL_2="207" WEIGHT="19.964842081527838"/>
<CONT_DATA CI_END="-0.06409933372147339" CI_START="-0.5359006662785263" EFFECT_SIZE="-0.2999999999999998" ESTIMABLE="YES" MEAN_1="1.6" MEAN_2="1.9" ORDER="1213" SD_1="0.87" SD_2="0.87" SE="0.1203596944327961" STUDY_ID="STD-Friedman-1996" TOTAL_1="105" TOTAL_2="104" WEIGHT="10.61491989640202"/>
<CONT_DATA CI_END="0.21308274647036107" CI_START="-0.01308274647036091" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="0.7" ORDER="1214" SD_1="0.55" SD_2="0.54" SE="0.057696338995177086" STUDY_ID="STD-Rennard-1996" TOTAL_1="183" TOTAL_2="174" WEIGHT="46.19365863745887"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="10.689612973121655" CI_END="0.9667544084021039" CI_START="0.5284703215713406" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.7147733998189711" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="111" I2="62.58049744122876" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="-0.01468383886664498" LOG_CI_START="-0.27697939726802895" LOG_EFFECT_SIZE="-0.14583161806733705" METHOD="PETO" NO="8" P_CHI2="0.030283023545583654" P_Q="1.0" P_Z="0.029301259150133267" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="928" TOTAL_2="930" WEIGHT="100.00000000000001" Z="2.1794095253552945">
<NAME>Number of subjects with medication related adverse events</NAME>
<GROUP_LABEL_1>ipratropium</GROUP_LABEL_1>
<GROUP_LABEL_2>beta-2 agonist</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ipratropium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours B-2 agonist</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.585273539065698" CI_START="0.5687008953064787" EFFECT_SIZE="1.2125375772646432" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="14" LOG_CI_END="0.41250650109412657" LOG_CI_START="-0.24511608803698795" LOG_EFFECT_SIZE="0.08369520652856921" ORDER="1217" O_E="1.2914798206278029" SE="0.3862907641399334" STUDY_ID="STD-Colice-1996" TOTAL_1="113" TOTAL_2="110" VAR="6.701489641424086" WEIGHT="15.908470525926514"/>
<DICH_DATA CI_END="2.040026974717671" CI_START="0.5630121907170543" EFFECT_SIZE="1.0717089419043218" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="20" LOG_CI_END="0.3096359100207925" LOG_CI_START="-0.24948220141183636" LOG_EFFECT_SIZE="0.03007685430447807" ORDER="1215" O_E="0.6420454545454533" SE="0.32842874633481434" STUDY_ID="STD-Combivent-1994" TOTAL_1="179" TOTAL_2="173" VAR="9.270809879829766" WEIGHT="22.007704796421844"/>
<DICH_DATA CI_END="1.3186091312457493" CI_START="0.36450089060653" EFFECT_SIZE="0.6932778683190302" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="24" LOG_CI_END="0.12011607886704298" LOG_CI_START="-0.438301406207381" LOG_EFFECT_SIZE="-0.159092663670169" ORDER="1216" O_E="-3.404651162790696" SE="0.3280171949438484" STUDY_ID="STD-Combivent-1997" TOTAL_1="214" TOTAL_2="216" VAR="9.294087978003608" WEIGHT="22.06296399378136"/>
<DICH_DATA CI_END="0.5462963286605889" CI_START="0.13073062486654763" EFFECT_SIZE="0.2672408284826622" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="28" LOG_CI_END="-0.26257171811584973" LOG_CI_START="-0.8836226629735499" LOG_EFFECT_SIZE="-0.5730971905446998" ORDER="1218" O_E="-9.91549295774648" SE="0.364808399261171" STUDY_ID="STD-Friedman-1996" TOTAL_1="106" TOTAL_2="107" VAR="7.513985320372943" WEIGHT="17.83723028720458"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1219" O_E="0.0" SE="0.0" STUDY_ID="STD-Gross-1998" TOTAL_1="184" TOTAL_2="195" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.4133332621476993" CI_START="0.39205581838383247" EFFECT_SIZE="0.7443826494084933" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="25" LOG_CI_END="0.15024457999887528" LOG_CI_START="-0.40665209652463796" LOG_EFFECT_SIZE="-0.12820375826288138" ORDER="1220" O_E="-2.758620689655171" SE="0.3271238644729197" STUDY_ID="STD-Tashkin-1986" TOTAL_1="132" TOTAL_2="129" VAR="9.344919052410134" WEIGHT="22.18363039666571"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="28.446444639472176" CI_END="0.20500272354240426" CI_START="0.1080738880522539" CI_STUDY="95" CI_TOTAL="95" DF="19.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.15653830579732908" ESTIMABLE="YES" I2="33.20782178298769" I2_Q="0.0" ID="CMP-001.09" MODIFIED="2008-07-03 16:42:31 +0100" MODIFIED_BY="Toby J Lasserson" NO="9" P_CHI2="0.07520561381824253" P_Q="0.934031704647288" P_Z="2.4419013475162066E-10" Q="0.42974458558816764" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="3096" TOTAL_2="3020" UNITS="" WEIGHT="400.0" Z="6.330612351055423">
<NAME>HRQL- Chronic Respiratory Disease Questionnaire: absolute scores</NAME>
<GROUP_LABEL_1>ipratropium</GROUP_LABEL_1>
<GROUP_LABEL_2>beta-2 agonist</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours B-2 agonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ipratropium</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="7.769038629540027" CI_END="0.22776958349336318" CI_START="0.08558945419859935" DF="4.0" EFFECT_SIZE="0.15667951884598127" ESTIMABLE="YES" I2="48.513578182107416" ID="CMP-001.09.01" MODIFIED="2008-07-03 16:42:31 +0100" MODIFIED_BY="Toby J Lasserson" NO="1" P_CHI2="0.10041468582452207" P_Z="1.5625677320820087E-5" STUDIES="5" TAU2="0.0" TOTAL_1="774" TOTAL_2="755" WEIGHT="100.0" Z="4.319678362600803">
<NAME>CRQ- DYSPNOEA DOMAIN</NAME>
<CONT_DATA CI_END="0.411367976640443" CI_START="-0.2113679766404437" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" MEAN_1="3.8" MEAN_2="3.7" ORDER="1223" SD_1="1.13" SD_2="1.15" SE="0.15886413173735547" STUDY_ID="STD-Colice-1996" TOTAL_1="101" TOTAL_2="105" WEIGHT="5.212786396904019"/>
<CONT_DATA CI_END="0.2496636133465256" CI_START="-0.049663613346525415" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="3.9" ORDER="1221" SD_1="0.72" SD_2="0.69" SE="0.07636038954136555" STUDY_ID="STD-Combivent-1994" TOTAL_1="176" TOTAL_2="165" WEIGHT="22.562403712432264"/>
<CONT_DATA CI_END="0.14696461462140986" CI_START="-0.34696461462141004" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="3.8" MEAN_2="3.9" ORDER="1222" SD_1="1.29" SD_2="1.28" SE="0.1260046697640545" STUDY_ID="STD-Combivent-1997" TOTAL_1="209" TOTAL_2="207" WEIGHT="8.286065372788634"/>
<CONT_DATA CI_END="0.7294437849601579" CI_START="0.070556215039841" EFFECT_SIZE="0.39999999999999947" ESTIMABLE="YES" MEAN_1="4.1" MEAN_2="3.7" ORDER="1224" SD_1="1.22" SD_2="1.21" SE="0.16808665238686477" STUDY_ID="STD-Friedman-1996" TOTAL_1="105" TOTAL_2="104" WEIGHT="4.656452536841817"/>
<CONT_DATA CI_END="0.2923307612252304" CI_START="0.1076692387747691" EFFECT_SIZE="0.19999999999999973" ESTIMABLE="YES" MEAN_1="3.8" MEAN_2="3.6" ORDER="1225" SD_1="0.45" SD_2="0.44" SE="0.04710839686520971" STUDY_ID="STD-Rennard-1996" TOTAL_1="183" TOTAL_2="174" WEIGHT="59.28229198103327"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="6.457448916213366" CI_END="0.23414352344484668" CI_START="0.02445119905356917" DF="4.0" EFFECT_SIZE="0.12929736124920793" ESTIMABLE="YES" I2="38.05603339800648" ID="CMP-001.09.02" MODIFIED="2008-07-03 16:42:31 +0100" MODIFIED_BY="Toby J Lasserson" NO="2" P_CHI2="0.1674913295222309" P_Z="0.015646968089504713" STUDIES="5" TAU2="0.0" TOTAL_1="774" TOTAL_2="755" WEIGHT="100.00000000000001" Z="2.4170476633340585">
<NAME>CRQ- FATIGUE DOMAIN</NAME>
<CONT_DATA CI_END="0.45780461224923613" CI_START="-0.25780461224923684" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" MEAN_1="4.1" MEAN_2="4.0" ORDER="1228" SD_1="1.3" SD_2="1.32" SE="0.18255672811926832" STUDY_ID="STD-Colice-1996" TOTAL_1="101" TOTAL_2="105" WEIGHT="8.586441338486052"/>
<CONT_DATA CI_END="0.49041235570325037" CI_START="-0.49041235570325037" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="4.0" ORDER="1226" SD_1="2.35" SD_2="2.27" SE="0.2502149833219184" STUDY_ID="STD-Combivent-1994" TOTAL_1="176" TOTAL_2="165" WEIGHT="4.5706952865606985"/>
<CONT_DATA CI_END="0.12486522734175334" CI_START="-0.3248652273417526" EFFECT_SIZE="-0.09999999999999964" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="4.1" ORDER="1227" SD_1="1.17" SD_2="1.17" SE="0.114729264984184" STUDY_ID="STD-Combivent-1997" TOTAL_1="209" TOTAL_2="207" WEIGHT="21.740046648516635"/>
<CONT_DATA CI_END="0.5996175416365039" CI_START="3.8245836349570794E-4" EFFECT_SIZE="0.2999999999999998" ESTIMABLE="YES" MEAN_1="4.1" MEAN_2="3.8" ORDER="1229" SD_1="1.11" SD_2="1.1" SE="0.15286890167362718" STUDY_ID="STD-Friedman-1996" TOTAL_1="105" TOTAL_2="104" WEIGHT="12.245333106365132"/>
<CONT_DATA CI_END="0.3442113014400423" CI_START="0.05578869855995802" EFFECT_SIZE="0.20000000000000018" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="3.8" ORDER="1230" SD_1="0.7" SD_2="0.69" SE="0.07357854663532723" STUDY_ID="STD-Rennard-1996" TOTAL_1="183" TOTAL_2="174" WEIGHT="52.8574836200715"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="8.076987729906756" CI_END="0.29441787823481486" CI_START="0.050512508155284755" DF="4.0" EFFECT_SIZE="0.1724651931950498" ESTIMABLE="YES" I2="50.47658689403287" ID="CMP-001.09.03" MODIFIED="2008-07-03 16:42:31 +0100" MODIFIED_BY="Toby J Lasserson" NO="3" P_CHI2="0.08879845820488985" P_Z="0.005575132810974907" STUDIES="5" TAU2="0.0" TOTAL_1="774" TOTAL_2="755" WEIGHT="100.0" Z="2.771776342102023">
<NAME>CRQ- EMOTION DOMAIN</NAME>
<CONT_DATA CI_END="0.3884511689124007" CI_START="0.011548831087599631" EFFECT_SIZE="0.20000000000000018" ESTIMABLE="YES" MEAN_1="4.7" MEAN_2="4.5" ORDER="1233" SD_1="0.68" SD_2="0.7" SE="0.09615032235228775" STUDY_ID="STD-Colice-1996" TOTAL_1="101" TOTAL_2="105" WEIGHT="41.877916060556345"/>
<CONT_DATA CI_END="0.16113292567433768" CI_START="-0.36113292567433697" EFFECT_SIZE="-0.09999999999999964" ESTIMABLE="YES" MEAN_1="4.7" MEAN_2="4.8" ORDER="1231" SD_1="1.25" SD_2="1.21" SE="0.13323353272515234" STUDY_ID="STD-Combivent-1994" TOTAL_1="176" TOTAL_2="165" WEIGHT="21.810190768761615"/>
<CONT_DATA CI_END="0.49681392701222715" CI_START="-0.49681392701222715" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="4.8" MEAN_2="4.8" ORDER="1232" SD_1="2.59" SD_2="2.58" SE="0.2534811511492211" STUDY_ID="STD-Combivent-1997" TOTAL_1="209" TOTAL_2="207" WEIGHT="6.025529399117531"/>
<CONT_DATA CI_END="0.644035172012269" CI_START="0.15596482798773165" EFFECT_SIZE="0.40000000000000036" ESTIMABLE="YES" MEAN_1="5.0" MEAN_2="4.6" ORDER="1234" SD_1="0.9" SD_2="0.9" SE="0.12451002872358216" STUDY_ID="STD-Friedman-1996" TOTAL_1="105" TOTAL_2="104" WEIGHT="24.97341214978473"/>
<CONT_DATA CI_END="0.7290825474755812" CI_START="-0.32908254747558086" EFFECT_SIZE="0.20000000000000018" ESTIMABLE="YES" MEAN_1="4.8" MEAN_2="4.6" ORDER="1235" SD_1="2.58" SD_2="2.52" SE="0.2699450355460185" STUDY_ID="STD-Rennard-1996" TOTAL_1="183" TOTAL_2="174" WEIGHT="5.312951621779782"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="5.713224778223859" CI_END="0.2961400616780945" CI_START="0.05652998133301193" DF="4.0" EFFECT_SIZE="0.1763350215055532" ESTIMABLE="YES" I2="29.987001119820643" ID="CMP-001.09.04" MODIFIED="2008-07-03 16:42:31 +0100" MODIFIED_BY="Toby J Lasserson" NO="4" P_CHI2="0.22161294314460522" P_Z="0.003916965411425116" STUDIES="5" TAU2="0.0" TOTAL_1="774" TOTAL_2="755" WEIGHT="100.00000000000001" Z="2.884772551023212">
<NAME>CRQ- MASTERY DOMAIN</NAME>
<CONT_DATA CI_END="0.4075709534309896" CI_START="-0.007570953430989236" EFFECT_SIZE="0.20000000000000018" ESTIMABLE="YES" MEAN_1="4.9" MEAN_2="4.7" ORDER="1238" SD_1="0.75" SD_2="0.77" SE="0.10590549370717146" STUDY_ID="STD-Colice-1996" TOTAL_1="101" TOTAL_2="105" WEIGHT="33.31325106660244"/>
<CONT_DATA CI_END="0.3271562437609018" CI_START="-0.12715624376090254" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" MEAN_1="5.1" MEAN_2="5.0" ORDER="1236" SD_1="1.09" SD_2="1.05" SE="0.11589817239126925" STUDY_ID="STD-Combivent-1994" TOTAL_1="176" TOTAL_2="165" WEIGHT="27.81639347545379"/>
<CONT_DATA CI_END="0.2622795207313974" CI_START="-0.46227952073139666" EFFECT_SIZE="-0.09999999999999964" ESTIMABLE="YES" MEAN_1="4.9" MEAN_2="5.0" ORDER="1237" SD_1="1.89" SD_2="1.88" SE="0.1848398866453729" STUDY_ID="STD-Combivent-1997" TOTAL_1="209" TOTAL_2="207" WEIGHT="10.936103434357834"/>
<CONT_DATA CI_END="0.6575926815685063" CI_START="0.1424073184314945" EFFECT_SIZE="0.40000000000000036" ESTIMABLE="YES" MEAN_1="5.2" MEAN_2="4.8" ORDER="1239" SD_1="0.95" SD_2="0.95" SE="0.13142725254155893" STUDY_ID="STD-Friedman-1996" TOTAL_1="105" TOTAL_2="104" WEIGHT="21.631325769222133"/>
<CONT_DATA CI_END="0.5772038910736583" CI_START="-0.377203891073659" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" MEAN_1="5.0" MEAN_2="4.9" ORDER="1240" SD_1="2.33" SD_2="2.27" SE="0.24347584692258736" STUDY_ID="STD-Rennard-1996" TOTAL_1="183" TOTAL_2="174" WEIGHT="6.302926254363815"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.09823179545330796" CI_END="0.7376708311071843" CI_START="0.3677419395340732" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.5208382687255879" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="93" I2="0.0" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="-0.13213738902317912" LOG_CI_START="-0.4344568377146076" LOG_EFFECT_SIZE="-0.2832971133688933" METHOD="PETO" NO="10" P_CHI2="0.9920487678702637" P_Q="1.0" P_Z="2.394559349000698E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="612" TOTAL_2="606" WEIGHT="100.0" Z="3.6732809717043815">
<NAME>Number of subjects adding or increasing systemic (oral) corticosteroids</NAME>
<GROUP_LABEL_1>ipratropium</GROUP_LABEL_1>
<GROUP_LABEL_2>beta-2 agonist</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ipratropium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours B-2 agonist</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1683311242254346" CI_START="0.20869800018076093" EFFECT_SIZE="0.4937898026233312" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="15" LOG_CI_END="0.06756594640959644" LOG_CI_START="-0.6804817124804085" LOG_EFFECT_SIZE="-0.306457883035406" ORDER="1243" O_E="-3.6547085201793728" SE="0.4394068977276199" STUDY_ID="STD-Colice-1996" TOTAL_1="113" TOTAL_2="110" VAR="5.179242666423185" WEIGHT="16.333288667647725"/>
<DICH_DATA CI_END="1.2178661853887263" CI_START="0.2669391858402867" EFFECT_SIZE="0.5701720862950783" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="18" LOG_CI_END="0.08559957225425842" LOG_CI_START="-0.5735876684566467" LOG_EFFECT_SIZE="-0.24399404810119416" ORDER="1241" O_E="-3.7471590909090917" SE="0.38720984822305266" STUDY_ID="STD-Combivent-1994" TOTAL_1="179" TOTAL_2="173" VAR="6.669713989582598" WEIGHT="21.033647376428956"/>
<DICH_DATA CI_END="0.8770186317313847" CI_START="0.28311011007978026" EFFECT_SIZE="0.49828991698758124" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="36" LOG_CI_END="-0.05699118021186497" LOG_CI_START="-0.5480446213679925" LOG_EFFECT_SIZE="-0.30251790078992874" ORDER="1242" O_E="-8.372093023255815" SE="0.2884472220888457" STUDY_ID="STD-Combivent-1997" TOTAL_1="214" TOTAL_2="216" VAR="12.018970753421808" WEIGHT="37.903093453473225"/>
<DICH_DATA CI_END="1.0764553435413822" CI_START="0.26550030281567394" EFFECT_SIZE="0.5346019263693195" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="24" LOG_CI_END="0.03199601794414879" LOG_CI_START="-0.5759349792487976" LOG_EFFECT_SIZE="-0.27196948065232435" ORDER="1244" O_E="-4.910798122065728" SE="0.35710167705810625" STUDY_ID="STD-Friedman-1996" TOTAL_1="106" TOTAL_2="107" VAR="7.841808283188962" WEIGHT="24.729970502450094"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.11" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="22" TOTAL_2="22" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Borg Dyspnoea Index</NAME>
<GROUP_LABEL_1>ipratropium</GROUP_LABEL_1>
<GROUP_LABEL_2>Beta-2 agonist</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ipratropium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours B-2 agonist</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.018015544992430188" CI_START="-1.9819844550075698" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="2.6" MEAN_2="3.6" ORDER="1245" SD_1="1.41" SD_2="1.88" SE="0.5010216834356844" STUDY_ID="STD-Hodzhev-1999" TOTAL_1="22" TOTAL_2="22" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.046783625730995315" CI_END="6.1892665271859375" CI_START="0.9686219245447939" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.448481009745331" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="0.7916391850346797" LOG_CI_START="-0.01384570501789104" LOG_EFFECT_SIZE="0.3888967400083943" METHOD="PETO" NO="12" P_CHI2="0.8287577936664177" P_Q="0.8287577936664177" P_Z="0.05841331346637676" Q="0.046783625730995315" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="38" TOTAL_2="32" WEIGHT="200.0" Z="1.8925832465255628">
<NAME>Borg dyspnoea score- reduction of 1 unit</NAME>
<GROUP_LABEL_1>ipratropium</GROUP_LABEL_1>
<GROUP_LABEL_2>fenoterol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ipratropium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours fenoterol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="10.067135396287343" CI_START="0.7307658668773579" DF="0.0" EFFECT_SIZE="2.71232721566548" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="6" I2="0.0" ID="CMP-001.12.01" LOG_CI_END="1.0029059096231128" LOG_CI_START="-0.13622174617583402" LOG_EFFECT_SIZE="0.4333420817236393" NO="1" P_CHI2="1.0" P_Z="0.1359083978439904" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="16" WEIGHT="100.0" Z="1.4912022701586511">
<NAME>Borg score reduced 1 unit</NAME>
<DICH_DATA CI_END="10.067135396287343" CI_START="0.7307658668773579" EFFECT_SIZE="2.71232721566548" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="6" LOG_CI_END="1.0029059096231128" LOG_CI_START="-0.13622174617583402" LOG_EFFECT_SIZE="0.4333420817236393" ORDER="1246" O_E="2.2285714285714278" SE="0.6691292237891385" STUDY_ID="STD-Hodzhev-1999" TOTAL_1="19" TOTAL_2="16" VAR="2.2334693877551017" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.203803060344153" CI_START="0.5955079592248689" DF="0.0" EFFECT_SIZE="2.2103008886457705" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="6" I2="0.0" ID="CMP-001.12.02" LOG_CI_END="0.9140152261926227" LOG_CI_START="-0.22511242960632394" LOG_EFFECT_SIZE="0.34445139829314947" NO="2" P_CHI2="1.0" P_Z="0.23589309428669902" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="16" WEIGHT="100.00000000000001" Z="1.185314624997903">
<NAME>Borg score reduced one unit after 6MWD test</NAME>
<DICH_DATA CI_END="8.203803060344153" CI_START="0.5955079592248691" EFFECT_SIZE="2.2103008886457705" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="6" LOG_CI_END="0.9140152261926227" LOG_CI_START="-0.2251124296063238" LOG_EFFECT_SIZE="0.34445139829314947" ORDER="1247" O_E="1.7714285714285722" SE="0.6691292237891384" STUDY_ID="STD-Hodzhev-1999" TOTAL_1="19" TOTAL_2="16" VAR="2.233469387755102" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="140.84588007844633" CI_START="-15.645880078446382" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="62.599999999999966" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.13" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="0.11686858963553319" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="206" TOTAL_2="217" UNITS="" WEIGHT="100.0" Z="1.5680537468451916">
<NAME>Six minute walk distance</NAME>
<GROUP_LABEL_1>ipratropium</GROUP_LABEL_1>
<GROUP_LABEL_2>Beta-2 agonist</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours B-2 agonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ipratropium</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.0" MEAN_2="0.0" ORDER="1248" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Gross-1998" TOTAL_1="184" TOTAL_2="195" WEIGHT="0.0"/>
<CONT_DATA CI_END="140.84588007844633" CI_START="-15.645880078446382" EFFECT_SIZE="62.599999999999966" ESTIMABLE="YES" MEAN_1="438.9" MEAN_2="376.3" ORDER="1249" SD_1="119.14" SD_2="144.46" SE="39.92210096493602" STUDY_ID="STD-Hodzhev-1999" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-001.14" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="14" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="19" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>Six minute walk distance test-improved at least 30 metres</NAME>
<GROUP_LABEL_1>ipratropium</GROUP_LABEL_1>
<GROUP_LABEL_2>fenoterol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fenoterol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ipratropium</GRAPH_LABEL_2>
<DICH_DATA CI_END="24.649189840344604" CI_START="1.7892663476192956" EFFECT_SIZE="6.641081679772357" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="4" LOG_CI_END="1.391802649631507" LOG_CI_START="0.2526749938325603" LOG_EFFECT_SIZE="0.8222388217320337" ORDER="1250" O_E="4.228571428571428" SE="0.6691292237891385" STUDY_ID="STD-Hodzhev-1999" TOTAL_1="19" TOTAL_2="16" VAR="2.2334693877551017" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2008-07-03 16:42:40 +0100" MODIFIED_BY="Toby J Lasserson" NO="2">
<NAME>Ipratropium bromide + short acting beta-2 agonist v. short-acting beta-2 agonist via nebuliser or MDI</NAME>
<CONT_OUTCOME CHI2="3.357430855958035" CI_END="0.03564717688277311" CI_START="-0.030139539046048918" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.002753818918362096" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.01" NO="1" P_CHI2="0.4998847941940153" P_Q="1.0" P_Z="0.8696623332524809" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1137" TOTAL_2="1115" UNITS="" WEIGHT="100.00000000000003" Z="0.1640874095546724">
<NAME>Test day 85 baseline FEV1(absolute, litres)</NAME>
<GROUP_LABEL_1>combination</GROUP_LABEL_1>
<GROUP_LABEL_2>beta-2 agonist</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours B-2 agonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours combination</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.0" MEAN_2="0.0" ORDER="1253" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Campbell-1999" TOTAL_1="176" TOTAL_2="180" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.1128063013948481" CI_START="-0.07280630139484806" EFFECT_SIZE="0.020000000000000018" ESTIMABLE="YES" MEAN_1="0.97" MEAN_2="0.95" ORDER="1251" SD_1="0.43" SD_2="0.44" SE="0.04735102385905677" STUDY_ID="STD-Combivent-1994" TOTAL_1="173" TOTAL_2="165" WEIGHT="12.562078194644636"/>
<CONT_DATA CI_END="0.07558022070093573" CI_START="-0.07558022070093573" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.91" MEAN_2="0.91" ORDER="1252" SD_1="0.39" SD_2="0.4" SE="0.03856204567895271" STUDY_ID="STD-Combivent-1997" TOTAL_1="213" TOTAL_2="207" WEIGHT="18.94087818900545"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.0" MEAN_2="0.0" ORDER="1254" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Gross-1998" TOTAL_1="195" TOTAL_2="195" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.030524654770977433" CI_START="-0.09052465477097749" EFFECT_SIZE="-0.030000000000000027" ESTIMABLE="YES" MEAN_1="0.96" MEAN_2="0.99" ORDER="1255" SD_1="0.22" SD_2="0.2" SE="0.030880493339871657" STUDY_ID="STD-Levin--1996" TOTAL_1="96" TOTAL_2="89" WEIGHT="29.536006896260766"/>
<CONT_DATA CI_END="0.16121870801336402" CI_START="-0.021218708013363882" EFFECT_SIZE="0.07000000000000006" ESTIMABLE="YES" MEAN_1="0.93" MEAN_2="0.86" ORDER="1256" SD_1="0.42" SD_2="0.45" SE="0.046541012351699045" STUDY_ID="STD-Rennard-1996" TOTAL_1="176" TOTAL_2="174" WEIGHT="13.003150497587708"/>
<CONT_DATA CI_END="0.06456149062903196" CI_START="-0.06456149062903196" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.97" MEAN_2="0.97" ORDER="1257" SD_1="0.23" SD_2="0.25" SE="0.032940141318047046" STUDY_ID="STD-Tashkin-1996" TOTAL_1="108" TOTAL_2="105" WEIGHT="25.957886222501454"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="8.375323014198884" CI_END="0.09120434372342051" CI_START="0.05195340344395232" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.07157887358368642" ESTIMABLE="YES" I2="52.240647993889844" I2_Q="0.0" ID="CMP-002.02" NO="2" P_CHI2="0.07875786165072984" P_Q="1.0" P_Z="8.775270972728797E-13" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1137" TOTAL_2="1111" UNITS="" WEIGHT="100.0" Z="7.148466420375479">
<NAME>Test day (last:29 or 85) peak FEV1 response (litres)</NAME>
<GROUP_LABEL_1>Combination</GROUP_LABEL_1>
<GROUP_LABEL_2>beta-2 agonist</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours B-2 agonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours combination</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.34" MEAN_2="0.27" ORDER="1260" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Campbell-1999" TOTAL_1="176" TOTAL_2="180" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.11949563861428561" CI_START="0.040504361385714414" EFFECT_SIZE="0.08000000000000002" ESTIMABLE="YES" MEAN_1="0.37" MEAN_2="0.29" ORDER="1258" SD_1="0.18" SD_2="0.19" SE="0.020151206310841503" STUDY_ID="STD-Combivent-1994" TOTAL_1="173" TOTAL_2="165" WEIGHT="24.691180698061395"/>
<CONT_DATA CI_END="0.08634555983412923" CI_START="0.01365444016587087" EFFECT_SIZE="0.050000000000000044" ESTIMABLE="YES" MEAN_1="0.34" MEAN_2="0.29" ORDER="1259" SD_1="0.19" SD_2="0.19" SE="0.018543993726832898" STUDY_ID="STD-Combivent-1997" TOTAL_1="213" TOTAL_2="207" WEIGHT="29.15663587769849"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.0" MEAN_2="0.0" ORDER="1261" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Gross-1998" TOTAL_1="195" TOTAL_2="195" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.12620295899295053" CI_START="0.013797041007049482" EFFECT_SIZE="0.07" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="0.33" ORDER="1262" SD_1="0.2" SD_2="0.19" SE="0.028675505997187854" STUDY_ID="STD-Levin--1996" TOTAL_1="96" TOTAL_2="89" WEIGHT="12.193314525358538"/>
<CONT_DATA CI_END="0.0987716612087545" CI_START="0.021228338791245506" EFFECT_SIZE="0.06" ESTIMABLE="YES" MEAN_1="0.31" MEAN_2="0.25" ORDER="1263" SD_1="0.19" SD_2="0.18" SE="0.019781823296030135" STUDY_ID="STD-Rennard-1996" TOTAL_1="176" TOTAL_2="174" WEIGHT="25.621899319573465"/>
<CONT_DATA CI_END="0.2279697951325891" CI_START="0.09203020486741084" EFFECT_SIZE="0.15999999999999998" ESTIMABLE="YES" MEAN_1="0.47" MEAN_2="0.31" ORDER="1264" SD_1="0.24" SD_2="0.26" SE="0.03467910414105882" STUDY_ID="STD-Tashkin-1996" TOTAL_1="108" TOTAL_2="101" WEIGHT="8.336969579308118"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="7.0133618253647585" CI_END="0.4870461327404475" CI_START="0.2460458898859219" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.3665460113131847" ESTIMABLE="YES" I2="42.966011171226526" I2_Q="0.0" ID="CMP-002.03" NO="3" P_CHI2="0.1351839881305077" P_Q="1.0" P_Z="2.4922919221832603E-9" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1137" TOTAL_2="1115" UNITS="" WEIGHT="100.0" Z="5.96196063822483">
<NAME>Test day 85 FEV1 AUC (0-8 hours), litres/hour</NAME>
<GROUP_LABEL_1>combination</GROUP_LABEL_1>
<GROUP_LABEL_2>beta-2 agonist</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours B-2 agonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours combination</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.0" MEAN_2="0.0" ORDER="1267" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Campbell-1999" TOTAL_1="176" TOTAL_2="180" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.6517248595468921" CI_START="0.14827514045310797" EFFECT_SIZE="0.4" ESTIMABLE="YES" MEAN_1="1.24" MEAN_2="0.84" ORDER="1265" SD_1="1.17" SD_2="1.19" SE="0.12843341078329276" STUDY_ID="STD-Combivent-1994" TOTAL_1="173" TOTAL_2="165" WEIGHT="22.915152651063224"/>
<CONT_DATA CI_END="0.5061415707576408" CI_START="0.0738584292423593" EFFECT_SIZE="0.29000000000000004" ESTIMABLE="YES" MEAN_1="1.06" MEAN_2="0.77" ORDER="1266" SD_1="1.14" SD_2="1.12" SE="0.11027833800138057" STUDY_ID="STD-Combivent-1997" TOTAL_1="213" TOTAL_2="207" WEIGHT="31.08124183896549"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.0" MEAN_2="0.0" ORDER="1268" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Gross-1998" TOTAL_1="195" TOTAL_2="195" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.8587821163917114" CI_START="0.20121788360828863" EFFECT_SIZE="0.53" ESTIMABLE="YES" MEAN_1="1.55" MEAN_2="1.02" ORDER="1269" SD_1="1.14" SD_2="1.14" SE="0.16774906017921898" STUDY_ID="STD-Levin--1996" TOTAL_1="96" TOTAL_2="89" WEIGHT="13.432554016014171"/>
<CONT_DATA CI_END="0.43940269251528563" CI_START="-0.05940269251528554" EFFECT_SIZE="0.19000000000000006" ESTIMABLE="YES" MEAN_1="1.08" MEAN_2="0.89" ORDER="1270" SD_1="1.17" SD_2="1.21" SE="0.12724860991454037" STUDY_ID="STD-Rennard-1996" TOTAL_1="176" TOTAL_2="174" WEIGHT="23.343861270289594"/>
<CONT_DATA CI_END="1.1466913654884656" CI_START="0.3533086345115344" EFFECT_SIZE="0.75" ESTIMABLE="YES" MEAN_1="1.8" MEAN_2="1.05" ORDER="1271" SD_1="1.42" SD_2="1.53" SE="0.2023972729180314" STUDY_ID="STD-Tashkin-1996" TOTAL_1="108" TOTAL_2="105" WEIGHT="9.227190223667536"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.841535602619026" CI_END="0.11515434342600048" CI_START="-0.015613187234729119" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.04977057809563568" ESTIMABLE="YES" I2="17.38158451553672" I2_Q="0.0" ID="CMP-002.04" NO="4" P_CHI2="0.30394703332056894" P_Q="1.0" P_Z="0.13571533355811904" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1137" TOTAL_2="1115" UNITS="" WEIGHT="100.0" Z="1.4919382520156215">
<NAME>Test day 85 baseline FVC</NAME>
<GROUP_LABEL_1>combination</GROUP_LABEL_1>
<GROUP_LABEL_2>beta-2 agonist</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours B-2 agonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours combination</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.0" MEAN_2="0.0" ORDER="1274" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Campbell-1999" TOTAL_1="176" TOTAL_2="180" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.24281696639417058" CI_START="-0.1028169663941709" EFFECT_SIZE="0.06999999999999984" ESTIMABLE="YES" MEAN_1="2.28" MEAN_2="2.21" ORDER="1272" SD_1="0.8" SD_2="0.82" SE="0.08817354183920159" STUDY_ID="STD-Combivent-1994" TOTAL_1="173" TOTAL_2="165" WEIGHT="14.314200619069114"/>
<CONT_DATA CI_END="0.20252972538371258" CI_START="-0.08252972538371248" EFFECT_SIZE="0.06000000000000005" ESTIMABLE="YES" MEAN_1="2.17" MEAN_2="2.11" ORDER="1273" SD_1="0.74" SD_2="0.75" SE="0.07272058390254556" STUDY_ID="STD-Combivent-1997" TOTAL_1="213" TOTAL_2="207" WEIGHT="21.044032198586073"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.0" MEAN_2="0.0" ORDER="1275" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Gross-1998" TOTAL_1="195" TOTAL_2="195" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.12689836071259036" CI_START="-0.12689836071259036" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="2.21" MEAN_2="2.21" ORDER="1276" SD_1="0.44" SD_2="0.44" SE="0.06474525129724241" STUDY_ID="STD-Levin--1996" TOTAL_1="96" TOTAL_2="89" WEIGHT="26.54775680924258"/>
<CONT_DATA CI_END="0.36453090320822296" CI_START="0.0354690967917774" EFFECT_SIZE="0.20000000000000018" ESTIMABLE="YES" MEAN_1="2.21" MEAN_2="2.01" ORDER="1277" SD_1="0.77" SD_2="0.8" SE="0.08394588089680298" STUDY_ID="STD-Rennard-1996" TOTAL_1="176" TOTAL_2="174" WEIGHT="15.79228200807095"/>
<CONT_DATA CI_END="0.1184524567028449" CI_START="-0.15845245670284494" EFFECT_SIZE="-0.020000000000000018" ESTIMABLE="YES" MEAN_1="2.19" MEAN_2="2.21" ORDER="1278" SD_1="0.5" SD_2="0.53" SE="0.07064030655406947" STUDY_ID="STD-Tashkin-1996" TOTAL_1="108" TOTAL_2="105" WEIGHT="22.301728365031288"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.737258798570835" CI_END="0.16274661616244307" CI_START="0.07605729196003415" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.1194019540612386" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.05" NO="5" P_CHI2="0.44273015461373577" P_Q="1.0" P_Z="6.696428583809665E-8" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1137" TOTAL_2="1115" UNITS="" WEIGHT="99.99999999999999" Z="5.399131480072853">
<NAME>Test day (last: 29 or 85) peak FVC response (litres)</NAME>
<GROUP_LABEL_1>combination</GROUP_LABEL_1>
<GROUP_LABEL_2>beta-2 agonist</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours B-2 agonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours combination</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.71" MEAN_2="0.61" ORDER="1281" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Campbell-1999" TOTAL_1="176" TOTAL_2="180" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.21178380784320794" CI_START="0.02821619215679229" EFFECT_SIZE="0.1200000000000001" ESTIMABLE="YES" MEAN_1="0.81" MEAN_2="0.69" ORDER="1279" SD_1="0.42" SD_2="0.44" SE="0.04682933388939122" STUDY_ID="STD-Combivent-1994" TOTAL_1="173" TOTAL_2="165" WEIGHT="22.301758092787384"/>
<CONT_DATA CI_END="0.16366745362537" CI_START="0.016332546374629928" EFFECT_SIZE="0.08999999999999997" ESTIMABLE="YES" MEAN_1="0.75" MEAN_2="0.66" ORDER="1280" SD_1="0.38" SD_2="0.39" SE="0.037586126177036674" STUDY_ID="STD-Combivent-1997" TOTAL_1="213" TOTAL_2="207" WEIGHT="34.6194310841479"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.0" MEAN_2="0.0" ORDER="1282" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Gross-1998" TOTAL_1="195" TOTAL_2="195" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.22401430706003145" CI_START="-0.024014307060031492" EFFECT_SIZE="0.09999999999999998" ESTIMABLE="YES" MEAN_1="0.84" MEAN_2="0.74" ORDER="1283" SD_1="0.43" SD_2="0.43" SE="0.06327376831321417" STUDY_ID="STD-Levin--1996" TOTAL_1="96" TOTAL_2="89" WEIGHT="12.215961673451659"/>
<CONT_DATA CI_END="0.21533700465069255" CI_START="0.024662995349307437" EFFECT_SIZE="0.12" ESTIMABLE="YES" MEAN_1="0.78" MEAN_2="0.66" ORDER="1284" SD_1="0.46" SD_2="0.45" SE="0.04864222271567165" STUDY_ID="STD-Rennard-1996" TOTAL_1="176" TOTAL_2="174" WEIGHT="20.670369381968626"/>
<CONT_DATA CI_END="0.3757674598707416" CI_START="0.10423254012925837" EFFECT_SIZE="0.24" ESTIMABLE="YES" MEAN_1="0.88" MEAN_2="0.64" ORDER="1285" SD_1="0.49" SD_2="0.52" SE="0.06927038503853031" STUDY_ID="STD-Tashkin-1996" TOTAL_1="108" TOTAL_2="105" WEIGHT="10.192479767644418"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.6302391165076275" CI_END="1.0472438869687575" CI_START="0.4990533644587233" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.7731486257137404" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.06" NO="6" P_CHI2="0.4583534471723516" P_Q="1.0" P_Z="3.229279867472726E-8" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1137" TOTAL_2="1115" UNITS="" WEIGHT="100.00000000000003" Z="5.528528490996786">
<NAME>Test day 85 FVC AUC (0-8 hours), litres/hour</NAME>
<GROUP_LABEL_1>combination</GROUP_LABEL_1>
<GROUP_LABEL_2>beta-2 agonist</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours B-2 agonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours combination</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.0" MEAN_2="0.0" ORDER="1288" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Campbell-1999" TOTAL_1="176" TOTAL_2="180" WEIGHT="0.0"/>
<CONT_DATA CI_END="1.6208821121770771" CI_START="0.539117887822923" EFFECT_SIZE="1.08" ESTIMABLE="YES" MEAN_1="2.91" MEAN_2="1.83" ORDER="1286" SD_1="2.5" SD_2="2.57" SE="0.2759653322425749" STUDY_ID="STD-Combivent-1994" TOTAL_1="173" TOTAL_2="165" WEIGHT="25.680165406047816"/>
<CONT_DATA CI_END="0.9853762899011863" CI_START="0.03462371009881371" EFFECT_SIZE="0.51" ESTIMABLE="YES" MEAN_1="2.48" MEAN_2="1.97" ORDER="1287" SD_1="2.48" SD_2="2.49" SE="0.2425433802105007" STUDY_ID="STD-Combivent-1997" TOTAL_1="213" TOTAL_2="207" WEIGHT="33.24512886864394"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.0" MEAN_2="0.0" ORDER="1289" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Gross-1998" TOTAL_1="195" TOTAL_2="195" WEIGHT="0.0"/>
<CONT_DATA CI_END="1.5930408774566063" CI_START="0.046959122543394405" EFFECT_SIZE="0.8200000000000003" ESTIMABLE="YES" MEAN_1="3.24" MEAN_2="2.42" ORDER="1290" SD_1="2.67" SD_2="2.69" SE="0.39441585843120264" STUDY_ID="STD-Levin--1996" TOTAL_1="96" TOTAL_2="89" WEIGHT="12.571819455872317"/>
<CONT_DATA CI_END="1.2092194961584612" CI_START="-0.06921949615846157" EFFECT_SIZE="0.5699999999999998" ESTIMABLE="YES" MEAN_1="2.82" MEAN_2="2.25" ORDER="1291" SD_1="3.0" SD_2="3.1" SE="0.3261383888686441" STUDY_ID="STD-Rennard-1996" TOTAL_1="176" TOTAL_2="174" WEIGHT="18.386667798702256"/>
<CONT_DATA CI_END="2.0317720953915455" CI_START="0.3082279046084554" EFFECT_SIZE="1.1700000000000004" ESTIMABLE="YES" MEAN_1="3.45" MEAN_2="2.28" ORDER="1292" SD_1="3.1" SD_2="3.31" SE="0.43968771987092276" STUDY_ID="STD-Tashkin-1996" TOTAL_1="108" TOTAL_2="105" WEIGHT="10.116218470733687"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.308734040393764" CI_END="0.03798883407177661" CI_START="-0.031142247740332463" CI_STUDY="95" CI_TOTAL="95" DF="19.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0034232931657220728" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.07" NO="7" P_CHI2="0.9998120708304663" P_Q="0.8338575294918915" P_Z="0.8460894308472782" Q="0.86503068028175" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="3593" TOTAL_2="3501" UNITS="" WEIGHT="400.0" Z="0.19411040988981376">
<NAME>Symptom Scores</NAME>
<GROUP_LABEL_1>combination</GROUP_LABEL_1>
<GROUP_LABEL_2>beta-2 agonist</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours combination</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours B-2 agonist</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.0251642446794704" CI_END="0.08224137163590502" CI_START="-0.07076817326966776" DF="4.0" EFFECT_SIZE="0.005736599183118623" ESTIMABLE="YES" I2="0.0" ID="CMP-002.07.01" NO="1" P_CHI2="0.9059566386443326" P_Z="0.8831596059590536" STUDIES="6" TAU2="0.0" TOTAL_1="942" TOTAL_2="920" WEIGHT="100.0" Z="0.14696505109655933">
<NAME>wheezing</NAME>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.8" MEAN_2="1.0" ORDER="1295" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Campbell-1999" TOTAL_1="176" TOTAL_2="180" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.135409039399535" CI_START="-0.135409039399535" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="1.1" MEAN_2="1.1" ORDER="1293" SD_1="0.64" SD_2="0.63" SE="0.06908751409088341" STUDY_ID="STD-Combivent-1994" TOTAL_1="173" TOTAL_2="165" WEIGHT="31.921386101080703"/>
<CONT_DATA CI_END="0.23856565926019235" CI_START="-0.4385656592601923" EFFECT_SIZE="-0.09999999999999998" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="0.9" ORDER="1294" SD_1="1.78" SD_2="1.76" SE="0.1727407554071172" STUDY_ID="STD-Combivent-1997" TOTAL_1="213" TOTAL_2="207" WEIGHT="5.106122675225908"/>
<CONT_DATA CI_END="0.1498893727636057" CI_START="-0.1498893727636057" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="2.1" ORDER="1296" SD_1="0.53" SD_2="0.51" SE="0.07647557503398733" STUDY_ID="STD-Levin--1996" TOTAL_1="96" TOTAL_2="89" WEIGHT="26.051658171516866"/>
<CONT_DATA CI_END="0.1498133313488183" CI_START="-0.1498133313488183" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.9" MEAN_2="0.9" ORDER="1297" SD_1="0.72" SD_2="0.71" SE="0.07643677768087921" STUDY_ID="STD-Rennard-1996" TOTAL_1="176" TOTAL_2="174" WEIGHT="26.078111193832008"/>
<CONT_DATA CI_END="0.33233753060628285" CI_START="-0.13233753060628267" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" MEAN_1="2.2" MEAN_2="2.1" ORDER="1298" SD_1="0.87" SD_2="0.86" SE="0.11854173466396911" STUDY_ID="STD-Tashkin-1996" TOTAL_1="108" TOTAL_2="105" WEIGHT="10.84272185834452"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.2182555509407083" CI_END="0.052903342918420526" CI_START="-0.049857152087317114" DF="4.0" EFFECT_SIZE="0.0015230954155517082" ESTIMABLE="YES" I2="0.0" ID="CMP-002.07.02" NO="2" P_CHI2="0.9944615393837961" P_Z="0.9536686677537395" STUDIES="6" TAU2="0.0" TOTAL_1="942" TOTAL_2="920" WEIGHT="99.99999999999999" Z="0.0581003849647228">
<NAME>coughing</NAME>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.8" MEAN_2="0.8" ORDER="1301" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Campbell-1999" TOTAL_1="176" TOTAL_2="180" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.05863527565685745" CI_START="-0.05863527565685745" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="1.2" ORDER="1299" SD_1="0.28" SD_2="0.27" SE="0.029916506690615248" STUDY_ID="STD-Combivent-1994" TOTAL_1="173" TOTAL_2="165" WEIGHT="76.78465574975421"/>
<CONT_DATA CI_END="0.24388604711571357" CI_START="-0.24388604711571357" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.9" MEAN_2="0.9" ORDER="1300" SD_1="1.28" SD_2="1.27" SE="0.12443394319459723" STUDY_ID="STD-Combivent-1997" TOTAL_1="213" TOTAL_2="207" WEIGHT="4.438318600600893"/>
<CONT_DATA CI_END="0.255111688793302" CI_START="-0.255111688793302" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="2.2" MEAN_2="2.2" ORDER="1302" SD_1="0.9" SD_2="0.87" SE="0.13016141664111708" STUDY_ID="STD-Levin--1996" TOTAL_1="96" TOTAL_2="89" WEIGHT="4.056314953251066"/>
<CONT_DATA CI_END="0.14143225305053617" CI_START="-0.14143225305053617" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="1.0" ORDER="1303" SD_1="0.68" SD_2="0.67" SE="0.07216063874955649" STUDY_ID="STD-Rennard-1996" TOTAL_1="176" TOTAL_2="174" WEIGHT="13.19761528084212"/>
<CONT_DATA CI_END="0.5163251397522358" CI_START="-0.31632513975223653" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" MEAN_1="2.3" MEAN_2="2.2" ORDER="1304" SD_1="1.56" SD_2="1.54" SE="0.21241468875762806" STUDY_ID="STD-Tashkin-1996" TOTAL_1="108" TOTAL_2="105" WEIGHT="1.5230954155517136"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.0377467556964408" CI_END="0.1328035343432764" CI_START="-0.054857877208059874" DF="4.0" EFFECT_SIZE="0.03897282856760827" ESTIMABLE="YES" I2="0.0" ID="CMP-002.07.03" NO="3" P_CHI2="0.9040194298809103" P_Z="0.41560133151392165" STUDIES="6" TAU2="0.0" TOTAL_1="767" TOTAL_2="741" WEIGHT="100.0" Z="0.8140761570182492">
<NAME>shortness of breath</NAME>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.0" MEAN_2="0.0" ORDER="1307" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Campbell-1999" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.135409039399535" CI_START="-0.135409039399535" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="1.5" ORDER="1305" SD_1="0.64" SD_2="0.63" SE="0.06908751409088341" STUDY_ID="STD-Combivent-1994" TOTAL_1="173" TOTAL_2="165" WEIGHT="48.01695896769815"/>
<CONT_DATA CI_END="0.2601373959736144" CI_START="-0.2601373959736144" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="1.5" ORDER="1306" SD_1="1.37" SD_2="1.35" SE="0.13272560007507533" STUDY_ID="STD-Combivent-1997" TOTAL_1="213" TOTAL_2="207" WEIGHT="13.01021246469361"/>
<CONT_DATA CI_END="0.5525516421824258" CI_START="-0.35255164218242563" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" MEAN_1="2.6" MEAN_2="2.5" ORDER="1308" SD_1="1.6" SD_2="1.54" SE="0.23089793779482445" STUDY_ID="STD-Levin--1996" TOTAL_1="96" TOTAL_2="89" WEIGHT="4.298863701228386"/>
<CONT_DATA CI_END="0.3189578614089844" CI_START="-0.11895786140898426" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="1.4" ORDER="1309" SD_1="1.05" SD_2="1.04" SE="0.11171524739030718" STUDY_ID="STD-Rennard-1996" TOTAL_1="176" TOTAL_2="174" WEIGHT="18.364067516632037"/>
<CONT_DATA CI_END="0.33233753060628285" CI_START="-0.13233753060628267" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" MEAN_1="2.6" MEAN_2="2.5" ORDER="1310" SD_1="0.87" SD_2="0.86" SE="0.11854173466396911" STUDY_ID="STD-Tashkin-1996" TOTAL_1="108" TOTAL_2="105" WEIGHT="16.30989734974781"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.1625368087953944" CI_END="0.05791710678199718" CI_START="-0.09381445620170645" DF="4.0" EFFECT_SIZE="-0.017948674709854638" ESTIMABLE="YES" I2="0.0" ID="CMP-002.07.04" NO="4" P_CHI2="0.8842273396872478" P_Z="0.6428646526447623" STUDIES="6" TAU2="0.0" TOTAL_1="942" TOTAL_2="920" WEIGHT="100.00000000000003" Z="0.463697273128575">
<NAME>chest tightness</NAME>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.6" MEAN_2="0.8" ORDER="1313" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Campbell-1999" TOTAL_1="176" TOTAL_2="180" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.07271601516197299" CI_START="-0.27271601516197297" EFFECT_SIZE="-0.09999999999999998" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="0.9" ORDER="1311" SD_1="0.82" SD_2="0.8" SE="0.08812203516204116" STUDY_ID="STD-Combivent-1994" TOTAL_1="173" TOTAL_2="165" WEIGHT="19.294194514422237"/>
<CONT_DATA CI_END="0.17119572364542707" CI_START="-0.17119572364542707" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.7" MEAN_2="0.7" ORDER="1312" SD_1="0.9" SD_2="0.89" SE="0.08734636197185106" STUDY_ID="STD-Combivent-1997" TOTAL_1="213" TOTAL_2="207" WEIGHT="19.638397553382593"/>
<CONT_DATA CI_END="0.1974413172469284" CI_START="-0.1974413172469284" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="1.9" MEAN_2="1.9" ORDER="1314" SD_1="0.7" SD_2="0.67" SE="0.10073721701231263" STUDY_ID="STD-Levin--1996" TOTAL_1="96" TOTAL_2="89" WEIGHT="14.764399640122491"/>
<CONT_DATA CI_END="0.11314748758114851" CI_START="-0.11314748758114851" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.7" MEAN_2="0.7" ORDER="1315" SD_1="0.54" SD_2="0.54" SE="0.057729370781117124" STUDY_ID="STD-Rennard-1996" TOTAL_1="176" TOTAL_2="174" WEIGHT="44.957488487505096"/>
<CONT_DATA CI_END="0.7540348476515645" CI_START="-0.5540348476515647" EFFECT_SIZE="0.09999999999999987" ESTIMABLE="YES" MEAN_1="1.9" MEAN_2="1.8" ORDER="1316" SD_1="2.45" SD_2="2.42" SE="0.33369738056949416" STUDY_ID="STD-Tashkin-1996" TOTAL_1="108" TOTAL_2="105" WEIGHT="1.3455198045675973"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.08" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="195" TOTAL_2="195" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Six minute walk distance (m)</NAME>
<GROUP_LABEL_1>combination</GROUP_LABEL_1>
<GROUP_LABEL_2>beta-2 agonist</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours B-2 agonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours combination</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.0" MEAN_2="0.0" ORDER="1317" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Gross-1998" TOTAL_1="195" TOTAL_2="195" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="15.669300249328245" CI_END="0.06578102720806413" CI_START="-0.0358916596911108" CI_STUDY="95" CI_TOTAL="95" DF="19.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.014944683758476667" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.09" MODIFIED="2008-07-03 16:42:40 +0100" MODIFIED_BY="Toby J Lasserson" NO="9" P_CHI2="0.679215920553917" P_Q="0.9943817606008597" P_Z="0.564491430291949" Q="0.07760929145388573" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="3064" TOTAL_2="2960" UNITS="" WEIGHT="400.0" Z="0.5761830993214886">
<NAME>Test day HRQL-Chronic Respiratory Disease Questionnaire</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours B-2 agonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours combination</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="4.698752521296866" CI_END="0.08231998069831437" CI_START="-0.06292740837217722" DF="4.0" EFFECT_SIZE="0.009696286163068574" ESTIMABLE="YES" I2="14.871022002750824" ID="CMP-002.09.01" MODIFIED="2008-07-03 16:42:40 +0100" MODIFIED_BY="Toby J Lasserson" NO="1" P_CHI2="0.319626711550391" P_Z="0.7935660031911307" STUDIES="5" TAU2="0.0" TOTAL_1="766" TOTAL_2="740" WEIGHT="99.99999999999999" Z="0.2616827990510075">
<NAME>CRQ- DYSPNOEA DOMAIN</NAME>
<CONT_DATA CI_END="0.24820522026321518" CI_START="-0.048205220263215" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="3.9" ORDER="1318" SD_1="0.7" SD_2="0.69" SE="0.07561629776477473" STUDY_ID="STD-Combivent-1994" TOTAL_1="173" TOTAL_2="165" WEIGHT="24.0120741108326"/>
<CONT_DATA CI_END="0.24674730817449897" CI_START="-0.24674730817449897" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="3.9" MEAN_2="3.9" ORDER="1319" SD_1="1.3" SD_2="1.28" SE="0.12589379709056403" STUDY_ID="STD-Combivent-1997" TOTAL_1="213" TOTAL_2="207" WEIGHT="8.662671193390352"/>
<CONT_DATA CI_END="0.04156354153713898" CI_START="-0.6415635415371386" EFFECT_SIZE="-0.2999999999999998" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="4.3" ORDER="1320" SD_1="1.21" SD_2="1.16" SE="0.1742703152870912" STUDY_ID="STD-Levin--1996" TOTAL_1="96" TOTAL_2="89" WEIGHT="4.5207830038334125"/>
<CONT_DATA CI_END="0.09219424914019507" CI_START="-0.09219424914019507" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="3.6" MEAN_2="3.6" ORDER="1321" SD_1="0.44" SD_2="0.44" SE="0.04703874656239173" STUDY_ID="STD-Rennard-1996" TOTAL_1="176" TOTAL_2="174" WEIGHT="62.051032755679806"/>
<CONT_DATA CI_END="0.7366702152219312" CI_START="-0.9366702152219314" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="3.9" MEAN_2="4.0" ORDER="1322" SD_1="3.14" SD_2="3.09" SE="0.42688040281427575" STUDY_ID="STD-Tashkin-1996" TOTAL_1="108" TOTAL_2="105" WEIGHT="0.7534389362638205"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="5.578958405163276" CI_END="0.1255137551513277" CI_START="-0.10095331054202446" DF="4.0" EFFECT_SIZE="0.012280222304651629" ESTIMABLE="YES" I2="28.30202863140124" ID="CMP-002.09.02" MODIFIED="2008-07-03 16:42:40 +0100" MODIFIED_BY="Toby J Lasserson" NO="2" P_CHI2="0.2328759357282384" P_Z="0.8316710440157715" STUDIES="5" TAU2="0.0" TOTAL_1="766" TOTAL_2="740" WEIGHT="100.0" Z="0.21255888458282948">
<NAME>CRQ- FATIGUE DOMAIN</NAME>
<CONT_DATA CI_END="0.5904244340155916" CI_START="-0.39042443401559235" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" MEAN_1="4.1" MEAN_2="4.0" ORDER="1323" SD_1="2.33" SD_2="2.27" SE="0.250221145839412" STUDY_ID="STD-Combivent-1994" TOTAL_1="173" TOTAL_2="165" WEIGHT="5.330966036217553"/>
<CONT_DATA CI_END="0.024756964691680705" CI_START="-0.42475696469168017" EFFECT_SIZE="-0.19999999999999973" ESTIMABLE="YES" MEAN_1="3.9" MEAN_2="4.1" ORDER="1324" SD_1="1.18" SD_2="1.17" SE="0.11467402792323465" STUDY_ID="STD-Combivent-1997" TOTAL_1="213" TOTAL_2="207" WEIGHT="25.3818806680677"/>
<CONT_DATA CI_END="0.3764894977910406" CI_START="-0.7764894977910409" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" MEAN_1="4.1" MEAN_2="4.3" ORDER="1325" SD_1="2.04" SD_2="1.96" SE="0.2941326995487245" STUDY_ID="STD-Levin--1996" TOTAL_1="96" TOTAL_2="89" WEIGHT="3.858045230381777"/>
<CONT_DATA CI_END="0.2445773452425787" CI_START="-0.04457734524257853" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" MEAN_1="3.9" MEAN_2="3.8" ORDER="1326" SD_1="0.69" SD_2="0.69" SE="0.0737653071092052" STUDY_ID="STD-Rennard-1996" TOTAL_1="176" TOTAL_2="174" WEIGHT="61.34082644782366"/>
<CONT_DATA CI_END="0.6600214417197688" CI_START="-0.46002144171976955" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" MEAN_1="4.1" MEAN_2="4.0" ORDER="1327" SD_1="2.1" SD_2="2.07" SE="0.285730475731772" STUDY_ID="STD-Tashkin-1996" TOTAL_1="108" TOTAL_2="105" WEIGHT="4.088281617509303"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.5052154773983986" CI_END="0.1627563376428611" CI_START="-0.12325502418089015" DF="4.0" EFFECT_SIZE="0.019750656730985465" ESTIMABLE="YES" I2="0.0" ID="CMP-002.09.03" MODIFIED="2008-07-03 16:42:40 +0100" MODIFIED_BY="Toby J Lasserson" NO="3" P_CHI2="0.8257173198052996" P_Z="0.7866274890395363" STUDIES="5" TAU2="0.0" TOTAL_1="766" TOTAL_2="740" WEIGHT="100.00000000000001" Z="0.27069257400759994">
<NAME>CRQ- EMOTION DOMAIN</NAME>
<CONT_DATA CI_END="0.361206618755114" CI_START="-0.16120661875511294" EFFECT_SIZE="0.10000000000000053" ESTIMABLE="YES" MEAN_1="4.9" MEAN_2="4.8" ORDER="1328" SD_1="1.24" SD_2="1.21" SE="0.13327113192664658" STUDY_ID="STD-Combivent-1994" TOTAL_1="173" TOTAL_2="165" WEIGHT="29.973552948988267"/>
<CONT_DATA CI_END="0.3963711310802443" CI_START="-0.5963711310802435" EFFECT_SIZE="-0.09999999999999964" ESTIMABLE="YES" MEAN_1="4.7" MEAN_2="4.8" ORDER="1329" SD_1="2.61" SD_2="2.58" SE="0.25325523070605177" STUDY_ID="STD-Combivent-1997" TOTAL_1="213" TOTAL_2="207" WEIGHT="8.300295429607232"/>
<CONT_DATA CI_END="0.2516835309115886" CI_START="-0.4516835309115879" EFFECT_SIZE="-0.09999999999999964" ESTIMABLE="YES" MEAN_1="5.0" MEAN_2="5.1" ORDER="1330" SD_1="1.24" SD_2="1.2" SE="0.17943367004986982" STUDY_ID="STD-Levin--1996" TOTAL_1="96" TOTAL_2="89" WEIGHT="16.534935996888766"/>
<CONT_DATA CI_END="0.729064321260401" CI_START="-0.32906432126040064" EFFECT_SIZE="0.20000000000000018" ESTIMABLE="YES" MEAN_1="4.8" MEAN_2="4.6" ORDER="1331" SD_1="2.53" SD_2="2.52" SE="0.2699357362857648" STUDY_ID="STD-Rennard-1996" TOTAL_1="176" TOTAL_2="174" WEIGHT="7.306167604246469"/>
<CONT_DATA CI_END="0.23233753060628276" CI_START="-0.23233753060628276" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="4.7" MEAN_2="4.7" ORDER="1332" SD_1="0.87" SD_2="0.86" SE="0.11854173466396911" STUDY_ID="STD-Tashkin-1996" TOTAL_1="108" TOTAL_2="105" WEIGHT="37.885048020269274"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.80876455401582" CI_END="0.14781948746996026" CI_START="-0.09045393628413707" DF="4.0" EFFECT_SIZE="0.028682775592911602" ESTIMABLE="YES" I2="0.0" ID="CMP-002.09.04" MODIFIED="2008-07-03 16:42:40 +0100" MODIFIED_BY="Toby J Lasserson" NO="4" P_CHI2="0.4325050511375651" P_Z="0.6370185841127178" STUDIES="5" TAU2="0.0" TOTAL_1="766" TOTAL_2="740" WEIGHT="100.0" Z="0.4718714009563102">
<NAME>CRQ- MASTERY DOMAIN</NAME>
<CONT_DATA CI_END="0.4270854458804555" CI_START="-0.027085445880455167" EFFECT_SIZE="0.20000000000000018" ESTIMABLE="YES" MEAN_1="5.2" MEAN_2="5.0" ORDER="1333" SD_1="1.08" SD_2="1.05" SE="0.11586205035994353" STUDY_ID="STD-Combivent-1994" TOTAL_1="173" TOTAL_2="165" WEIGHT="27.524067714717884"/>
<CONT_DATA CI_END="0.26246950020622367" CI_START="-0.46246950020622296" EFFECT_SIZE="-0.09999999999999964" ESTIMABLE="YES" MEAN_1="4.9" MEAN_2="5.0" ORDER="1334" SD_1="1.91" SD_2="1.88" SE="0.18493681672996876" STUDY_ID="STD-Combivent-1997" TOTAL_1="213" TOTAL_2="207" WEIGHT="10.803097139659299"/>
<CONT_DATA CI_END="0.15511168879330234" CI_START="-0.3551116887933016" EFFECT_SIZE="-0.09999999999999964" ESTIMABLE="YES" MEAN_1="5.2" MEAN_2="5.3" ORDER="1335" SD_1="0.9" SD_2="0.87" SE="0.13016141664111708" STUDY_ID="STD-Levin--1996" TOTAL_1="96" TOTAL_2="89" WEIGHT="21.808736424375187"/>
<CONT_DATA CI_END="0.5766813391444484" CI_START="-0.3766813391444491" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" MEAN_1="5.0" MEAN_2="4.9" ORDER="1336" SD_1="2.28" SD_2="2.27" SE="0.24320923389636254" STUDY_ID="STD-Rennard-1996" TOTAL_1="176" TOTAL_2="174" WEIGHT="6.2464737275101685"/>
<CONT_DATA CI_END="0.20547646967566757" CI_START="-0.20547646967566757" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="5.0" MEAN_2="5.0" ORDER="1337" SD_1="0.77" SD_2="0.76" SE="0.10483685990989618" STUDY_ID="STD-Tashkin-1996" TOTAL_1="108" TOTAL_2="105" WEIGHT="33.61762499373747"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-002.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="177" TOTAL_2="180" WEIGHT="0.0" Z="0.0">
<NAME>Number of subjects with at least one exacerbation during 12 week study</NAME>
<GROUP_LABEL_1>combination</GROUP_LABEL_1>
<GROUP_LABEL_2>beta-2 agonist</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours combination</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours B-2 agonist</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9553931941723247" CI_START="0.1826218459509753" EFFECT_SIZE="0.41770284740320907" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="17" LOG_CI_END="-0.019817856776688274" LOG_CI_START="-0.7384472716622505" LOG_EFFECT_SIZE="-0.37913256421946934" ORDER="1338" O_E="-4.899159663865547" SE="0.4221264755767538" STUDY_ID="STD-Campbell-1999" TOTAL_1="177" TOTAL_2="180" VAR="5.611963225475254" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.4762768334452967" CI_END="0.9380694796257147" CI_START="0.5019909131174508" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.6862232542292082" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="112" I2="13.700774025331706" I2_Q="0.0" ID="CMP-002.11" LOG_CI_END="-0.027764993709891612" LOG_CI_START="-0.299304144246747" LOG_EFFECT_SIZE="-0.1635345689783193" METHOD="PETO" NO="11" P_CHI2="0.3238521132900053" P_Q="1.0" P_Z="0.018236629825933586" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="807" TOTAL_2="784" WEIGHT="100.0" Z="2.360778287706128">
<NAME>Number of subjects adding or increasing systemic (oral) corticosteroids</NAME>
<GROUP_LABEL_1>combination</GROUP_LABEL_1>
<GROUP_LABEL_2>beta-2 agonist</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours combination</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours B-2 agonist</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8296270757986078" CI_START="0.1634433482291449" EFFECT_SIZE="0.3682350160564297" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="18" LOG_CI_END="-0.08111708270623273" LOG_CI_START="-0.7866327495171441" LOG_EFFECT_SIZE="-0.4338749161116884" ORDER="1339" O_E="-5.816901408450704" SE="0.4144233950436041" STUDY_ID="STD-Combivent-1994" TOTAL_1="182" TOTAL_2="173" VAR="5.822526469391666" WEIGHT="14.813292065491742"/>
<DICH_DATA CI_END="1.0947370652940334" CI_START="0.3714625411006301" EFFECT_SIZE="0.6376941368016238" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="36" LOG_CI_END="0.03930982255143198" LOG_CI_START="-0.4300849746719732" LOG_EFFECT_SIZE="-0.1953875760602706" ORDER="1340" O_E="-5.917808219178081" SE="0.27572482743074805" STUDY_ID="STD-Combivent-1997" TOTAL_1="222" TOTAL_2="216" VAR="13.153709700344345" WEIGHT="33.46481026066515"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1341" O_E="0.0" SE="0.0" STUDY_ID="STD-Gross-1998" TOTAL_1="195" TOTAL_2="195" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.790456122549954" CI_START="0.48776762651547795" EFFECT_SIZE="0.9345194130013013" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="24" LOG_CI_END="0.252963682528639" LOG_CI_START="-0.31178702749963805" LOG_EFFECT_SIZE="-0.02941167248549958" ORDER="1342" O_E="-0.6153846153846168" SE="0.3317373626317108" STUDY_ID="STD-Levin--1996" TOTAL_1="100" TOTAL_2="95" VAR="9.086805343744281" WEIGHT="23.118057462986275"/>
<DICH_DATA CI_END="1.442754151588803" CI_START="0.4482053073637575" EFFECT_SIZE="0.8041455514788332" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="34" LOG_CI_END="0.15919233268405442" LOG_CI_START="-0.3485230051299483" LOG_EFFECT_SIZE="-0.09466533622294691" ORDER="1343" O_E="-2.450704225352112" SE="0.29823450266340024" STUDY_ID="STD-Tashkin-1996" TOTAL_1="108" TOTAL_2="105" VAR="11.243052254531708" WEIGHT="28.603840210856834"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.7174007194575194" CI_END="1.569820356649363" CI_START="0.8626878120634505" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.163728872551723" ESTIMABLE="YES" EVENTS_1="112" EVENTS_2="96" I2="0.0" I2_Q="0.0" ID="CMP-002.12" LOG_CI_END="0.19584995649856662" LOG_CI_START="-0.06414633757238913" LOG_EFFECT_SIZE="0.06585180946308873" METHOD="PETO" NO="12" P_CHI2="0.4456002392508751" P_Q="1.0" P_Z="0.3207886417151683" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="789" TOTAL_2="769" WEIGHT="100.00000000000001" Z="0.9928385735315449">
<NAME>Number of subjects experiencing adverse event related to medication</NAME>
<GROUP_LABEL_1>combination</GROUP_LABEL_1>
<GROUP_LABEL_2>beta-2 agonist</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours combination</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours B-2 agonist</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8855460812020821" CI_START="0.4037228266702786" EFFECT_SIZE="0.8724895378856822" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="15" LOG_CI_END="0.2754371506728155" LOG_CI_START="-0.39391669469005686" LOG_EFFECT_SIZE="-0.05923977200862064" ORDER="1346" O_E="-0.882352941176471" SE="0.3931817621211229" STUDY_ID="STD-Campbell-1999" TOTAL_1="177" TOTAL_2="180" VAR="6.468644298433187" WEIGHT="15.087691310305896"/>
<DICH_DATA CI_END="1.733686876000014" CI_START="0.4589113888949166" EFFECT_SIZE="0.8919689748943376" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="20" LOG_CI_END="0.2389706615916822" LOG_CI_START="-0.3382711641993434" LOG_EFFECT_SIZE="-0.049650251303830606" ORDER="1344" O_E="-0.9943661971830977" SE="0.33907470586276955" STUDY_ID="STD-Combivent-1994" TOTAL_1="182" TOTAL_2="173" VAR="8.697795904094898" WEIGHT="20.28704217247079"/>
<DICH_DATA CI_END="1.7652060292517582" CI_START="0.532763908987819" EFFECT_SIZE="0.9697618595887514" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="24" LOG_CI_END="0.24679540215737608" LOG_CI_START="-0.27346520324152884" LOG_EFFECT_SIZE="-0.013334900542076379" ORDER="1345" O_E="-0.32876712328767255" SE="0.3056036549428479" STUDY_ID="STD-Combivent-1997" TOTAL_1="222" TOTAL_2="216" VAR="10.707372509042317" WEIGHT="24.97424865361912"/>
<DICH_DATA CI_END="3.903811040027777" CI_START="0.7095390219453979" EFFECT_SIZE="1.6643035381807476" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="9" LOG_CI_END="0.5914887879241307" LOG_CI_START="-0.14902371500630957" LOG_EFFECT_SIZE="0.22123253645891058" ORDER="1347" O_E="2.6923076923076916" SE="0.43498070981734815" STUDY_ID="STD-Levin--1996" TOTAL_1="100" TOTAL_2="95" VAR="5.285182699932898" WEIGHT="12.327344249624499"/>
<DICH_DATA CI_END="2.962469876374683" CI_START="0.9424608040991236" EFFECT_SIZE="1.670931399491767" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="28" LOG_CI_END="0.47165394295376734" LOG_CI_START="-0.025736702573027598" LOG_EFFECT_SIZE="0.22295862019036986" ORDER="1348" O_E="6.014084507042256" SE="0.2921697273058433" STUDY_ID="STD-Tashkin-1996" TOTAL_1="108" TOTAL_2="105" VAR="11.714656795409715" WEIGHT="27.323673613979697"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2009-04-27 14:01:53 +0100" MODIFIED_BY="Toby J Lasserson">
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2009-04-27 14:01:53 +0100" MODIFIED_BY="Toby J Lasserson" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAK8AAAIWCAIAAACuqkq2AAAQIElEQVR42u3dv47UShrGYUskBAQT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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2008-07-03 16:43:08 +0100" MODIFIED_BY="Toby J Lasserson" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Graphic to demonstrate that in the treatment of COPD with either ipratropium or short-acting beta-agonist, 15 people would need to be treated ipratropium in order to prevent one person requiring a course oral steroids.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAkwAAAG/CAIAAAAl6B++AABLD0lEQVR42u2dLXDjTJe2Bc0kaNaC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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2008-07-03 16:43:08 +0100" MODIFIED_BY="Toby J Lasserson" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Graphic to demonstrate that in the treatment of COPD with either combination ipratropium and short-acting beta-agonist or short-acting beta-agonist alone, 20 people would need to be treated ipratropium in order to prevent one person requiring a course oral steroids.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAkkAAAHBCAIAAADy6bhLAABLX0lEQVR42u29L2zjXri/aRhmo1XY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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2008-07-03 16:43:08 +0100" MODIFIED_BY="Toby J Lasserson" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Funnel plot demonstrating possible publication bias</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAm8AAAHpCAIAAABbVUyHAAAULUlEQVR42u3d65LauBaAUR49b66p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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>